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Abstract 
 
Introduction: Short bowel syndrome is characterised by a severe reduction in the 
amount of functional intestine available as an absorptive surface. Attempts to lengthen 
the intestine by interposition of artificial tubular scaffolds juxtaposed between healthy 
tissues have shown limited success. Transplantation is limited due to organ shortage. 
The most promising solution may be implantation of tissue-engineered small intestine 
using natural scaffold.   
Materials and Results: Using a completely novel approach, up to 30cm lengths of 
ileum with the attached vasculature were harvested from porcine donors. Separate 
intestinal and vascular loops were identified and de-cellularised using individually 
tailored detergent-enzymatic protocols. The resulting scaffold was compared to native 
tissue in terms of retention of cellular and nuclear remnants, as well as structural and 
functional proteins. Its biocompatibility was assessed by subcutaneous implantation of 
1cm2 pieces into rat recipients. The remodeling fate of grafts was determined by time 
related changes in the ratio of sub-populations of residual macrophages. Its 
mechanical strength and ease of handling was evaluated by performing a left-sided 
nephrectomy in an unrelated pig model, followed by end-to-end anastomosis of the 
de-cellularised scaffolds’ mesenteric vasculature to the appropriate renal artery and 
vein. In the last stage, porcine organoid units were isolated and their yield estimated 
for future in vitro studies.  
Conclusions: It is possible to simultaneously de-cellularise two different tissues of 
varying cellular configuration and composition effectively and efficiently over a 
relatively short period of time. The two key features of the de-cellularised scaffold are 
that 1) the scaffold has in place the necessary architectural topography of small 
intestine (including mucosal villi) and molecular cues for optimum re-cellularisation 
and 2) the attached vascular tree provides an ideal conduit for re-cellularisation using 
either vascular committed endothelial or progenitor cells. Ultimately, this scaffold can 
be used for constructing long segments of bio-engineered intestine with the possibility 
of immediate blood supply and re-vascularisation.    
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Glossary 
 
!-Gal - epitope responsible for hyperacute rejection in xenotransplantation 
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Biodegradable Scaffold - capable of being decomposed by the action of biological 
agents scaffold 
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sample 
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Dynamic Culture - the maintenance or growth of cells/tissues/organs in non-static 
conditions, e.g. using perfusion or elecrostimulation 
  
Elastin - a protein of ECM that is elastic and allows many tissues in the body to 
resume their shape after stretching or contracting 
 
Embryonic Stem Cell - pluripotent stem cells derived from the inner cell mass of the 
blastocyst 
 
Endothelium - the thin layer of endothelial cells that lines the interior surface of 
blood vessels, forming an interface between circulating blood in the lumen and the 
rest of the vessel wall 
 
Explant – tissue or its part removed from the body 
 
Extracellular matrix - is the extracellular part of animal tissue that usually provides 
structural support to the cells in addition to performing various other important 
functions 
 
Fibrosis - the formation of excess fibrous connective tissue in an organ or tissue in a 
reparative or reactive process 
 
Foreign Body Reaction - a granulomatous inflammatory response evoked by the 
presence of a foreign body in the tissues; a characteristic feature of this is the 
formation of foreign body giant cells 
 
Glycosaminoglycans - long unbranched polysaccharides consisting of a repeating 
disaccharide unit, residual within the cells as well as ECM 
 
Heparin - a highly-sulfated glycosaminoglycan, widely used as an anticoagulant 
 
Histology - the study of the microscopic anatomy of cells and tissues 
 
Hybrid Scaffold – in tissue engineering scaffold composed of biologic and synthetic 
elements 
 
Immune Reaction - the reaction resulting from the recognition and binding of an 
antigen by its specific antibody or by a previously sensitized lymphocyte, also called 
immunoreaction 
 
Immunocytochemistry - a common laboratory technique that uses antibodies that 
target specific peptides or protein antigens in the cell via specific epitopes 
 
Immunohistochemistry - a common laboratory technique that uses antibodies that 
target specific peptides or protein antigens in the tissue via specific epitopes 
 
Immunosuppression - the reduction or de-activation of efficacy of the immune 
system 
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Implant - a piece of tissue, prosthetic device, or other object implanted in the body 
Inflammation – nonspecific, early stage immune response, manifest by increased 
blood supply and vascular permeability which, in technical terms, allows chemotactic 
peptides, neutrophils, and mononuclear cells to leave the intravascular compartment 
 
Intestinal adaptation - process in which the small intestine increases in size so it has 
more surface area through which to absorb nutrients, often occurring after bowel 
resection surgery 
 
Intestinal epithelium - simple columnar and conciliated epithelium that covers the 
small and large intestine  
 
Intestinal failure - reduced intestinal absorption so that macronutrient and/or water 
and electrolyte supplements are needed to maintain health or growth 
 
In Vitro - refers to studies in experimental biology that are conducted using 
components of an organism that have been isolated from their usual biological context 
in order to permit a more detailed or more convenient analysis than can be done with 
whole organisms 
 
In Vivo - is experimentation using a whole, living organism as opposed to a partial or 
dead organism 
 
Macrophages - white blood cells produced by the differentiation of monocytes in 
tissues 
 
Mesenteric Arcade - a branch of blood vessels, nerves, and lymphatics within the 
mesentery to supply the intestine 
 
Mucosa - the innermost layer of the gastrointestinal wall that is surrounding the 
lumen, or open space within the tube; this layer comes in direct contact with food 
called bolus, and is responsible for absorption, digestion and secretion 
 
Neomucosa – tissue-engineered mucosa 
 
Neonatal – new-born 
 
Number Density – stereologicaly estimated numerical density of the objects  
 
Organoid Units - multi cellular aggregates containing polarised epithelium including 
the epithelial and epithelial stem cells, surrounding a core of mesenchymal derived 
stromal cells (all of the cells of a full-thickness intestinal section) 
 
Organ Re-perfusion – intraluminal introduction of fluid (usually blood) into a blood 
vessel in order to reach an organ or tissues, usually to supply nutrients and oxygen 
post-trans-/implantation 
 
Parental feeding - intravenous bypassing the usual process of eating and digestion 
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Progenitor Cells - a biological cell that, like a stem cell, has a tendency to 
differentiate into a specific type of cell, but is already more specific than a stem cell 
and is pushed to differentiate into its "target" cell 
 
Regenerative medicine - the process of creating living, functional tissues to repair or 
replace tissue or organ function lost due to damage, or congenital defects; synonym of 
tissue engineering involving stem cells use 
 
Scaffold - structure capable of supporting three-dimensional tissue formation 
 
Seeding of a Scaffold – introduction of cells into the scaffold 
 
Serosa - serous coat of the small intestine; the peritoneal covering of the external 
surface of the small intestine 
 
Short Bowel Syndrome - a malabsorption disorder caused by the surgical removal of 
the small intestine, or rarely due to the complete dysfunction of a large segment of 
bowel 
 
Stem Cell - biological cells found in all multicellular organisms, that can divide 
through mitosis and differentiate into diverse specialized cell types and can self renew 
to produce more stem cells 
 
Stereology - an interdisciplinary field that is largely concerned with the three-
dimensional interpretation of planar sections of materials or tissues 
 
Subcutaneous - just under the dermis 
 
Submucosa - a dense irregular layer of connective tissue within the intestine with 
large blood vessels, lymphatics, and nerves branching into the mucosa and muscularis 
externa 
 
Surface Marker - a molecule usually found on the plasma membrane of a specific 
cell type or a limited number of cell types 
 
Tissue Graft - tissue surgically moved from one site to another on the body, or from 
another individual, without bringing its own blood supply with it 
 
Thrombogenicity - tendency of a material in contact with the blood to produce a 
thrombus, or a blood clot 
 
Thrombus - late product of the blood coagulation 
 
Tissue engineering - use of a combination of cells, engineering and materials 
methods, and suitable biochemical and physio-chemical factors to improve or replace 
biological functions 
 
Tissue remodeling - the reorganization or renovation of existing tissues 
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Unbiased Counting Frame – a tool used in stereology to assist in implementing the 
counting rules resulting in all particles having an equal probability of being selected, 
regardless of shape, size, orientation, and distribution. 
 
Warfarin – anticoagulative drug 
 
Xenograft - a surgical graft of tissue from one to another species 
 
Xylene – organic solvent used in fixed tissue processing 
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Chapter 1. 
General Introduction 
 
In the 1990’s tissue engineering moved from a concept to an approachable and 
viable clinical solution.  Its branching into regenerative therapies provided an 
opportunity for exploration of alternative treatments for end-stage organ/tissue 
failures.  
Chronic intestinal failures are often severe conditions requiring long-term 
management or/and intestinal transplantation which significantly decrease quality of 
life. They are also a source of considerable morbidity and mortality. Investigations 
into the possibility of using bio-engineered bowel as an alternative treatment option 
has been mostly performed using small animal models and artificial scaffolds. Early 
research within the field proved that even though intestine is an organ with the highest 
rate of proliferation, the source of cells needed to create “off-the-shelf” intestine is 
very limited. It also became obvious that the straight forward intestinal interposition 
of synthetic tubular scaffold is currently not viable to make a transition into the clinics 
(82, 83).  
 
 The aim of the present thesis is to investigate the possibility of creating a 
scaffold for small intestine tissue engineering that could be successfully used in a 
large animal model. As patients suffering from end-stage bowel failure require 
significant improvements in absorptive function, engineering biologically derived 
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grafts approximately 50cm in length could be considered clinically relevant. To avoid 
graft necrosis and rejection, large constructs need to be provided with immediate re-
vascularisation post-implantation.  The thesis will explore the method of obtaining 
lengths of de-cellularised porcine ileum together with its attached mesenteric vascular 
arcade as a single entity, which can be easily anastomosed to native tissue. The 
evaluation of the scaffold and sources of cells for seeding it will also be described.  
 
Chapter 1 of the thesis describes the definition, possible outcomes and managements 
of intestinal failure focusing on patients suffering from short bowel syndrome. It also 
gives a general introduction into tissue engineering principles, and in particular the 
branch using de-cellularised organs and tissues. The achievements of tissue 
engineering in the field of bowel regeneration are also discussed.  
 
Chapter 2 to 7 focus on experimental development of a model and bio-tools for the 
investigation into the small intestine tissue engineering. Chapter 2 investigates the use 
of a hybrid scaffold for intestinal regeneration in rodents. It also highlights the 
advantages of further use of a porcine model. Chapter 3 presents a novel method of 
de-cellularisation, which allows production of capillarised and ready-to-implant 
intestinal scaffold. Biocompatibility tests of the produced matrix are described in 
Chapter 4. Chapter 5 explains how short-term animal studies can give a good 
prediction of the type of immune response taking place within the scaffold and 
possibility of implant rejection or acceptance. Chapter 6 presents the results of bio-
mechanical performance of acellular scaffold in vivo. The last part of experimental 
work (Chapter 7) shows possible sources of cells that could be used in future 
investigation of small intestine regeneration. It focuses on sources, methods of 
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isolation and characterization of cells that could be used for seeding acellular, 
intestinal lumen and acellular vascular conduits of the scaffold.  
 
Finally the thesis concludes with a general discussion of the finding of the studies 
described previously. Chapter 8 presents final conclusions and contemplates the 
production of intestinal substitutes as an alternative to existing management of 
intestinal failure, shows the importance of using large animal models, as well as tools 
to reduce time and subsequently the number of animals needed to predict the outcome 
of the graft’s implantation. Furthermore, the sources of cells that could possibly be 
used in further studies are discussed. Moreover, the chapter summarizes the limitation 
of the current trend in creating bio-engineered bowel as well as the limitations of the 
studies. It concludes with a discussion regarding the transition of the presented results 
into the clinical phase. Chapter finishes with the presentation of the aims of future 
investigations into studies presented in thesis.  
 
1.1. Intestinal failure  
 Intestinal failure (loss of absorptive function) most commonly occurs from a 
loss of intestinal length. It can also occur due to impaired intestinal motility, mucosal 
function or combination of all three (1). Resection is performed generally for disease, 
injury or dysfunction sometimes resulting in a short bowel syndrome (SBS) 
(subcategory of intestinal failure) followed by inadequate enteral caloric absorption, 
electrolyte, or micronutrient balance for maintenance in adults and growth in children 
(2). As prolonged malabsorption leads to deficiencies of micronutrients and growth 
retardations (3), SBS patients are known to require prolonged periods of parenteral 
nutrition (PN).  
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The normal small bowel length is estimated to be approximately 600cm. Short 
bowel was first defined by Rickham (4) as an intestinal remnant of 30% or less, which 
is a maximum of 75cm of normal small bowel length in neonates and 150 - 200 cm in 
adults. The incidence of SBS has been estimated to be between 3 and 24.5/100 000 
births per year (5).  
 Extensive small intestinal resection in animals results in marked structural and 
functional change in the residual intestine, with a significant increase in intestinal 
mass over a period of weeks post-operatively, called intestinal adaptation (6). It can 
last up to two years but the ability to become independent from parenteral feeding as a 
result of intestinal adaptation is possible only in very few patients (7).  
 The goal of medical therapies is to improve the absorption of enteral calories 
in order to promote adaptation and weaning of PN.  The management of intestinal 
failure can be achieved either via a surgical or non-surgical route, but favourable 
outcomes are achieved through the efforts of a multidisciplinary management 
approach (8).  
 PN is linked to many complications and the main goal of treating SBS-patients 
is weaning them off it. Some patients also achieve a plateau in enteral or parenteral 
nutrition and further intestinal failure management is the only option to facilitate 
advancement (9). Although PN revolutionized intestinal failure treatment it reduces 
quality of life as it may be responsible for various complications including growth 
failure, metabolic disorders and bone disease.  
 Pharmacological and hormonal adjuncts to promote increase in intestinal 
absorptive capacity are in the early stage of development. Although some studies 
show a positive effect of epithelial growth factor (EGF) glutamine, glucagon-like-
peptide-2 (GLP-2) and growth hormone (GH) in the treatment of SBS (10).  
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 Numerous surgical options have been pursued to attempt to improve 
absorption of nutrients from intestinal content. The main goal of these procedures is to 
slow intestinal transit, taper dilated bowel and promote intestinal adaptation. 
Experience of these techniques is limited in adults with the majority of surgeries being 
performed in infants and children.  
 In patients who are unable to wean off the PN small bowel transplantation is 
been used as a rescue procedure. Intestinal transplantation offers the possibility of 
small intestine replacement, albeit with the burden of long term immunosuppressive 
therapy. For the majority of patients, small intestinal transplantation is indicated only 
when irreversible small intestinal failure coexists with the failure of PN (loss of 
venous access due to venous thrombosis, PN related liver failure, and recurrent line 
related sepsis) (7). Even though performing earlier intestine transplantation could stop 
the development of irreversible liver failure, earlier transplantation may not improve 
the quality of life if renal failure, infection, malignancy and graft dysfunction lead to 
frequent hospitalization (11). Combined liver and small bowel transplantation offers a 
treatment option in cases where there is irreversible liver damage. There are a number 
of technical issues with such a procedure (12).  
 Chronic intestinal failure requiring long term nutritional support is a source of 
considerable morbidity and mortality. The overall related mortality in infants with 
SBS ranges from 15 to 25%, and in adults from 15 to 47%. Babies with a congenital 
SBS, with only 30-40 cm of remaining small intestine and severely disturbed motility 
represent a special subgroup, characterised by 80% mortality rate (9). Reported 
patient survival of 95% in group weaned from PN contrasts highly with those 
remaining PN dependant (52%) at 5 years (13).  
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The pre-transplant mortality remains higher than any other group awaiting 
solid-organ (kidney, liver, heart) transplantation (2). Little improvement in graft 
survival over the last 5 years suggests that a ceiling may have been reached. Almost 
all patients experience at least one infection following transplantation (12). 
Complications after intestinal transplantation occur frequently even after the first year 
and hospital readmission rates are higher than after other solid organ transplants (11). 
 There has been little improvement in the methods of management of intestinal 
failure. It can indicate that the plateau has been reached and alternative methods of 
treatment need to be considered. Taking all treatment options (including 
transplantation), only 20% SBS patients succeed to wean off PN (14). Only every fifth 
patient has a chance to be completely treated and it is crucial to develop a uniform in 
terms of outcome method of treatment that would increase this rate. Poor quality of 
life after development of intestinal failure and high costs of its management are 
additional reasons for investigating new solutions. At the moment each little step 
towards a successful outcome in SBS patients is difficult to achieve, and progress 
follows an exponential curve in regards to time and cost (9).  
 The last 20 years has brought a new solution to some end-stage organ failures. 
Tissue engineering allows constructing the failing organ/tissue using autologus cells, 
which can eliminate immunosuppression-related complications. Small intestine tissue 
engineering could create an opportunity to use ex vivo grown autografts to lengthen 
small intestine in SBS patients. This would not preclude more traditional lengthening 
but in fact could potentially increase the overall gain if both techniques could be used 
either sequentially or simultaneously making this strategy especially attractive. Tissue 
engineered grafts could have potential to become indications not only for life 
threatening complications, but also for improved quality of life. Moreover, bio-
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engineered grafts could potentially be grown appropriately early, and implanted while 
resecting the diseased bowel. This would eliminate the need for multiple procedures 
and lower the risk of surgical complications. The rate of adaptation of the remaining 
bowel following resection is highest within the first few weeks after the operation. 
Therefore grafts implanted at resection time would have a grater chance to undergo 
adaptation at the same rate as the remnant bowel. In vitro manipulation and pre-
conditioning (e.g. with GLP-2 or GH) of grafts could also benefit the adaptation 
process.  
 
1.2. Tissue engineering: general introduction 
 Scientists in the field of regenerative medicine and tissue engineering are now 
applying the principles of cell transplantation, material science, and bio-engineering 
to construct biological substitutes that will restore and maintain normal function in 
diseased and injured tissues (15). Application of tissue engineering technology may 
offer novel therapies for patients with injuries, end-stage organ failures, or other 
clinical problems (15).  
 New techniques of cell harvesting, in vitro culturing and extracellular matrix 
(ECM) analysis led the way to more advanced understanding of the tissues’ 
functionality, proliferation and differentiation. This was the beginning of an era, when 
scientists started combining the devices and materials with a cell biology concept, 
creating a new field called tissue engineering (16).  
Tissue engineering was brought into the public eye with the airing of a BBC 
broadcast on the potential of tissue-engineering cartilage using images of the now 
infamous ‘mouse with the human ear’, later called auriculosaurus. Since then science-
fiction dogma started to form a more realistic shape, and the new field underwent 
                                                                                   Chapter 1: Introduction! 
 
 35 
drastic development. In the last few decades scientists have attempted to grow native 
and stem cells, engineer tissue and design treatment method using regenerative 
medicine techniques for virtually every tissue of the human body (17). 
 Engineering new tissues, ideally from the patient’s own body cells to prevent 
rejection by the immune system, has got to be seen as the way forward also when 
alternative SBS management is considered. Tissue engineering rests on three pillars: 
cells, supporting structures (scaffold) and stimulating biomolecules.  
It entails the in vitro generation of biological tissue from individual cells with 
the aid of support structures and growth factors. This approach differs from in vivo 
guided tissue regeneration which is based on implanting matrices that are populated 
with the patient’s cells to support the regenerative abilities of the body. A widely used 
basic strategy has been to harvest cells from a patient, expand them in cell culture, and 
seed them onto a scaffold that provides a biomechanical environment that drives 
formation of the required tissue until the cells produce their own ECM. After 
implantation, the tissue engineered construct must be able to survive, restore normal 
function, and integrate with the surrounding tissues (18). Success in tissue engineering 
will only be achievable if issues at these three different levels: cell technology, 
construct technology and integration into the living system can be addressed.  
 
 
1.2.1. Scaffolds in tissue engineering 
 The design and choice of biomaterials is critical in the development of 
engineered tissues. The biomaterial must be capable of controlling the structure and 
function of the engineered tissue in a predesigned manner by interacting with 
transplanted cells and/or the host cells. Generally, the ideal scaffold should be 
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biocompatible, promote cellular interaction and tissue development, and possess 
proper mechanical and physical properties. If the selected biomaterial is 
biodegradable, the degradation products should not provoke inflammation or toxicity 
and must be removed from the body via metabolic pathways. The degradation rate 
and the concentration of degradation products in the tissue surrounding the implant 
must be at a tolerable level (19). The biomaterial should provide an appropriate 
regulation of cell behaviour, such as adhesion, proliferation, migration and 
differentiation in order to promote the development of functional new tissue. Most 
mammalian cells will die if no cell-adhesion substrate is available, therefore scaffolds 
should provide a cell-adhesion substrate that can deliver cells to specific sites in the 
body with high loading efficiency. Cell behaviour in engineered tissues is regulated 
by multiple interactions with microenvironment, including interactions with cell 
ligands and growth factors (20). The biomaterials should possess appropriate 
mechanical properties to regenerate tissue with predefined sizes and shapes. The 
composition, structure, and therefore the mechanical properties of the ECM can be 
specific to each organ or tissue. Therefore, scaffolds for certain applications should 
provide temporary mechanical support sufficient to withstand in vivo forces put on 
them by the surrounding tissue and to maintain space for potential tissue development. 
The scaffolds should also be maintained until neotissue has sufficient mechanical 
integrity and strength to support itself. It must also allow cells to be supplied with 
nutrients during vascularisation (21).  
The scaffolds used in tissue engineering can be biologically derived or 
synthetic. As the field evolved it became obvious that engineering soft tissues mostly 
needs the involvement of the biological materials whereas regeneration of bones and 
cartilages usually requires use of artificial, mechanically stronger scaffolds. The third 
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group are hybrid scaffolds, which are fabricated from naturally derived (collagen) and 
synthetic (polymers) ingredients. They express characteristics of both subgroups 
depending on the ratio of biologic/artificial elements.  
 
1.2.2. Sources of cells in tissue engineering 
 Something very important for the success of tissue engineering is the ability to 
generate sufficient numbers of cells that maintain the appropriate phenotype and 
perform the required biological functions. For example cells need to produce the ECM 
in the correct organisation, secret cytokines and other signalling molecules, and 
interact with neighbouring cells/tissue. This immediately rises a number of potential 
problems, not least of which is obtaining appropriate cell numbers to promote repair. 
Cells used in tissue engineering could be primary cells or stem cells (including 
embryonic, fetal and adult stem cells). They can come from three sources: the patient 
him/herself (autologus cells), another donor of the same species (allogeneic cells) or 
another species (xenogeneic cells) (22). Deriving cells from the patient by biopsy is 
advantageous as it avoids an immune reaction and has a low risk of infection. 
However, the availability might be limited, depending on the cells that are needed.   
Therapeutic cloning, cellular reprogramming and gene therapy may one day 
provide a potentially limitless sources of cells for tissue engineering applications, but 
currently none of them are widely investigated in tissue engineered constructs (15).  
 The fundamental biophysical constrain of mass transfer of living tissue needs 
to be understood and dealt with on an individual basis as tissue engineering moves 
towards human applications. Large masses of cells for tissue engineering need to be 
kept alive, not only in vitro but also in vivo. The design of systems to accomplish this, 
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including in vitro bioreactors and in vivo strategies for maintenance of cell mass, 
presents an enormous challenge, in which significant advances have been made.  
 
1.2.3. In vitro and in vivo development of tissue engineered 
constructs 
Once a scaffold and the cells that are to be employed have been selected, there 
are other issues to address. A critical one is what will be the environment that will 
foster the appropriate growth and/or conditioning of the tissue substitute. 
 In vitro tissue engineering involves manipulation of the cells in the culture, 
before implanting into the in vivo environment.  Controlled incubation conditions play 
an important role in the construction and use of modern in vitro systems for tissue 
engineering (23).  
 An overall comparison of different culture methods shows clearly the 
advantage of bioreactor culture. The most common approach in culturing specimens 
for organ or tissue replacement is to immobilize appropriate cells in the scaffold and 
use a bioreactor that confers a dynamic in vitro environment for tissue growth (24). 
The design of bioreactors intended for tissue engineering is focused upon 
influencing cell behaviour, and incorporates such features as the controlled and steady 
flow of cell media, pulsatile fluid flow, or culture vessel rotation to influence tissue 
development (25). These attributes are pivotal not only for controlled, reproducible 
investigations but also for routine manufacturing of tissues for clinical applications 
(26).  
Fluid dynamic stress, or ‘shear stress’, induced by the fluid flowing across the 
construct surface and into the porous space, is believed to be the most important 
mechanical stimulus in activating the mechano-transduction signalling. Consequently, 
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fluid flow induces mechanical stimuli. Pulsatile fluid flow has been used to develop 
tissue engineered heart valves and blood vessels, which makes them better adapted 
and pre-conditioned for in vivo placement tissue (27). The cyclic stress increases 
tissue organization and expression of elastin by smooth muscle cells (SMC) as well as 
stimulates glycosaminoglycans (GAGs) synthesis (28). Controlled flow of cell media 
has also been used for the dynamic seeding, which in the cases of many organs is 
more efficient than a static one (29). Currently most of the bioreactors used in vitro 
fail to provide all the necessary stimuli, but it is very encouraging that most of the 
studies move from static to dynamic culturing (20).  
Like most areas involving biologicals, the translational lag from experimental 
work to clinical applications has varied depending on the complexity involved. 
Preclinical studies are another step in decreasing this lag and they usually follow the 
in vitro stage of developing tissue engineering therapy. Elegant methods of in vitro 
tissue engineering are very often difficult to transfer to the patient and that is where in 
vivo studies become essential precursors to clinical applications. The choices of in 
vivo remodelling systems are many, including rodent animal models, large anima 
models and eventually nonhuman primates.  The choice of the system depends on the 
type of the construct being tested, the variable we want to asses (e.g. biocompatibility 
tests, survival rate of seeded cells, neo-vascularisation), time of the planned 
experiments, similarities of the pathophysiology, physiology and structural 
components and last but not least the costs and availability of the animal facilities 
(30).  
 The final analysis of tissue engineered products need to be performed in vivo 
in order to evaluate mammalian response to the implant. Tests of in vitro constructs 
implanted in vivo focus on maximizing cell survival and differentiation after grafting  
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and assessment of their biocompatibility and toxicity (31). The most important is the 
potential immune response that the graft could induce. The bioengineered materials 
tested in pre-clinical studies are of various biocompatibilities and therefore acute or 
chronic immune responses towards the end products should be evaluated in vivo. This 
usually involves the use of rodent model (in instance of this thesis: rat) to check for 
immediate toxicity and distinguish between acute and chronic reactions. It is 
important to be aware of the species differences (especially considering rat vice 
human ones) but as a general it is very likely that if a material elicits chronic 
inflammation and is rejected in rodents it will do so when implanted in humans. At 
the same time the reverse assumption is more difficult to certify. Even with primate 
systems (the most sophisticated and costly tests) there still remains a question of the 
eventual outcome in humans, thus the necessity for phased human clinical trials (30).  
 In vivo methods in tissue engineering can be used as testing systems for 
constructs developed in vitro or they can be an integral part of the actual remodelling 
process. In vivo remodelling processes rely on the body’s natural ability to regenerate 
over non-cell-seeded biomaterials. In many situations, remodelling may facilitate or 
be necessary for successful integration of the tissue-engineered construct. Host 
remodelling is viewed as an inevitable and often beneficial stage of the tissue-
engineering process (32).  
Recently scientists recognized the importance of two key issues when they 
started to use animal models: vascularisation and innervation (33). Moreover, an 
importance of achieving ‘ready-to-anastomosed’ constructs has been discussed (34). 
In addition, there is a significant need for development of methods to evaluate 
quantitatively the performance of an implant (35).  
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1.2.4. Biomechanical properties of tissue engineered 
constructs 
The in vivo and in vitro systems presented above play a key role in the 
advancement of the tissue-engineered products. Tissue culture systems provide 
dynamic media fluids flow around or within the tissue-engineered construct to not 
only enhance nutrient and waste exchange but also improve mass transport delivering 
flow-mediated sheer-stress to the specimen. Exposure to these load-bearing situations 
requires the consideration of biomechanical aspects for their integrity and function. 
Almost every scaffold developed for load-bearing situations must obviously sustain 
the stress it will be exposed to (36).  Thus, in the design of a scaffold, the 
biomechanics is very crucial to insure its functional and structural integrity.  
At first, the mechanical properties of the tissue should be well defined. For 
intestine, it includes all its morphological and functional aspects, and most 
importantly its peristalsis, which is directly affected by functionality of Muscularis 
Externa and luminal content flow. Biomechanics highlight many challenges when 
considering replacing tissues like small bowel that function within complex and 
demanding mechanical environment in vivo. Therefore material properties of the 
scaffold used for intestinal regeneration need to be taken into account when designing 
intestinal scaffolds. The particular loading conditions need to be evaluated in relevant 
in vivo and/or in vitro tests linked to the clinical application target (as lack of motility 
and peristalsis is second to surgical resection cause of SBS). Most common estimation 
of soft, contractible constructs (blood vessels, intestine, bladder) includes values of 
burst pressure, which state of their elasticity to expanding volumes. 
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Moreover, the success of the given scaffold is only complete when the decreasing 
mechanical properties during its biodegradation will be compensated by appropriately 
organised new-formed tissue (36), and ease of handling by surgeons (37).  
Biomechanical properties are also very important in directing tissue-
engineered construct maturation stimulating (by e.g. cyclic distension, stretching, 
compression, elecrostimulation) specific cell lines (e.g. endothelial, smooth muscle), 
which differentiation is modulated by varying the stiffness of the underlying matrix  
(38). Local stresses and strains play a ubiquitous role in modulating cell behaviour 
and thus the tissues they create and maintain.  
Testing and optimization of the biomechanical properties of constructs fall 
outside the scope of the present thesis. It should however be noted that such 
biomechanical properties are likely to have a significant bearing on the viability of the 
construct post-implantation. Thus, the biomechanical evaluation needs to precede 
further in vitro and in vivo studies, especially when designing a bioreactor that will 
use the optimal mechanical conditioning strategies to grow functional tissue.  
 
 
1.3. Engineering of tissues/organs using de-
cellularised matrices 
  Scaffolds that provide a favourable environment for normal cellular growth, 
differentiation and angiogenesis are important components for tissue engineered grafts 
because rapid integration with the host tissue is essential for long term graft viability. 
Biologically derived scaffold materials upon implantation elicit such response and 
therefore contribute considerably to restoration of structure and function specific to 
the grafted site.  
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1.3.1. The concept of ECM scaffolds  
Removal of cells from a tissue or organ leaves behind a complex mixture of structural 
and functional proteins that constitute the ECM and provide cell-to-cell, and cell-to-
matrix contact creating an ideal environment for the growth of new tissue. It provides 
a source for allogeneic and xenogeneic whole-organ grafts (32). Crucial for the use of 
ECM as a scaffold for tissue engineering is that growth factors, cytokines and other 
small molecules, released from cells during the de-cellularisation process stay within 
the ECM, survive tissue processing and sterilization, and maintain their functionality 
(39). The therapeutic approach where growth factors and cytokines are loaded onto 
the synthetic or biologically derived scaffolds has struggled in determining the 
optimal dose, sustained and localized release at the desired site, and the inability to 
turn the factors ‘on’ and ‘off’ as needed during the course of tissue repair.  
There are two main approaches to using these biologically occurring matrices 
in repair and regeneration of the tissues. In the first approach tissues, that have been 
denuded of cellular and nuclear content are implanted as intact acellular grafts, which 
act as the scaffold for ingrown of the host cells. This approach places high priority on 
the native structure and composition of ECM and its inherent ability to interact with 
the host tissue. The other approach focuses less on the bioactive molecules and more 
on the scaffolds macrostructure. This approach first requires for the scaffold to 
support in vitro cell growth. Autologus cells are grown to confluence or are sculptured 
into bioartificial organs that are then returned to the patient as a ‘living’ tissue (40). 
Most of the preclinical and clinical work uses the first approach or uses acellular 
matrices, which are seeded with cells, but not cultured in vitro for a long time, prior to 
implantation into the recipient.  
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Components of the ECM are generally conserved among species and are 
tolerated well even by xenogeneic recipients (41). Those matrixes, though harvested 
from different body systems, all share similarities when processed into a graft 
material. Acellular matrices keep their natural, 3D structure almost identical to their 
native tissue, which can significantly influence proliferation and differentiation of 
host-derived cells seeded onto the scaffold (42). The internal geometry of a tissue 
engineered scaffold specific to a particular tissue or organ will not only direct new 
tissue formation unique to that particular topography but also allow for mass transport 
properties sufficient for the exchange of biological nutrients and waste.  
The composition of ECM is a polymeric network consisting of 
macromolecules encapsulating smaller molecules, ions and water. The 
macromolecules are a complex mixture of polymer forming proteins, 
glycosaminoglycans, glycoproteins and micromolecules in a unique, tissue specific 
3D architecture (43). Whilst all ECM share these basic components, the organisation 
and mechanical properties of ECM are influenced by the chemical composition and 
3D configurations of its components and can vary widely in different tissue. Thus, the 
ability of the ECM harvested from one tissue to function as a biological scaffold 
material for different tissue may vary (44). 
Use of ECM prevents many of the complications associated with foreign 
materials as they are known to induce less of adverse responses due to removal of 
most of the cell-related epitopes from the tissue, preserving naturally existing proteins 
in specific body locations (40). 
The foremost features of ECM include recruitment of host cells followed by 
smart remodelling which when not cross-linked causes degradation of the ECM, and 
replacement of the scaffold by the new host-derived matrix (45). This smart, ECM-
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induced remodelling response is a distinctly different phenomenon from that of scar 
tissue formation. These features are highly advantageous making de-cellularised 
tissues and organs ideal scaffolds. The mechanical behaviour of ECM scaffolds 
changes during the process of in vivo remodelling, and these changes are dependant 
on factors such as local tissue microenvironment, the rate of scaffold degradation, 
forces present within the mechanical environment, and the rate and extent to which 
the infiltrating cells deposit new ECM and interact with it (46). Structural changes 
that occur during in vivo remodelling of ECM scaffolds are associated with marked 
changes in scaffold strength. Shortly after implantation, ECM scaffolds typically 
show a decrease in strength that is temporally associated with the rapid in vivo 
degradation of the scaffold (47). However, once the infiltrating cells have established 
residence and begin producing site-specific new ECM, rapid scaffold remodelling 
occurs, with an increase in the strength and site-appropriate mechanical behaviour 
(48). Furthermore, active loading of a remodelled ECM scaffold accelerates the 
formation of robust site-specific tissue by facilitating normal ratio of different types of 
collagen and distribution of collagen fibril diameters (49).  
 Angiogenesis is another common event during the remodelling of ECM 
scaffolds. Peptides that modulate angiogenesis and the recruitment of endothelial cells 
facilitate the development of a rich blood supply to the remodelling tissue for as long 
as 6-8 weeks (50). 
The tissue from which the ECM is harvested, the species of origin, the de-
cellularisation method and the method of terminal manipulations of the scaffold vary 
widely, and they all affect the composition and ultrastructure of the ECM and 
accordingly, following implantation affect the host response to the matrix.   
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1.3.2. Methods of de-cellularisation 
The goal of de-cellularisation is to remove all cellular and nuclear material 
while minimizing any adverse effect on biological composition, ECM activity, and 
mechanical integrity of the remaining structure. The process itself affects the 
biochemical composition of ECM, tissue ultrastructure and to some extent the 
mechanical behaviour of ECM. Essential during the removal of cellular components 
of the tissue is disruption of the ECM to allow adequate exposure of all cells to the 
lyses-inducing agents and to provide a path for cellular material to be removed from 
the tissue (51). The efficiency of de-cellularisation depends upon the origin of the 
tissue, method of cell removal, and the technique used for terminal sterilization of the 
ECM. As studies advance towards tissue with more complex geometries, the de-
cellularisation process has evolved to meet stricter standards needed for allo- and 
xenograft studies. While a de-cellularisation treatment may efficiently remove cellular 
material in some tissues, denser, thicker tissues and organs may need improved 
penetration into the tissue (51). All methods of de-cellularisation will alter the native 
3D architecture of the ECM and the most commonly used methods aim to restrict this 
drawback to a minimum. After determining methods of de-cellularisation, 
optimization of de-cellularisation reagent incubation times, temperature, concentration 
or number of solvent cycles have to be optimized (52). Agents most commonly used 
in de-cellularisation of specific organs and tissues have been summarised in Table 1 
(Appendix 1). 
 
1.3.3. Manipulation of de-cellularised tissues/organs 
Cross-linking and terminal sterilization are two most commonly used 
modifications of ECM scaffolds. ECM scaffolds can also be dehydrated to minimize 
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changes in the tissue architecture (collapse of collagen fibres upon each other, 
formation of physical bonds between ECM molecules) caused by disinfection and 
sterilization. Cross linking may be necessary when using scaffolds for mechano-
skeletal applications in order to increase ECM strength and allow neo-tissue formation 
over longer period of time than when using a non-modified scaffold. Sterilization 
processes are always necessary prior to in vivo evaluation.  
 Generally, in vivo and in vitro performance of non-modified scaffolds is better 
than the modified ones, and the optimal configuration and method of processing ECM 
scaffolds should be determined for each scaffold and application (bearing in mind 
clinical use).  
 
1.3.4. Immune response to ECM scaffolds  
Variables that affect the host response include manufacturing process, the rate 
of scaffold degradation, and the presence of cross species antigens. In spite of 
extensive measures taken to de-cellularise tissues in the preparation of ECM 
scaffolds, the complete elimination of all cell membrane and nuclear material is very 
difficult and perhaps impossible.   
 The long term immune response in the host of implanted ECM scaffold has 
yet to be fully elucidated, but includes chronic inflammation, fibrosis, scarring and 
encapsulation or acute inflammation and immune response followed by site 
appropriate tissue remodelling (53). An immune reaction to biomaterials starts with 
the immediate recruitment of protein adsorption onto the biomaterial surface, this in 
turn attract neutrophils followed closely by macrophages resulting in a fibrotic 
encapsulation or smart remodeling (54).  
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A host immune reaction to a biological ECM scaffold is both acquired and 
innate and is material specific (initial source of the ECM and the methods used to 
manufacture it). This device specificity was highlighted in a recent study investigating 
host immune response to five commercially available ECM based devices (53) and 
concluded that scaffolds composed of ECM differ noticeably in the elicited host 
immune response. This made also clear that traditional histological methods of 
evaluating the host response are not necessarily predictive of the long term 
remodelling outcome (55). Use of ECM scaffolds that are completely de-cellularised 
and not cross-linked has been proven in most cases not to induce fibrosis or results in 
noticeable voiding dysfunction (56). 
Immediately following implantation of the ECM scaffolds in vivo, there is an 
intense cellular infiltrate consisting of equal numbers of polymorph nuclear 
leukocytes and mononuclear cells. After 72 h post implantation, the infiltrate is almost 
entirely mononuclear cell in appearance with early evidence for neovascularisation 
(57). Between days 3 and 14, the number of mononuclear cells increases, 
vascularisation becomes intense, and there is a progressive degradation of the non-
cross-linked scaffold with associated deposition of host derived neomatrix. Post 14 
days, the mononuclear cell infiltrate diminishes and there is the appearance of site 
specific parenchymal cells that orient along lines of stress (56).  
 
1.3.4.1. DNA-induced response  
As mentioned earlier it is highly unlikely that all cellular or nuclear material 
will be effectively removed from biological scaffolds, especially from relatively dense 
tissues (e.g. dermis). DNA residual in bioscaffolds has been suggested to be 
responsible in some cases for the inflammatory reaction after implanting in patients or 
animals (53). Remnant DNA found in most commercially available ECM is short 
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strand DNA of less than 300 base pairs. (58). The quantity of remaining DNA after 
reaching a certain threshold may influence the process of ECM remodelling or induce 
an inflammatory response (53).  
 
1.3.4.3. Th1 and Th2 lymphocyte response 
Several studies have examined the role of Th1 and Th2 lymphocytes in cell 
mediated immune response to ECM grafts. Activation of the Th1 pathway produces 
interleukin – 2 (IL-2), interferon gamma (IFN") and tumour necrosis factor beta 
(TNF#) leading to macrophage activation, stimulation of complement fixing 
immunoglobulin (IgG) isotypes (2a and 2b) and differentiation of CD8+ cells to a 
cytotoxic phenotype. Activation of this pathway is associated with both allogeneic 
and xenogeneic transplant rejections. The Th2 lymphocyte response produces IL-4, 
IL-5, IL-6 and IL-10, cytokines that do not activate cytotoxic macrophages and lead to 
the production of non-complement fixing antibody isotypes (IgG1). The Th2 pathway 
is associated with transplant acceptance. In summary, the immune response to ECM 
scaffolds that are acellular and non-cross-linked has been partially characterized and 
suggests a Th2 restricted type of response. The pathophysiology of this response is 
unknown, but the lack of cellular component within the grafts is likely to be an 
important mediator of the host tissue response of Th2 character (53). 
 
1.3.4.4. M1 and M2 macrophage response  
 Phenotypic and functional polarization of the mononuclear macrophages 
has recently been described (59). It is similar in its polarization to Th1 and Th2 host 
response pattern. The pro-inflammatory, cytotoxic macrophage phenotype (M1) is 
characterised by pathogen killing cells and cells associated with classic signs of 
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inflammation (especially chronic one). The anti-inflammatory macrophage phenotype 
(M2), promotes immunoregulation, tissue repair and constructive remodelling. These 
two phenotypes are only distinguishable by analysis of their surface markers, and 
cytokine and gene expression profiles (60). M1 macrophages are CD68+, CCR7+ and 
CD80+ in terms of surface markers (there are some species differences though). They 
secrete large amounts of nitric oxide and other reactive oxygen intermediates, and 
copious amounts of inflammatory cytokines such as IL-12 and TNF!. M2 type 
produce high levels of IL-10 and TGF-# and arginase, and they also inhibit release of 
pro-inflammatory cytokines, scavenge debris, promote angiogenesis, and recruit cells 
involved in constructive tissue modelling. They express CD163 as their surface 
marker and no CD80 or CCR7, but again species differences exist.   
 
1.3.5. Application of de-cellularised tissues in preclinical and 
clinical studies 
 Today more than 500,000 human patients have been implanted with de-
cellularised scaffolds (61). The ECM scaffolds have been mostly used to repair or 
restore the tissues, but the first implantation of a bio-engineered trachea can be 
considered as an application towards regeneration of an organ (62). Examples of use 
of the ECM scaffolds for repair of tissues and organs in preclinical and human studies 
have been presented in Table 2 (Appendix 2).  
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1.4. Tissue engineering of the small intestine: current 
status 
The native small intestine composed of duodenum, jejunum, and ileum, is the 
most critical portion of the gastrointestinal tract. It is a complex and unique organ due 
to its digestion and gradient transport (absorption and secretion) capabilities. The 
digestion and absorption capacity of the small intestine is facilitated by its highly 
specialised columnar epithelium, which features microscopic, finger-like projections, 
known as villi, which help to increase total surface area. Brush border enzymes 
facilitate the digestion of carbohydrates as they are absorbed. In addition, each villus 
contains a lacteal and capillaries. The lacteal absorb the digested fat into the 
lymphatic system, whereas the capillaries absorb all other digested nutrients. By the 
time the remaining products have reached the end of the small intestine, almost all 
nutrients and 90% of the water have been absorbed. The smooth muscle layers of the 
small intestine are well organised and consist of an inner circular layer and an outer 
longitudinal layer. Intestinal smooth muscle helps to initiate peristalsis. Both muscle 
layers are innervated intrinsically by autonomic nerve fibres and extrinsically by vagal 
and sympathetic nerve fibres. The celiac and superior mesenteric arteries provide 
essential arterial blood flow to the entire small intestine. The organ is a rich source of 
regulatory peptides, including secretin, cholecystokinin, and somatostatin, which are 
important for the control of various aspects of gut function. The mucosal immune 
system within the small intestine is critically important for defence against toxic and 
pathogenic threats from the lumenal content (63). Such structural and functional 
complexity is partly a cause of the fact that tissue engineering of the small intestine is 
still in its infancy.  
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1.4.1. Approaches to tissue engineering of the small intestine 
 Conceptually, there are two possible approaches to tissue engineering of the 
small intestine. The first approach is to try to replicate the anatomical structure of the 
small intestine with the assumption that this will produce functional replacement 
tissue. But recapturing such complexity is almost impossible. The second approach is 
to concentrate primarily on producing a functional absorptive surface without 
necessarily reproducing the exact anatomical structure of the small intestine. While 
ultimately this is likely to be inferior to the production of functional replica tissue, 
which would be considered to be the gold standard of tissue engineering, it is likely to 
yield greater therapeutic possibilities in the short to medium term. 
The majority of studies to date have concentrated on the production of a tissue 
engineered layer of small intestinal mucosa, often referred to as neomucosa. 
Generation of an intact neomucosal layer is understandably considered to be vital for 
the manufacture of a functional replacement intestinal tissue (neointestine). However, 
it must be remembered that the function of the small intestine is also dependent on an 
adequate vascular supply and lymphatic drainage as well as coordinated peristalsis 
dependent on correctly innervated muscular layers.  
 
1.4.2. Possible source of intestinal regeneration  
 Native intestinal mucosa has an impressive capacity for replication and 
regeneration both under normal physiological conditions and following injury. This 
regenerative capacity is dependent on the activity of intestinal epithelial stem cells. 
Advances in the ability to identify and culture intestinal stem cell populations have 
made it possible to transplant stem cells onto artificial scaffolds in order to create 
neointestine.   
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1.4.2.1. Epithelial cell lineages of the small intestine 
 The epithelium of the intestine is a confluent cell layer consisting of a number 
of cell subtypes each with specialized functions that help it to perform its two major 
physiological functions: providing an effective barrier between the lumenal contents 
of the intestinal tract and underlying sterile mucosa, and efficiently absorbing 
nutrients and water from ingested food (64). The epithelial lining of the intestine is 
folded into invaginations called crypts, which vary in size, depending on their 
location, species, age and their function. In addition, the surface area is further 
increased by the formation of lumenal prominences called villi.  
 Intestinal epithelium consists of five cell lineages. Enterocytes also called 
columnar or absorptive cells, are the most abundant cell type. They are responsible for 
membrane digestion and absorption of nutrients within the lumen of gut. They are 
facilitated by the presence of microvilli at their apical surface that increase the 
absorptive surface area. Goblet cells are found scattered between enterocytes and can 
be easily identified by the large mucin filled vacuole in their cytoplasm (Fig.1). 
Enteroendocrine cells secrete peptide hormones and are found scattered throughout 
the epithelium. M (membranous or microfold) cells are antigen-sampling cells and are 
found near lymphoid follicles. Paneth cells are found at the base of crypts and are 
packed with strongly eosinophilic granules, which contain lysozyme and antibacterial 
defensins. Enterocytes, goblet cells and enteroendocrine cells become more 
differentiated as they mature and migrate upward from the base of the crypt towards 
the villous tip. Paneth cells differ and migrate down towards the crypt base (65). Once 
the epithelial cells reach the tip of the villi they undergo spontaneous apoptosis and 
are shed into the lumen or phagocytosed. In the healthy gut the net amount of 
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apoptosis equals the influx of epithelial cells migrating onto the villi per day, 
maintaining homeostasis of the epithelial cell population (66).  
 
 
Fig. 1. Epithelial cell lineages of the small intestine; the arrows indicate the direction of proliferating 
and moving towards tip of the villi enterocytes, goblet and enteroendocrine cells. 
http://medicine.emory.edu/divisions/gi/research/yang_lab.cfm 
 
1.4.2.2. Epithelial stem cells of small intestine  
 The intestinal mucosa has an amazing regenerative capacity, enabling rapid 
restoration of its physiological functions following injury. Mucosal epithelium 
undergoes a continuous rapid turnover throughout life, with the entire epithelial lining 
being replaced every 3-5 days. However the potential capacity of this mechanism is 
only demonstrated during pathological conditions when major damage has occurred to 
the intestine, for example following trauma or disease, resulting in increased epithelial 
regeneration. The ability to do this resides with the epithelial stem cells (64). This 
Vill
i 
Crypt 
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ability is now recognised as a potential therapeutic strategy for conditions where the 
absorptive and/or barrier function of the intestine are insufficient, and that recognition 
is especially strong in the new field of tissue engineering.   
 Intestinal epithelial stem cells reside in specific niches within crypts, on the 
mucosal surface also known as the ‘stem cell niche’ (67) (Fig. 1). This niche 
comprises the intestinal epithelial stem cell, neighbouring proliferating cells, and 
adjacent mesenchymal cells such as the pericryptal fibroblasts and intestinal 
subepithelial myofibroblasts. These mesenchymal cells are believed to play an 
important role in the maintenance of the stem cell population and the control and 
regulation of proliferation via the secretion of various peptides including hepatocyte 
growth factor, keratinocyte growth factor and tissue growth factor-# (67). There are 
complex signalling pathways between the different components of the stem cell niche, 
including the Wnt, hedgehog and notch pathways and understanding of this signalling 
is increasing rapidly (67) Despite the lack of well-characterised molecular stem cell 
markers, the likely location and identity of the intestinal stem cells has been 
determined using both cell morphological and functional criteria. Morphologically, 
stem cells appear undifferentiated and may exhibit embryonic cell-like features (68). 
Functional characteristics include the ability to proliferate to replicate and to 
regenerate the lineage precursors that differentiate and produce mature cell 
populations that migrate upwards from the crypt base. The regenerative capacity of 
intestinal stem cells following pathological damage has for the first time been 
demonstrated by microcolony assays after cytotoxic radiation of intestine (69). 
 Small intestinal stem cells are located in the base of the crypts (70). These 
stem cells are interspersed with Paneth cells and daughter cells, which move up the 
crypt, where they make up a population of transit cells. The transit cells in turn supply 
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mature enterocytes for the surrounding villi and replace those enterocytes that are lost 
at the villus tip (71). 
The number of stem cells per crypt has not been established and estimates vary 
between few to few tens per crypt. This variation depends on differences of opinion 
regarding what defines a stem cell, species and stage of development (72). More and 
more authors accept the fact that 4-6 intestinal stem cells may residing in one crypt 
(64). 
 Unitarian hypothesis, that a single intestinal stem cell can give rise to all 
intestinal epithelial cell lines is supported by a significant body of evidence and, 
appears to apply to both rodents and humans (67).  Stem cells, daughter cells, and 
initial transit cells retain their clonogenicity and are able to revert back to stem cells if 
the crypt is damaged and existing stem cells are lost. However, as the transit cells 
divide further they lose their capacity for clonal expansion. Furthermore, it is well 
proven that villi are derived from stem cells of more than one crypt and intestinal 
crypts are monoclonal and derived from a single multipotential stem cell (20).  
 
1.4.2.3. Organoid units 
 A major advancement for small intestine tissue engineering resulted from the 
development of a reproducible method suitable for isolating and growing small 
intestinal epithelium in primary cultures. One of the most commonly used techniques 
involves the gentle enzymatic digestion (using cocktail of collagenase and dispase) of 
tissue fragments of neonatal intestine into multi cellular aggregates, named organoid 
units (OU) that contain polarised epithelium including the epithelial and epithelial 
stem cells, surrounding a core of mesenchymal derived stromal cells (all of the cells 
of a full-thickness intestinal section). Interestingly, more extensive dissociation by 
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prolonged enzymatic action to yield single cell suspensions appeared to inhibit cell 
proliferation (73). This would appear to support the importance of maintaining the 
stem cell niche.   
Approximately 50 000 organoid units, each measuring 100-200 microns in 
diameter, could be isolated per neonatal rat intestine. In vitro culture of these 
organoids was demonstrated for up to 14 days (73). The majority of researchers have 
adopted this method as a primary technique in isolating intestinal stem cells. There is 
even a report presenting continuous in vivo observation using an optical tissue 
window for engrafted organoid units promoting intestinal regeneration (74). 
Weiser described his method where he alternatively dissociated cells using a 
citrate buffer and obtained sequential fractions of epithelial cells in a villus-to-crypt 
gradient by a series of incubations and washing of gut loops avoiding 
overmanipulation (75). Subsequent experiments demonstrated that suspensions of 
intestinal organoids transplanted into subcutaneous pockets in adult rodents could 
develop into small, short, tubular structures which consisted of a central mucin filled 
lumen surrounded by a epithelial layer (76). At the same time implantation of single 
cell suspensions did not result in the formation of cysts containing neomucosa (77). 
This neomucosa was shown to contain all epithelial cell lineages including Paneth 
cells which were not identified in six day old neonatal small intestine (76). This is of 
particular relevance as it suggests development of these cells from pluripotent stem 
cells in the transplanted intestinal organoids rather than simply from multiplication of 
more differentiated cells already in the transplanted tissue. Lactase, sucrase, 
aminopeptidase and alkaline phosphatase activity was also demonstrated in the 
neomucosa as was sodium-dependent glucose transport (78) suggesting that the 
neointestine had functional potential. In addition to the neomucosal components, 
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smooth muscle-like cells were identified adjacent to the neomucosa although they had 
not developed into discrete muscle layers (76).  
Sattar et al. demonstrated that intestinal organoids produced from human fetal 
small intestine could be successfully implanted subcutaneously into immuno-deficient 
mice to produce cysts of neomucosa similar to that described in rat models (79).   
Recently it was reported that the organoid units could also be isolated and 
promote intestinal regeneration in juvenile pigs (80)  and dogs (81).  
 
1.4.3. Animal studies in regeneration of the small intestine 
Although the study of intestinal regeneration and the attempt to tissue engineer 
neointestine is a relatively novel field of study, investigators have developed some 
creative animal models in this pursuit.  
Scaffold materials used in tissue engineering of the small intestine are either 
synthetic or natural. Natural materials have been used principally as scaffolds for 
intestinal lengthening procedures, where experiments attempting to create neointestine 
by transplanting stem cell cultures have employed synthetic scaffolds. In the field of 
small intestine tissue engineering, most studies have used synthetic polymers, (82) 
and some naturally derived SIS, acellular dermis, and collagen sponges (83).  
All studies investigating small intestine tissue engineering have used in vivo 
implantation of cell-scaffold constructs or acellular scaffolds only. This is due to the 
poor understanding of ex vivo behaviour of the intestinal epithelium and intestinal 
stem cells.  
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1.4.3.1. Intestinal lengthening using artificial tubular scaffolds  
 Joseph Vacanti and his colleagues (82) in Boston have been pioneers in tissue 
engineering neointestine using an absorbable synthetic material. Their methodology 
consisted of seeding intestinal organoid units onto a tubular scaffold made of PGA 
and PLLA. Each tube (1 cm long) was highly porous and had a mean pore size of 250 
microns to accommodate the size of the organoid units (84). The constructs were 
implanted into syngeneic rat omentum where within two to eight weeks they 
developed into vascularised cystic structures lined with intestinal neomucosa (this was 
also confirmed by other investigators) (85). Moreover, the scaffold wascompletely 
absorbed and immunohistochemical (IHC) staining for alpha smooth muscle actin 
(!SMA) was positive in the stroma adjacent to the neomucosa, suggesting of the 
appropriate reconstitution of an intestinal smooth muscle layer. S-100 stained 
neuronal cells have also been detected in these constructs. Histologically, the 
neomucosa was characterised by columnar epithelium containing goblet and Paneth 
cells. Crypt-like invaginations that resembled crypt-villus structures were also 
evident. The neointestine had the histological appearance of small bowel and severe 
biochemical features of digestive enterocyte function, mucus secretion and polarity 
have been demonstrated in these cysts. Electrophysiology studies of the neomucosa 
revealed similar transepithelial resistance values to adult rat ileum mucosa, but 
decreased active transepithelial ion-transport. The brush border enzyme sucrase and 
basement membrane protein laminin also had a similar distribution to that found in 
adult rat ileum (86). As a continuum of this prior work, the mature, vascularised cysts 
were placed in continuity with the gastrointestinal tract following an 85% enterectomy 
in rats. Most compelling was the rapid return to preoperative weight in the animal 
implanted with tissue engineered cysts when compared with the animals undergoing 
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small bowel resection alone. Again the histology of the harvested anastomosed cysts 
was similar to that of normal adjacent intestine. Anastomosis to the native small 
bowel resulted in the exposure of the neomucosa to lumenal content including 
bacteria, gastrointestinal secretions and nutrients, which coincided with the 
development of a mucosal of a mucosal immune system that contained a similar 
population of immune cells to that of native jejunum (87). The lumens of these 
engineered intestinal grafts has been maintained open for up to 36 weeks, where non-
anastomosed grafts could survive only up to ten weeks (88). The short survival time 
of similarly prepared constructs was confirmed by different group (89). Lymphoid 
aggregates similar to Peyer’s patches or isolated lymphoid follicles were identified in 
the tissue engineered cysts, but the phenotype of the follicle associated epithelium 
overlying the gut associated lymphoid tissue or presence of M cells were not reported. 
Furthermore, the neointestine was shown to have preserved expression of green 
fluorescent protein (GFP) that had been introduced into the organoid units prior to 
implantation. The inclusion of this marker strongly suggests that the neointestine was 
derived primarily from the neonatal-derived organoid units, as opposed to ingrowth of 
the adjacent recipient intestine (90). It also was demonstrated that massive small 
bowel resection contributes significantly to regenerative stimuli for the 
heterotropically transplanted tissue engineered intestine (91).  Additionally, it has 
been shown that anastomosis between the tissue engineered small intestine and native 
small bowel contributes significant trophic effects on neomucosal morphogenesis. 
Anastomosis of intestinal cysts to native intestine enhanced expression of the sodium-
dependent glucose transporter (SGLT1) (92). Mucosal growth and SGLT1 expression 
could also be augmented in this model if rats were given GLP-2 (93). This study 
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emphasizes also the importance of the growth factors (EGF,HGF and VEGF) which 
need to be considered after implantation of tissue engineered small intestine (82). 
 All this data suggests that tissue engineered intestinal cysts measuring as little 
as 10% of the length of native small intestine may be enough to provide adequate 
absorptive function in a rat model. In light of these promising results, large animal 
studies using the same approach have been initiated and have since demonstrated 
successful generation of tissue engineered small intestine from autologus tissue in a 
juvenile porcine model (80). The resulting neointestine was composed of all anatomic 
layers of the native intestine, including a mucosa, with all of the epithelial cell types 
adjacent to an innervated muscularis. In addition, the presence of intestinal stem cells 
and the corresponding mesenchymal supporting cells, intestinal subepithelial 
myofibroblasts that are thought to sustain the intestinal stem cell niche through 
mesenchyme-epithelium cross-talk was proved.  
 An intriguing variation to the Boston group approach was the implantation of 
a tubular PGLA foam scaffold subcutaneously into rats (94). The PLGA had a 
thickness of two millimetres and was supported by inner silicone tubing. After five 
weeks, the silicone tubing was removed, and the lumen was filled with intestinal 
organoid units suspended in ECM gel. All constructs examined four weeks later 
revealed spheroid cysts with evidence of intestinal mucosa within the lumen. A 
potential benefit of this approach is the efficiency by which neomucosa can be 
generated from a given sample of donor tissue. It was possible to populate nine 
scaffolds, each with an internal surface area of 0.6cm2, with organoid units extracted 
from a single neonatal rat intestine, which was a four-fold improvement in yield 
compared to the technique used by Vacanti’s group. It was also shown that 
neointestinal mucosa could be maintained for at least 12 weeks on a subcutaneous 
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PLGA scaffold, and the presence of actively proliferating cells at that point suggest 
potential for further development beyond 12 weeks (95).  
A perfusion bioreactor, fabricated using specific parameters was successfully 
designed and manufactured to keep organoid units seeded onto polymer scaffold 
viable and in differentiated state for up to two days (96).  
 
1.4.3.2. Intestinal lengthening using biological scaffolds  
 As far as cell attachment and natural cues of ECM for cellular re-population 
are concerned acellular matrices have an obvious advantage over the polymers in 
small intestine tissue engineering. The most commonly ECM scaffold used in the 
field is SIS. The use of SIS as a scaffold for intestinal engineering makes intuitive 
sense because it is an acellular matrix harvested from a gastrointestinal source. 
Unfortunately the results using SIS have generally been more mixed than when 
applying Vacanti’s method. Chen and Badylak have repaired partial and 
circumferential defects in the small intestine using either single layer or multilayered 
SIS in canine models (97). None of these scaffolds were seeded with cells or organoid 
units prior to implantation. Evaluation of the partial circumferential repairs showed no 
lumenal narrowing when followed up one year postoperatively. Histology at later time 
points demonstrated layers of remodelled wall containing a mucosal epithelium as 
well as varying amounts of smooth muscle and collagen that resembled native small 
intestine. Unfortunately, all dogs that received a tubular segment of SIS placed as 
interposition graft had significant problems, including obstruction and anastomotic 
leakage and subsequently died. The authors concluded that SIS patches can be used 
for small bowel regeneration but tubular segment replacement is not feasible.  
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 The use of rat derived-SIS as an interposition graft in an ileal loop in rodent 
model has also been reported (98). A four-ply layer of two centimetres tubular SIS 
without any cell seeding was interposed into isolated ileal loop and the authors 
experienced no complications with this material. However, up to 40% graft shrinkage 
was observed when rats were followed for 24 weeks post-operatively. Histologically, 
the neointestine wall showed three layers of mucosa, smooth muscle and serosa, 
although no neuronal cells could be demonstrated within the grafts, but re-innervation 
usually takes much longer than that (99). The pathologic finding in this study showed 
one feature of SIS graft involving early capillary growth into the graft tissue. The rich 
and rapid blood supply to the grafts is probably the responsible for graft viability and 
infection resistance.  
Similar studies performed in a rat model using Surgisis (porcine SIS) were able to 
prove innervation of three centimetres long tubular graft within 24 weeks post-
implantation (100). 
 Contradicting results were reported by Lee et al. using the same rat model. 
Here a significant shrinkage was observed and none of the implanted scaffolds 
supported significant amount of intestinal regeneration up to eight weeks post-
implantation (101).  
 De Ugarte et al. reported experience with SIS after duodenostomy in a rodent 
model and observed complete epithelialisation of a 6-mm-diameter defect by four 
weeks post-operatively (102). Nevertheless, the muscularis layer was notably absent 
in all examined species.  
 SIS showed effectiveness in intestinal patching in a rabbit model (103). 
Elliptical SIS grafts measuring six centimetres long and two centimetres wide were 
sutured to the jejunal defects as a patch graft. The grafts were covered with a 
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complete intestinal mucosa as soon as six weeks post-implantation, nevertheless the 
mortality of the study was very high due to anastomotic leakage. Significant graft 
contractions were also observed.  
 Efficacy of acellular dermal matrix for intestinal elongation in a rabbit model 
was also investigated (104). The animals survived the interposition of three 
centimetres long graft, however severe adhesions were found between the graft and 
surrounding intestine. Almost all of the grafts were completely absorbed within two to 
three months, and histological observation showed inflammation in the grafts with 
fibrinoid necroses, infiltration of a large amount of neutrophils and leukomonocytes. 
The neointestine with well-formed structures was not observed in the study. 
Therefore, it was concluded that acellular dermal matrix is not suitable as a scaffold 
material for intestinal elongation. Pahari et al. used the acellular human dermis in the 
form of tubular scaffold for intestinal patching, and showed intact mucosa with well-
formed crypts evident at six months post-implantation (105).  However when the 
same scaffold was used in elongation studies using tubular ECM all animals 
developed peritonitis and were sacrificed within one week postoperatively.  
 Parnigotto et al. (106) used homologous, two centimetres long, tubular, 
acellular matrix obtained from the gastric wall to increase the small bowel surface by 
interposition into an isolated loop of rat intestine. They proved that this method can 
support cell migration and the reconstructions of the intestinal wall without inducing 
any adverse symptoms.  
 Collagen sponge is another natural scaffold that has been used in small 
intestine tissue engineering (107). In a canine model, a portion of jejunum (5 cm) has 
been resected and reconstructed using an acellular collagen sponge, enzymatically 
processed from porcine skin, supported by a silicon stent. The stent was removed 
                                                                                   Chapter 1: Introduction! 
 
 65 
endoscopically at one month. By four months, the collagen sponge was resorbed and 
the small intestine epithelium was present overlying these grafts at harvest. However, 
no muscle layer, essential for peristalsis was present. In follow up studies, cell seeding 
of the collagen sponge with gastric smooth muscle cells, but not bone marrow-derived 
mesenchymal stem cells, seem to induce long-term formation of smooth muscle layer 
beneath the intestinal epithelium in a canine patching model (108). Also nerve and 
endocrine cells regeneration was reported by this group (109). 
 None of the naturally-derived scaffold straight forward interposition studies 
included use of organoid units. Nevertheless, one group developed a method to 
transplant intestinal stem cells to rats that underwent resection of the distal 25% of 
their small intestine (ileum). Organoid units were harvested from neonatal donors, the 
mucosa from a segment of proximal intestine (jejunum) was removed, and organoid 
units were implanted into the debrided segment of jejunum. After four weeks, the 
animals had developed a functional neomucosa, and neointestine segment was 
inserted into continuity as a substitute ileum. Postoperative measurements of faecal 
bile acid excretion showed that it was possible to reverse the malabsorption syndrome 
in this model (85). Even though this model is not suitable to help patients with 
malabsorption caused by SBS, as they need generation of intestine de novo, it shows 
the possibility of transplanting intestinal stem cells on acellular, ‘off-the-shelf’ 
scaffolds.  
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1.4.4. Limitations of current approaches and clinical viability 
of tissue engineered small intestine 
 Despite the first pioneering investigations in the field of intestinal 
bioengineering date back to the 1990’s, the initial excitement has been blunted by the 
considerable limitations encountered in the course of experimental investigations. The 
main reason for this is the complexity of intestinal anatomy and the various functions 
of the intestine.  
The technology using organoid units and synthetic scaffolds is not efficient, as 
the whole intestine of a neonatal rat is necessary to produce organoid units sufficient 
for regeneration of only few centimetres of intestine. Moreover, organoid units at this 
point can not be cultured and grown in vitro. In clinical application use of organoid 
units is hardly feasible as there is no access to fetal tissue that can be easily obtained, 
and even if it was, the problem of immunosuppression would still be valid. Harvesting 
a sufficient amount of intestinal stem cells from SBS patients is almost impossible, 
unless the organoid units could be isolated from the patients at the time of resection 
and cultured in the bioreactor to grow a sufficient amount of tissue. At this point it is 
crucial to fill the gap in the knowledge of OU behaviour in the appropriate bioreactor 
systems. At the same time humans would require a much greater absorptive area to 
overcome SBS.  
Secondly, apart from absorption the intestine exhibits peristalsis. However, 
tissue engineered intestinal constructs lack proper motility based on both 
morphological and functional criteria, which is the reason why many of the intestinal 
constructs exhibit intestinal obstruction, become dilated and result in faecal stasis and 
bacterial overgrowth due to aperistalsis. Generation of smooth muscles has been 
already reported but growing innervated tissue is very difficult and time consuming. 
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It’s important to understand that at this stage of development within the field of 
intestinal regeneration the attempts are exclusively focused on delivering new 
absorptive surface. The difficulty in re-creating peristalsis will be as big obstacle as 
regeneration of mucosal layer. Non-innervated and non-muscular bowel ould become 
obstructed within hours after intestinal interposition. It is possible that neo-mucosal 
segments will have to primarily be isolated or form a digestive pouch, and only when 
generation of Muscularis Externa is achieved the graft could be incorporated in-
between the native motile intestine.  The aim of the thesis presented here was to 
prepare scaffold and cellular ingredients for regeneration of mucosal layer only. 
However, it should be highlighted that this would not provide complete intestinal 
function in all its complexity. As a matter of fact, in many studies it has been 
suggested that the weight gain and reduced malabsorption in animal models of 
intestinal regeneration is caused by the construct slowing down the transit time due to 
amotility of the tissue engineered construct rather than increasing functional 
absorptive surface (110). 
Most of the studies using synthetic scaffolds seeded with organoid units are 
limited to rodent models with only one exception of a juvenile porcine model. This 
indicates how difficult it is to obtain sufficient amount of neointestine to perform 
interposition in animals with a bigger diameter of small intestine. Furthermore, in 
studies where biologically-derived acellular materials were used none of the scaffolds 
were shown to be seeded with organoid units. The possibility of incorporating the two 
most successful components used in both artificial and natural scaffold studies (easily 
vascularised scaffold containing natural cues for ingrowth of intestinal neomucosa 
and organoid units respectively) is exciting and is a main aim at filling this gap in the 
knowledge of intestinal regeneration. It is likely to improve the yield of intestinal 
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tissue engineering by modulating the scaffold properties in order to accelerate and 
augment neointestinal growth and development. As mentioned above, intestinal 
organoids grafted onto denuded bowel appear more successful than engraftment onto 
synthetic scaffolds as suggested by the lower number of intestinal organoids required.  
 
1.5. Aim of thesis  
The aim of the present thesis is the development of an acellular biological 
scaffold which can be used to investigate small intestine tissue engineering as a new 
approach in the treatment of chronic intestinal failure. 
Crucially, the new biological scaffold needs (i) to allow the creation of 
sufficient  lengths of neo-mucosa for SBS patients, (ii) to be fully biocompatible and 
(iii) to promote the survival of seeded and/or cultured cells.  
The fulfilment of these three criteria requires culture of the intestinal 
constructs in complex bioreactors, and the present thesis is focused on the design and 
manufacturing of such a system. In terms of validation of the acellular intestinal 
scaffolds produced by the novel bioreactor, the present thesis goes as far as to fully 
characterise the biocompatibility of the construct following implantation in vivo and 
to test the function of isolated porcine organoid units that could be used to seed the 
implant.  
Assessment of the functionality of the construct in enabling the regeneration of 
porcine neo-mucosa and of its biomechanical properties both before and after 
implantation fall outside the scope of the present thesis and are proposed as future 
work.
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Hypothesis 
Intestinal tissue can be subjected to enzymatic removal of living cells whilst 
still retaining the 3D structure and matrix properties, necessary to allow its use in 
tissue engineering.  
Successfully de-cellularised porcine ileum with attached mesentery provides 
a highly biocompatible matrix that can provide immediate blood supply post-
implantation to all parts of the scaffold.  
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Chapter 2.  
Small intestine tissue engineering using 
biological/synthetic hybrid scaffold in rat model 
 
2.1. Background and aims   
 As stated previously the biggest and most significant finding in the field of 
small intestine tissue engineering was the use of organoid units to grow the 
neomucosa when seeded onto the polymeric scaffold and implanted into the rats 
omentum (84) or subcutaneously (94). These intestinal organoids are believed to 
contain intestinal epithelial stem cells maintained in the stem cell niche which 
supports ongoing replication and regeneration of the intestinal mucosa.  
When biologically derived scaffolds were used for intestinal elongation or 
patching smart remodelling caused immediate neovascularisation, and in most cases 
grafts were rapidly infiltrated with host cells. Moreover, all three layers of intestine 
regenerated over the patch (97;103). However, the acellular, biological scaffolds were 
never combined with organoid units in order to create intestinal tissue de novo. This is 
despite the finding that coating of the synthetic scaffolds with type I collagen 
improved intestinal organoid engraftment (111). It is also noteworthy that no attempt 
has been made to combine intestinal organoid transplantation with intestinal 
lengthening procedures as part of a combined small intestinal tissue engineering 
technique. 
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Previously conducted studies in this department highlighted the possibility of 
incorporating acellular rat intestine into neomucosa regeneration. Acellular intestine 
provides the natural architecture of the intestine and ideal conditions for in vivo 
neovascularisation and therefore repopulation and survival of seeded organoid units. 
However, cell removal impaired the physical properties of the de-cellularised tissue so 
when prepared scaffolds seeded with organoid units were subcutaneously implanted 
into rat recipients most of them did not keep their lumens open over the period of 
study and failed to regenerate the neomucosa. 
One of the methods previously used to strengthen ECM resulting from the de-
cellularisation process was creating matrix/polymer hybrid scaffolds for tissue 
engineering of the heart and aortic valves in rabbit and sheep models (112).  
The aim of the experiments presented below was to generate a graft composed 
of acellular intestine seeded with organoid units, which lumen could be kept open 
over a certain amount of time in subcutaneous position in vivo. To address the issue of 
poor mechanical properties of de-cellularised rat intestine, ECM/polymer composite 
based on acellular tissue that is coated with biodegradable, porous polymer was 
developed. The hybrid scaffold (a de-cellularised rat small intestine, coated with 
porous layer of polymer) was created to make the de-cellularised rat intestine stronger 
to withstand the in vivo loading. The behaviour of the construct in vivo was tested 
when they were seeded with intestinal organoid units derived from a neonatal rat and 
subcutaneously implanted into adult rat recipients. This behaviour was compared to a 
performance of control scaffolds (de-cellularised rat intestine, not coated with the 
polymer) seeded with organoid units and implanted in a similar way. 
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2.2. Methodology  
2.2.1. Materials 
 The list of materials and equipment used in experiments described in this 
chapter is presented in Appendix 4.  
 
2.2.2. Solutions   
Solutions used in experiments presented in this chapter are described in Appendix 10.  
 
2.2.3. Animal husbandry 
All animals were maintained and handled in accordance with the Animals 
(Scientific Procedures) Act 1986 and the study performed following guidelines 
stipulated by the UK Home Office. Experiments were performed using inbred male 
Sprague-Dawley rats (Harlan UK Ltd). All animals were kept under standard 
laboratory conditions and fed a commercial pelleted diet. 
 Surgery on live rats was performed after general anaesthesia using 0.25ml 
intramuscular Hypnorm (0.315mg/ml Fentanyl Citrate and 10mg/ml Fluanisone) and 
1mg intraperitoneal Diazepam. Prior to incision, the skin was cleaned with 
Chlorhexidine solution and aseptic techniques were used subsequently. Post-
operatively, all rats received analgesia using subcutaneous Carpofen; 8mg/kg 
intramuscular Gentamicin was given to all animals as prophylaxis against sepsis. Rats 
were encouraged to resume an oral pelleted diet post-operatively. Those rats that did 
not appear to be maintaining sufficient fluid intake were given supplemental boluses 
of 0.9% sodium chloride solution subcutaneously as required. Tissue was harvested 
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from animals after termination either by cervical dislocation (neonatal rats) or by 
lethal injection of sodium pentobarbitone (adult rats). 
  
2.2.4. Preparation of organoid units from neonatal rats  
 Intestinal organoid units were isolated as described by Evans et al. (73). A six-
days old Sprague-Dawley rat was sacrificed by cervical dislocation, and the entire 
neonatal small bowel was resected. The harvested intestine was opened longitudinally 
and cut into two millimetres-long segments.  These intestinal pieces were washed six 
times in 50 ml of HBSS solution, and minced into pieces smaller than 1mm3, 
transferred into 20 ml of enzyme solution and incubated at room temperature on a 
roller for 25 minutes. Subsequently the suspension was shaken vigorously and 
allowed to sediment for about one minute. The supernatant was carefully transferred 
to a new tube and pellet discarded. This process was repeated three times, clearing the 
suspension of larger debris. The cleared solution was then mixed with equal amount 
of DMEM solution and centrifuged for three minutes at 300rpm at room temperature. 
Supernatant was discarded and pellet was washed with DMEM solution three times 
more, centrifuging in between the washes. 100$l of the suspension was used for yield 
analysis and the rest was resuspended in growth medium. Yield of isolation procedure 
was measured by counting (using hemocytometer) organoid units in one millilitre of 
solution after adding 0.4% trypan blue.  
Each 200$l of the organoid units suspension was supplemented with one volume of 
ice cold ECM and used for the seeding of one scaffold.  
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2.2.5. Preparation of biological/synthetic hybrid scaffold  
 The whole length of small intestine and colon was harvested from adult 
Sprague-Dawley rats and washed thoroughly in 0.9% saline solution. This intestinal 
tissue was transferred to Tissue Science Laboratories-TSL (UK) for further 
processing. There the specimens underwent a patented process of de-cellularisation 
and cross-linking in order to preserve the tissue architecture and prevent 
biodegradation. In summary, the intestinal tissue was chemically defatted in acetone 
for 37 hours. It was then rinsed in 0.9% saline for 3 hours and underwent de-
cellularisation in a trypsin solution for a further 24 hours. The tissue was then rinsed 
in acetone for 3 hours and cross-linked for 20 hours (with hexamethylene di-
isocyanate: HMDI). Finally it was rinsed in acetone for 3 hours, 0.9% saline for 3 
hours, and finally sterilised and packed prior to return. The entire process was 
performed under sterile conditions. On return, the processed tissue was either fixed in 
10% NBF overnight and used for H&E analysis or used for the preparation of hybrid 
scaffolds.  
 Biodegradable polymer solution was supplied by Professor Aldo Boccaccini 
from Imperial College London. Poly(3-hydroxy)butyrate (P3HB) was dissolved in 
chloroform to final concentration of 4%. Secondly polymer solution was thoroughly 
mixed with fine brown sugar (0.2g of sugar per 0.1g of polymer) in order to create 
pores. So prepared polymer solution was used for coating experiments.  
 Glass stents were inserted into the lumens of the two-centimetres-long 
segments of de-cellularised rat small intestine. Secondly the specimens were 
dehydrated in a gradient of ethanol (EtOH) and dipped in P3HB solution supplied 
with sugar (3x5min). Subsequently scaffolds were dried in vacuo for two weeks to 
allow solvent evaporation and rehydrated in the gradient of EtOH. Glass stents were 
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removed and segments of hybrid scaffold were sterilised by UV light and stored in 
sterile PBS until the day of implantation.  
 
2.2.6. In vivo studies of hybrid scaffolds seeded with organoid 
units 
 
To investigate the mechanical and biological properties of hybrid scaffolds, 
400$l of the organoid units suspension (organoid units isolate mixed with ice cold 
ECM gel 1:1) was seeded onto each scaffold by injecting the suspension into the 
lumen of 1cm long segments of scaffolds (control and hybrid scaffolds) using a 5ml 
pipette tip. The edges of tubular segments of the scaffolds were closed with 4.0 
Ethicon sutures and so prepared constructs were implanted bilaterally (one hybrid and 
one control-uncoated scaffold) into subcutaneous pockets formed in the inguinal folds 
of two male adults 210-260g Sprague-Dawley rats within two hours. The skin was 
closed with 3/0 Mersilk® sutures and the animals were allowed to recover. After one 
and two weeks sacrificed and the grafts were explanted and prepared for histology 
using xylene-free process. 
 
2.2.7. Tissue preparation 
 Harvested tissue was fixed in 10% Natural Buffered Saline (NBF) for at least 
48 hours. Due to the fact that used polymer dissolves when exposed to xylene, tissue 
was processed to wax using an automated xylene-free processor (Table 9, Appendix 
11) and then embedded into wax blocks. Five microns sections were cut using a rotary 
microtome, mounted onto glass microscope slides using a 40-45ºC water bath, and 
left to dry at 60ºC for up to 72 hours. Prior to staining, slides with mounted tissue 
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were dewaxed and rehydrated using a xylene-free protocol. That included incubation 
in two changes of Soap Water (30 seconds each) followed by five seconds in distilled 
water (all warmed up to 90ºC). Secondly sections were rinsed in tap water two times 
for five seconds and histological staining of H&E was conducted accordingly to 
protocol presented in Table 5 (Appendix 6).                                                      
 
2.2.8. Histology  
2.2.8.1. Haematoxylin and eosin staining 
Haematoxylin and Eosin (H&E) staining was performed in order to assess 
basic implant morphology (Table 6, Appendix 7).  
 
2.3. Results  
2.3.1. Preparation of the organoid units from neonatal rats  
 The intestinal organoids isolation was performed twice prior to the constructs 
implantation and the yield of these procedures was 34 000 organoid units /ml and 64 
000 organoid units/ml (which equals 34 000 and 64 000 organoid units per isolation 
and per length of neonatal small intestine). The third batch, used for implantations had 
a yield of 52 000 organoid units/ml, which means around 10 400 organoid units were 
seeded per 1-1.5cm of the scaffold (either hybrid or uncoated).  
 The overall viability of the organoid units was ranging from 86-90% with only 
few peripheral cells dead within the clusters (that was indicated by the intake of 
trypan blue solution through the cell membrane).  
2.3.2. Preparation of biological/synthetic hybrid scaffold  
 The de-cellularisation procedures removed all the intact cells of the rat 
intestine preserving the structure of ECM, with easily distinguishable collagen of villi, 
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submucosa and serosa (Fig.2). There was some cellular debris within the scaffolds but 
as mentioned in Chapter 1 a complete de-cellularisation is almost impossible and 
small amounts of nuclear and cellular remnants (as long as they do not induce 
inflammation or rejection of an implant) are acceptable.  
 
Fig. 2 H&E of a cross section of a rat de-cellularised small intestine showing ECM layers of native 
tissue. Yellow bar indicates the scale of the image.  
 
 The surface of the tubular ECM scaffold was covered by a thin, polymer layer, 
which could be seen after separating it from the ECM scaffold using a dissecting 
microscope (Fig.3).  
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 Fig. 3 De-cellularised rat intestine coated with a thin layer of P3HB (arrow).   
 
2.3.3. In vivo studies of seeded with organoid units hybrid 
scaffolds  
All animals survived from the initial scaffold implantation to the final scaffold 
harvesting without any significant complications. The scaffolds were easily 
identifiable at harvesting as firm spheroid cyst-like structures measuring 12 mm to 17 
mm in length and approximately 5mm in diameter (Fig.4). There was slight size 
difference between test (hybrid) and ECM scaffold constructs (with hybrid grafts 
being smaller) at one week post-implantation. There was no noticeable difference in 
gross-appearance and the sizes between the two hybrid cysts. 
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Fig. 4 Cyst-like structures explanted from an adult rat one-week post-implantation. A-test-hybrid 
scaffold graft; B- graft of a control de-cellularised rat small intestine.  
 
Histological findings showed that the lumen of the control graft (uncoated 
ECM scaffold) was open at the time of first harvesting (one week post-surgery), and 
not open at two weeks post-implantation. In the case of latter H&E sections it was 
difficult to distinguish the scaffold from the surrounding tissue.  
A 
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The thickness of the polymer layer was estimated on H&E slides to be about 
30-50$m. The hybrid graft harvested one week after implantation showed extensive 
inflammation taking place on the periphery of the scaffold. Wherever the wall of the 
hybrid construct was fractured or misplaced the inflammatory cells were penetrating 
the lumen of the cyst (Fig. 5).  
 
 Fig. 5 H&E cross section of the hybrid cyst harvested one week post-implantation. Extensive 
inflammation can be seen around the graft. De-cellularised scaffold (dashed arrow) was successfully 
coated with the thin layer of polymer (dotted arrow). The plain arrow indicates the place where 
inflammatory cells infiltrate the ECM-gel-filled lumen of the cyst in the place of scaffold’s fracture. 
There is very few cells repopulating the hybrid lumen and most of the organoid units seeded into the 
lumen of the hybrid scaffold were not present anymore.  Yellow bar indicates the scale of the image. 
 
 
However, the histological analysis showed that the very few cells repopulating the 
hybrid scaffold were of inflammatory origin including neutrophils, lymphocytes and 
monocytes only without any characteristics of columnar epithelial lining.  
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At the same time the control scaffold kept the continuity of the wall and it’s 
lumen stayed open. Moreover, it showed a much higher rate of cellular infiltration 
with some of the cells lining the lumen (Fig. 6). However, abundant amounts of 
inflammatory cells were also present in the outer parts of the cyst. Also here no 
neomucosa formation could be identified.  
 
 Fig. 6 H&E cross section of the control cyst harvested one week post-implantation. Extensive 
inflammation and the beginning of fibroblasts deposition can be seen around the graft. ECM scaffold 
was repopulated with cells and some of them were lining the lumen of the scaffold (arrows).  
Neovascularisation could be seen within the scaffold (blue arrow) and within the surrounding tissue 
(yellow arrows). Yellow bar indicates the scale of the image. 
 
 In terms of histological findings there was very little difference in the 
appearance of the hybrid scaffold-grafts harvested at both of the time points. Still no 
cellular infiltration was present within the scaffold and there was evidence of 
inflammatory cells being replaced by fibroblasts. The scaffold’s lumen did not stay 
open and part of it was discontinued and folded (under the weight of fibrotic capsule) 
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towards the half that managed to keep the lumen open (Fig. 7). Some sections of the 
grafts showed large amounts of cellular remnants and apoptotic cells surrounded by 
macrophages in the centre of the lumen within the ECM gel.  
 
 Fig. 7 H&E cross section of the hybrid cyst harvested two weeks post-implantation indicating 
extensive inflammation around the graft. The scaffold was infiltrated with very few cells and no 
neomucosa formation could be seen in any part of it. The beginning of fibrotic capsule formation can 
be seen around the graft. Inflammatory cells penetrate the lumen where the wall of the tubular scaffold 
was discontinued   Yellow bar indicates the scale of the image. 
 
 
2.4. Discussion 
 Previous studies proved that biologically-derived matrices can serve as 
scaffolds that promote growth of neomucosa. Nevertheless, the process of de-
cellularisation inevitably weakened the structure of remaining ECM, which caused 
scaffolds to collapse when implanted subcutaneously into rat recipients. Therefore, it 
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was sought to combine the advantageous properties of the native ECM scaffold with 
those of an artificial polymer as it previously been done with heart and aortic valves in 
rabbit and sheep studies (112). Such solution would provide anatomically shaped 
readily implantable small intestine scaffold exhibiting physical strength, capable of 
bearing subcutaneous loads in vivo.  
 In order to check the biocompatibility of so prepared scaffolds, subcutaneous 
implantations in rat model were performed. The method of isolation of reliable 
amounts of organoid units was established by Evans et al. (73), and the yield studies 
described in this chapter had only a confirmatory character and were not an aim of the 
presented experiments. Nevertheless, it was important to establish the amount of 
organoid units that were used for seeding hybrid and control scaffolds in order to 
evaluate biological performance of the grafts and compare it to published data. The 
yield values, ranging between 30-60 000 organoid units per length of neonatal small 
intestine, were very similar to ones published in other reports (73). More thorough 
analysis of intestinal organoid units were not performed as much published data 
describing their morphology already exists. Furthermore, lack of reliable markers of 
intestinal stem cells makes it difficult to characterise stem cell populations. IHC 
staining of Musashi-1 (proposed intestinal stem cell marker) (113) has been 
attempted, but none of the antibodies currently available on the market gave reliable 
repeatable results when using control tissue (cortex and small intestine: data not 
shown), and therefore they could not be used for identification of organoid units. The 
amount seeded onto the scaffolds organoid units was calculated accordingly to 
suggested optimal seeding densities (10 000 organoid units per 1.5cm of a scaffold) in 
similar animal models (114).  
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 The process of de-cellularisation was successful and removed most of the 
cellular content of the rat intestine, leaving only some cellular debris preserving the 
structure of native ECM (Fig. 2). Even the fine collagen fibres of the villi were still 
visible in a H&E staining of a cross section of de-cellularised small intestine (Fig. 2). 
Whether these villous remnants are maintained after implantation and whether they 
have a beneficial effect on the generation of neomucosa can only be postulated. It is 
certainly possible that they would aid the regeneration of crypt-villus architecture.   
All the de-cellularised segments of rat intestine that were destined to become 
hybrid scaffolds were successfully coated with a thin layer of P3HB, which was 
shown on histology slides of harvested grafts (Fig. 5). Nevertheless, both of the 
hybrid constructs failed to stay intact and open and H&E sections showed that the 
wall of the both scaffolds was fractured or missing. This could be caused by the 
dense, growing fibroblasts population gathering at the outside of the scaffold and the 
fact that P3HB has been reported rather brittle and shown decreased bending stiffness, 
which does not makes it very suitable for soft tissue applications (112). On the other 
hand, the lumen of the control scaffold was able to stay open but only as long as the 
surrounding tissue was composed of inflammatory cells and not densely packed 
fibroblasts. The coating thickness was deducted from H&E slides and was estimated 
at about 30-50$m. Such thickness is comparable to the coating of more dense ECM 
scaffolds (for example sheep heart valves) (112) and might have not been ideal for the 
fragile ECM of rat intestine.  To incorporate more adequate coating or impregnating 
techniques (112) much more complex laboratory requirements would be necessary.  
 Interestingly the rate of cellular infiltration was much lower within the hybrid 
scaffolds than within the un-coated controls. The hybrid scaffolds were hardly 
infiltrated with any cells where control graft at one week post-implantation showed 
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even cellular repopulation with inflammatory cells (Fig 5. vice 6. and 7.).  At both 
time points all the scaffolds were surrounded by the layer of dense inflammatory cells 
but that layer seemed thicker and much more compact in the hybrid grafts. It was 
obvious that both kinds of the scaffolds induced a brisk extensive inflammatory 
reaction, which at one-week post implantation is a common outcome. However, the 
two-week old graft of the hybrid scaffold showed the beginning of a fibrotic capsule 
formation, which is a characteristic of foreign body reaction rather than constructive 
remodelling. It has been shown that P3HB can induce a prolonged acute and chronic 
inflammatory response (115) so the choice of polymer could have been wrong for that 
particular application. The extensive inflammation caused by the control graft could 
be a result of cross-linking, which as mentioned before can induce a foreign body 
reaction towards the implanted matrix. Moreover, attachment of organoid units to the 
scaffold is critical for survival and proliferation of seeded cell populations, and cross-
linked acellular scaffolds were proven to have worse biocompatibility properties than 
non-cross-linked ones. 
Seeded intestinal organoid units did not cause any mucosa regeneration. What 
is more, hardly any cells could grow within the scaffolds. It seems that the choice of 
the rat strain could cause the immune reaction towards the seeded organoid units. 
When inbred Lewis rats were used in previously conducted studies no host reaction 
towards organoid units derived from the neonatal donor rat was seen. In this study 
some sections of all the grafts showed extensive immune reaction towards remnants 
and apoptotic cells suspended in the ECM gel within the lumen of the cysts. It was 
speculated that ECM gel can exhibit growth of epithelial cells derived from organoid 
units (73), however similarly designed study to the presented one proved it wrong 
(116). Most of the cases of neomucosa regeneration state that the minimum time 
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needed for its generation is two to four weeks (20), but considering the fact that only a 
small amount of inflammatory cells could be seen at the lumen of the control scaffold 
at one week post-implantation, it is very unlikely that neomucosa would form within 
next couple of weeks.  
In general the outcome of control implants was much better than the hybrid 
grafts. The application of synthetic/natural hybrid scaffold for subcutaneous 
implantations of organoid units and neomucosa regeneration was unsuccessful, but 
acellular matrix on its own could not survive physiological loading at the place of 
grafting. All the scaffolds within the presented rat model failed to provide an 
environment in which the organoid units could survive and generate neomucosa, and 
therefore the other aspects of intestinal regeneration were considered.  
The de-cellularised porcine intestine is much stronger, and what is more, 
subcutaneous implantations are of very limited use in swine models. Therefore there 
is no need for mechanical strengthening of the porcine scaffold. If the methodological 
limitations of the study start to arise, and the ‘proof-of-concept’ using simple 
experimental model, the transition to more complicated, large animal model, is 
advisable. Therefore, it was quite obvious that transition into porcine model, which 
would not require a polymer coating, was the next step. The de-cellularised porcine 
intestine is much stronger, and what is more, subcutaneous implantations are of very 
limited use in swine models. Thus, a decision to move into animal porcine model that 
more closely resembles human anatomy and physiology was made. Promising results 
in simultaneous development of pig-derived scaffold for small intestine tissue 
engineering justified that decision even more.   
 
                                           Chapter 3: De-cellularisation of porcine intestine! 
 
 87 
 
Chapter 3. 
De-cellularisation of a segment of porcine small 
intestine with its attached vasculature as a 
single entity 
 
3.1. Background and aims   
In recent years bio-engineered products have become viable treatment option 
for the repair and regeneration of tissues and organs. Nevertheless, the principles of 
tissue engineering meet many limitations when applied to the restoration of the 
functionality of more complex organs such as the heart, liver or intestine (117). Tissue 
thicker than 0.8mm requires growth of blood vessels to supply all cellular components 
with oxygen and nutrients to inhibit graft degeneration and cell death after 
implantation (118). De novo creation of thick tissues consisting of a few layers, and 
their in vivo implantation require generation of vascularized bio-elements.  
Complex structures require not only neo-vascularisation at a capillary level but 
they also need to be provided with a whole network of vessels, consisting of 
implantable, large, feeding pedicles dividing into smaller vessels and capillaries.  
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The small intestine is an organ that is not only very sophisticated in its 
morphology, but also its function is length dependant. SBS patients have 100-150 cm 
of functional bowel and another 50-100 cm could wean them off the PN (119). 
Therefore, creating a single construct smaller than 50 cm in length may not be 
regarded as a clinically viable treatment for SBS patients who have undergone 
multiple, surgical interventions. Unless the method to provide the appropriate vascular 
supply to the engineered intestine is established, its dimensions will be restricted by 
the diffusion distances (120). Solid organs such as intestine have an intricate vascular 
tree, which, through a series of branching vessels, forms a pervasive capillary network 
that ensures that all cells in the organ are no more than 1mm from nutrient and oxygen 
sources (121). Researchers have used various techniques in polymer biochemistry and 
scaffold design (122) to mimic the structure of this vascular network in engineered 
tissues. However, these efforts have fallen short of producing scaffolds that contain a 
vascular tree with centralized inlet and outlet vessels that are suitable for implantation 
and capable of nutrient and gas exchange.  
The above problem was approached by the preparation of ready to re-
vascularise scaffold-construct developed primarily for bio-engineering of long 
segments of small intestine. Using a completely novel approach, up to 30 cm segment 
of porcine ileum with attached vasculature was de-cellularised via perfusion. The 
preserved ECM of the intestine and mesenteric vessels could allow future culturing 
and growth of two different types of tissues (intestinal epithelium and endothelial 
cells) possible. Such a construct could provide absorptive function immediately after 
implantation.  
The generated scaffold was evaluated using histological, IHC and molecular 
tools. The aims and methods for evaluation of the scaffold as well as the tests that 
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were not performed are gathered in Table 10.  The aim of the scaffold analysis 
presented in this chapter was to show a completely de-cellularised construct that 
maintained its 3D integrity and functional elements post-treatment. The following 
chapters present biocompatibility of the scaffold upon implantation.  
Table 10. Evaluation of acellular intestinal scaffold. 
'
,EFGH'IJ'*&:'
KLMJJIGH'FNMGOMPEIQ'
'
/J'
PFKPFH'
:FPRIH'OKFH'
Quality of de-
cellularisation 
Yes H&E, DAPI staining 
Quality of collagen Yes 
Picro Sirius Red staining and polarised light 
microscopy 
Quantity of collagen  No - 
Distribution of collagen  Yes IHC: ColI and Col III staining 
Quality of elastin Yes  Miller’s elastin staining 
Quantity of elastin No - 
Quantity of GAGs Yes 
BLYSCAN quantification of sulphated 
GAGs in fresh tissue 
Residual DNA Yes DNA isolation and separation o agarose gel 
Biomechanics No - 
Biocompatibility Yes 
In vivo implantation into rat and porcine 
recipient; and histological and IHC analysis 
of the implants 
 
The results indicate the practicability of generating ready-to-implant scaffold 
for small intestine tissue engineering.  
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3.2. Methodology  
3.2.1. Materials 
 The list of materials and equipment used in experiments described in this 
chapter is presented in Appendix 4.  
3.2.2. Solutions   
Solutions used in experiments presented in this chapter are described in Appendix 
12.  
 
3.2.3. Animal husbandry 
All animals were maintained and handled in accordance with the Animals 
(Scientific Procedures) Act 1986 and the study performed following guidelines 
stipulated by the UK Home Office. Experiments were performed using Large White 
Landrace crossbreed pigs. All animals were kept under standard laboratory conditions 
and fed a commercial pelleted diet. 
 Prior to surgery, pigs were given intramuscular injection of Ampicillin LA 
(25mg/kg) and a subcutaneous injection of Ivermectin (0.2mg/kg) to kill any internal 
or external parasites. On the day of surgery, the pig was given premedication of 
Ketamine (5mg/kg) and Xylazine (1mg/kg) intramuscularly. Anaesthesia was induced 
and maintained with Isofluorane over nitrous oxide and oxygen delivered by 
endotracheal intubation. Anaesthesia was monitored throughout the procedure by 
recording the pulse rate and core body temperature. Any adverse clinical signs were 
recorded. At the end of the harvesting procedure pigs were terminated by lethal 
injection of sodium pentobarbitone (100mg/kg).  
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3.2.4. Harvesting of porcine tissue  
Following intravenous administration of heparin (7 000 U) in a 60-65kg Large 
White Landrace crossbreed pig a midline incision was created and segment of ileum 
was isolated together with its attached vascular supply approximately 20cm in length. 
Residual lymph nodes in the mesentery were dissected; keeping the whole specimen 
leak proof; the distal end of pedicle was tied off and isolated. The proximal end of the 
artery was cannulated with a 14G Radiopaque I.V. cannula and flushed with 0.9% 
sodium chloride (NaCl) containing heparin (2 000U) until there was no blood in the 
outflow at the proximal end of the vein. To maintain intralumenal pressure within the 
vasculature and maintain their lumen’s open, a pulsatile pump perfusing heparinised 
(2000U/l) 0.9% NaCl through the pedicle was attached to the arterial cannula. All 
vessels not involved in supplying the section of the small intestine that was to be 
harvested were tied off, and the whole tissue segment was removed from the animal. 
At the end of the procedure, the animal was terminated by intravenous overdose of 
anaesthesia. The vascular circuit was checked for any leakage and the intestinal lumen 
was flushed with 1 litre of 0.9% NaCl. At both ends of the ileac segment, silicon tubes 
were attached with purse-string sutures, and this segment of small intestine was 
attached to the second perfusion circuit. The harvested specimen was then ready for 
de-cellularisation.  
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3.2.5. Development of a protocol for simultaneous de-
cellularisation of porcine small intestine together with its 
vasculature  
 Immediately after harvesting, heparinised saline solution was flushed through 
the vasculature and de-cellularising solutions were introduced into the two separate 
circuits of the specimen. Circuit I was attached via a cannula into the main artery and 
exited via the main vein and circuit II was attached to the silicon tubes tied to each 
end of the explanted segment of ileum.  
 The optimization of the de-cellularisation protocol involved application of many 
different agents, such as 0.05-0.2% trypsin solution, Triton X-100 solution, Triton X-
100 solution followed by nucleases (deoxyrybonuclease I: DNaseI) treatment, 0.075-
1.5% SDS solution, SDX solution, one or two cycles, and combined SDS and trypsin 
treatment (1-3 cycles). The outcome of each process was evaluated using H&E and 
Picro Sirius red stainings as well as checking the amount of remaining DNA. The 
optimal de-cellularisation protocol is presented in Table 11.  
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Table 11. De-cellularisation of small intestine and its vascular pedicle. 
 CIRCUIT I AND II 
Solution Time Temperature 
1. 0.075% SDS solution 90min 25°C 
2. Antibiotics solution 3 changes; 15 min each 25°C 
3. 0.05% Trypsin solution 90min 37°C 
4. Antibiotics solution 3 changes; 15 min each 25°C 
5. DNase I solution 120min 37°C 
6. Antibiotics solution Overnight 4°C 
7. 0.075% SDS solution 90min 25°C 
8. Antibiotics solution 3 changes; 15 min each 25°C 
9. 0.05% Trypsin solution 90min 37°C 
10. Antibiotics solution 3 changes; 15 min each 25°C 
 Circuit I 
11. Antibiotics solution Till the end of process 25-37°C 
 Circuit II 
11. 0.075% SDS solution 90min 25°C 
12. Antibiotics solution 3 changes; 15 min each 25°C 
13. 0.05% Trypsin solution 90min 37°C 
14. Antibiotics solution 3 changes; 15 min each 25°C 
 
 
The specimen was submerged in the solutions used for perfusion through circuit I (Fig 
8).  
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Fig. 8 Perfusion system for de-cellularisation of porcine intestine 
 
 Perfusion was conducted with a pulsatile rate of 30-60rpm throughout the whole 
process, preserving physiological direction of the intraluminal flow (intestinal: 
proximal to distal; vascular arterial to venous). The cells, cytoplasmic components 
and finally deoxyribonucleic acids were broken down by subsequent perfusions of 
SDS, trypsin and DNase I solutions, washed between each step with PBS supplied 
with antibiotics. After the last stage of the de-cellularisation process the acellular 
scaffold was sterilized by perfusing a solution of paracetic acid (PA) in PBS for three 
hours at room temperature in the laminar flow cabinet. Subsequently, the specimen 
was washed in sterile PBS supplemented with antibiotics.  
 
3.2.6. Analysis of de-cellularised tissue  
 
3.2.6.1. Macroscopic 
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Once the scaffold-construct was de-cellularised and detached from the 
perfusion circuits, care was taken to keep the vascular part of it filled with liquid in 
order to prevent fragile vessels and capillaries from collapsing. General macroscopic 
appearance of the scaffold was checked. To confirm that the scaffold could be easily 
perfused, and to visualize vessel’s ability to perfuse 0.01% Evans Blue solution was 
injected via arterial cannula and its outflow was identified on the venous side of the 
pedicle.     
 
3.2.6.2. Histological  
 Tissue for histological analysis was fixed in 10% Natural Buffered Saline 
(NBF) for at least 48 hours. Prior to sectioning, tissue was processed to wax using an 
automated processor (Table 4, Appendix 5) and then embedded into wax blocks. 
Five microns sections were cut using a rotary microtome, mounted onto glass 
microscope slides using a 40-45ºC water bath, and left to dry at 60ºC for up to 72 
hours. Tissue that was to undergo IHC was mounted onto slides coated with 3-
aminopropyltriethoxysilane (APTS) to improve adhesion. Prior to staining, slide 
mounted tissue was dewaxed and rehydrated using a standard protocol (Table 5, 
Appendix 6).  
Histological analyses were conducted on scaffolds prepared using protocols 
undergoing optimisation (n=1 for each of the protocols) and on scaffolds prepared 
using the optimal one (n=3). A whole segment of the main vein and artery, as well as 
seven samples from the mesenteric vascular arcade and ileal segments of the acellular 
scaffold were selected for histological analysis (Fig 9). The remaining part of the 
specimen was frozen in liquid nitrogen and stored at -20°C for molecular analysis. For 
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comparative studies samples of control intestinal tissue, harvested from animals at the 
same age and of the same weight were prepared. 
 
Fig 9. Layout of sampling sites for histological analysis in porcine acellular scaffold. I1-7: samples of 
ileum, V1-7: samples of vasculature. 
 
Haematoxylin and Eosin (H&E) staining was performed in order to assess 
basic tissue morphology and as a control for the decellularization process (Table 6, 
Appendix 7).  
Picro-Sirius Red staining was employed in order to identify collagen in the 
tissue and acellular scaffolds and to asses its status using biofringed light under light 
microscope. Miller’s elastin was used to visualize elastin within the vasculature of de-
cellularised tissue (Table 7, Appendix 8).  
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Sections of the scaffolds obtained using the optimised protocol also underwent 
4’,6-diamidino-2-phenylindole (DAPI) staining to visualise any remaining nuclear 
material. All histological sections of the specimen were compared with native tissue. 
 
3.2.6.3. Immunohistochemical 
Indirect IHC was performed to visualise the expression of collagen I (Col I) 
and collagen III (Col III) and to track changes in the presence and layout of the two 
types of collagen abundant in small intestine before and after de-cellularisation.   
Prior to IHC staining all sections were dewaxed and rehydrated in a gradient 
of alcohol solutions. Any necessary antigen retrieval was carried out at this point. All 
sections were treated with a solution of hydrogen peroxide (H2O2) in methanol 
(MeOH) to block endogenous peroxidase activity before being washed with adequate 
wash buffer 3x3min. Sections were then treated with non-specific block to prevent 
non-specific staining before being incubated with the primary antibody. The primary 
antibody was conjugated with a species-appropriate biotinylated secondary antibody 
and Avidin-Biotin-Complex (ABC), or with species-appropriate universal secondary 
antibody kit (ImmPress Kit). Following 3x3min wash immunoreactivity was 
visualized with a 3’, 3-diaminobenzidine (DAB) substrate. Finally sections were 
washed for five minutes in distilled water and counterstained with Harris 
haematoxylin, dehydrated, cleared in xylene and mounted with cover slips. Specific 
IHC protocols are summarised in Table 8 (Appendix 9).  
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3.2.6.4. Molecular  
Samples obtained from scaffolds produced while optimizing de-cellularisation 
process (n=1), using optimal protocol (n=3) and samples harvested from control 
native small intestine underwent DNA isolation and quantification. The amount of 
GAG’s surviving the de-cellularisation process was checked in scaffolds produced 
using combined (optimal) protocol, and compared to the amounts found in native 
small intestine (n=3).   
 
3.2.6.4.1. DNA  
Samples of the scaffolds and control tissue were defrosted and 0.025g of each 
was used for DNA isolation using GenElute Mammalian Genomic DNA Miniprep Kit 
according to manufacturer’s instructions. Isolated DNA was stored at -20°C until 
further use.  
Electrophoretic separation of DNA was conducted in order to show the 
presence of DNA in the samples of acellular bowel and to compare the amount of 
DNA remaining within the scaffold while optimizing de-cellularisation process. DNA 
was separated on 1% agarose gel in Tris-acetate ethylendiaminetetraacetic acid (TAE) 
buffer for 2h at 100V. Subsequently, the gel was stained with ethidium bromide 
solution for 15 min. The gel was viewed and photographed on a long wave A) 
transilluminator.  
The amount of DNA residual in the vascular and intestinal part of the scaffold-
construct as well as DNA isolated from native ileum and vessels were quantified 
using spectrophotometer (absorbance (AD)=260, AD260/280). 
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3.2.6.4.2. GAG’s isolation and quantification 
The quantity of GAG’s in acellular scaffold was tested using Blyscan 
Sulphated Glycosaminoglycan Assay according to the manufacturer’s instructions. 
The assay was used to calculate the total sulphated glycan content according to 
spectrophotometric (656nm) absorbance values of sulphation level (dye-binding 
capability) as calculated using the supplied assay standards (range 2-50$g/ml) of 
GAG’s. GAG’s were isolated from 3 different batches of specimen, and the 
concentration was calculated using a standard curve. The results were presented as 
$g/g of wet weight. Values obtained for the acellular scaffold were compared to 
values for control porcine intestinal tissue. 
 
3.2.7. Statistical analysis  
All continuous data was expressed as the mean ± Standard Error of the Mean 
(SEM) and p<0.05 was taken as significant. p Values were estimated using one-way 
Analysis Of Variance (ANOVA) with post hoc Tukey intergroup comparison, and all 
computations were performed using GraphPad Prism 4 software.  
 
3.3. Results  
3.3.1. Development of a protocol for de-cellularisation of 
porcine small intestine together with its vasculature  
A procedure was developed whereby segments of ileum together with an intact 
vasculature could be harvested. The de-cellularisation reagents were successfully 
applied via the organ’s vasculature, and the perfusion of the whole segment of ileum 
could be maintained during the whole process. Few vessels within mesenteric arcade 
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that showed some leakage were tied off whilst undergoing de-cellularisation. The 
application of other solutions than the ones used in the final optimal protocol resulted 
in various amounts of cellular and nuclear content remaining within the tissue after 
the process. Briefly, high concentrations of trypsin damaged collagen and lower ones 
resulted in an abundant amount of DNA and cellular remnants in the de-cellularised 
tissue. Triton X-100 was successful in removing nuclear content only when combined 
with nucleases treatment, but even then the removal of the cellular debris from the 
tissue was incomplete. Nevertheless, it was the least disruptive protocol in terms of 
ECM structure. Application of single cycle of SDX was unsuccessful in removal of 
cellular and nuclear content. The outcome was better when two cycles were applied. 
Yet in comparison with SDS treatment it was unfavourable in terms of collagen 
degradation.  
Joint enzymatic-chemical process allowed the continuity of the cell membrane 
to be broken and then digestion using proteases and nucleases of the cellular 
remnants. However, only the application of three cycles was successful in removing 
cells and DNA from the intestinal part of the scaffold. Such treatment was too harsh 
for the fragile ECM of the mesenteric arcade and intestinal capillaries. They were 
shown to be completely de-cellularised after only two cycles of combined protocol 
(trypsin and SDS). Thus, after the second cycle of de-cellularising reagents the two 
circuits (intestinal and vascular) were separated and the process followed as described 
previously (Table 11).  
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3.3.1. Analysis of de-cellularised tissue  
3.3.1.1. Macroscopic 
De-cellularised ileum and its vasculature maintained its overall shape and 
macroscopic structure (Fig. 9). During the de-cellularisation process, the specimen 
continuously lost its natural colour until it became translucent beginning with the 
mesenteric arcade, and then the intestine. The de-cellularised bowel dilated showing 
0.5-1.5 fold increase in length and ~0.5 fold increase in diameter. The measurements 
of the de-cellularised intestinal segment are presented in Fig. 10, which should be also 
treated as a scale reference for any following macroscopic photographs of the 
scaffold.  
 
Fig. 10 Average reference scale of the macroscopic view of the acellular segment of small intestine 
with intact mesenteric arcade. 
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Injection of 50ml of Evans Blue solution into the vascular pedicle, via the 
arterial cannula revealed that the perfusability of the capillaries within the de-
cellularised ileum was preserved throughout the process and venous outflow of circuit 
I was viable at the end of de-cellularisation process (Fig. 11).  
 
 
 
 
 
Fig. 11 Vasculature of the scaffold visualized by the injection of 0.01% Evans Blue solution. Whole 
scaffold was perfused by the dye (A), including capillaries within the intestinal part (B). Following 
fluid injection the clamped main vessel expanded as shown (arrow) (C). 
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3.3.1.2. Histological   
 H&E and DAPI stains were used as a first line of inspection to determine if 
remnant nuclear structures could be observed. Picro Sirius red and Miller’s elastin 
stains revealed the state of the remaining ECM after de-cellularisation. Following 
Picro Sirius red staining the intensity of the biofringence increases proportionally to 
collagen fibres thickness. Therefore the comparison of control, native tissue with de-
cellularised intestine could show the rate of the collagenous fibres destruction. When 
viewed using polarised light the thick fibres are usually yellowish-orange-to-red and 
thin fibres are green (112). If the native tissue would contain mostly orange and red 
fibres and the scaffold only green fibres it could be concluded that the de-
cellularisation process visibly destructs the collagen structure.  
 
3.3.1.2.1. H&E and DAPI 
H&E staining revealed that no remaining intact cells could be seen at the end 
of the process in any parts of the specimen. Throughout the preserved vascular arcade 
neither endothelial cells nor smooth muscle cells could be seen (Fig. 12). The 
intestinal part of the scaffold was also cell-free, showing only the eosinophilic 
staining of the collagen. Furthermore, the histological structure of the intestinal layers 
was preserved, showing serosal, submucosal and ECM of intestinal crypts and villi 
(Fig. 13). 
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Fig. 12 Representative H&E stained section of the main pedicle showing the absence of nuclear and 
cellular staining after de-cellularisation. A- native vessel supplying ileum; visible purple haematoxylin 
staining indicates nuclei of endothelial cells lining the lumen (black arrows) and smooth muscle cells 
within the vessel wall (yellow arrows); B- de-cellularised vessel supplying the ileum with no nuclei 
stained within the lumen or the vascular wall. 
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Fig. 13 Representative H&E stained section of native and acellular ileum. A - cross section of the 
native ileum with visible haematoxylin-stained nuclei and eosin-stained cytoplasm of intact cells; B - 
de-cellularised ileum with no eosin staining of cytoplasm or haematoxylin-stained nuclei, and 
preserved histological layout of intestinal tissue, including organised ECM crypts and villi (arrows 
indicate obvious acellular crypts). 
 
No nuclei were evident by DAPI staining in the vascular part (Fig. 14) and the 
intestinal part of the scaffold (Fig. 15), confirming the success of the de-
cellularisation.  
Lumen 
Serosa 
Muscularis 
externa 
Submucosa 
Villi 
Crypts 
A 
Lumen 
Submucosa 
B 
                                           Chapter 3: De-cellularisation of porcine intestine! 
 
 106 
 
 
 
Fig. 14 Representative DAPI stained section of the main pedicle. A- native vessel supplying the ileum 
with visible fluorescent staining of nuclei; B- de-cellularised vessel supplying the ileum with no 
fluorescent staining of nuclei. Red arrows indicate DAPI stained nuclei.  
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Fig. 15 Representative DAPI stained section of ileum. A- native intestine with visible fluorescent 
staining of nuclei; B- de-cellularised ileum with no fluorescent staining of nuclei. Red arrows indicate 
DAPI stained nuclei. Yellow bar indicates the scale of the images. 
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3.3.1.2.2. Picro Sirius red/Miller’s elastin 
 Picro Sirius red staining showed that the organisation and status of collagen 
fibres of the arcade and main pedicle within the scaffold and native tissue remained 
similar (arterial collagen fibres are thicker - orange-to-red in colour, and venous 
collagen fibres are thinner – green-to-yellow).  
Intestinal ECM of native tissue was mostly composed of yellow, orange and orange-
to-red fibres. De-cellularised ileum predominantly contained thinner than tissue than 
native, green-to-yellow, yellow, yellow-to-orange and orange fibres (Fig. 16) but in 
general the collagen status and layout was similar in native and de-cellularised 
intestine. The histological layers of the ECM were well preserved and easily 
identifiable after the process. The removal of the cells caused a decrease in thickness 
of mucosal layer which even in native tissue is composed of very fine collagen fibres 
(Fig. 17).  
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Fig. 16 Representative Picro Sirius red stained section of ileum viewed under polarised light. A- native 
intestine composed of thick orange-to-red collagen fibres within the submucosa and thin green fibres of 
villi and crypts; B- de-cellularised ileum showing mainly yellow-to-orange collagen fibres of 
submucosa and thin, green fibres of mucosal layer.  
 
Elastin was preserved in all the parts of de-cellularised specimen, including 
internal elastin within arteries and veins, as well as external elastin within the arteries. 
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What is more, the elastin of small vessels within the acellular ileum was also present 
(Fig. 17).  
 
 
 
 
Fig. 17 Representative Picro Sirius red/Miller’s elastin stained section of ileum. A- native intestine 
with easily distinguishable histological layers, thick mucosal layer (double arrow) and blue-stained 
elastin of intestinal vessels within the submucosa (arrows); B- de-cellularised ileum showing all 
histological layers, thinner than in native tissue mucosal layer (double arrow) and blue-stained elastin 
of intestinal vessels within the submucosa (arrows). 
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3.3.1.3. Immunohistochemical 
 IHC staining of Col I and Col III showed that both types of collagen are 
present in a de-cellularised specimen. There are no changes in the distribution of Col I 
(Fig. 18) and Col III (Fig. 19) between normal ileum and acellular scaffold.  
 
 
 
Fig. 18 IHC staining (brown, double arrow) of Col I within control porcine intestinal tissue (A), and 
de-cellularised porcine ileum (B).   
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Fig. 19IHC staining (brown, double arrow) of Col III within control porcine intestinal tissue (A), and 
de-cellularised porcine ileum (B).  Yellow bar indicates the scale of the images. 
 
3.3.1.4. Molecular  
A 
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3.3.1.4.1. DNA   
 While optimizing the de-cellularisation protocol the amount of residual DNA 
in the tissue after the process was checked with every change in the protocol. None of 
the protocols completely removed all DNA. However, based on histological and 
molecular findings the most successful protocol was chosen. Use of Triton X 100 or 
trypsin resulted in significantly larger amounts of remaining in the scaffold nuclear 
material, than when ionic detergents (SDS, SDX) or their combinations (SDS and 
trypsin) were applied (Fig. 20).  
 
 
Fig. 20 DNA quantities in control ileum and tissue de-cellularised using different protocols while 
optimizing the process; lanes contain DNA extracted from: scaffolds prepared using 0.2-0.05% trypsin 
solutions (Trp), Triton X100 with (Tx100/Nucl) or without nucleases (Tx100), 0.075-1.5% SDS, one 
(SDX) and two (SDX2nd) cycles of SDX, one, two or three cycles of combined SDS-trypsin protocol 
(SDS/Trpx1-3), as well as control ileum (Ctr), and porcine ileum de-cellularised using commercial 
protocol (TSL). M- molecular marker.  
 
Residual DNA was detected in both vascular and intestinal part of the scaffold 
prepared using the optimised protocol (Fig. 20). Quantitative analysis of DNA content 
within the scaffold showed a significant decrease in the amount of detectable residual 
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DNA in the native tissue. The amount of DNA found in the intestinal part of the 
scaffold was 3.9 ± ng/mg of fresh weight, which constituted to only 0.75% of the 
DNA found in native tissue (0.74 ± 0.17$g DNA/mg tissue). The amount of DNA 
characterised in the de-cellularised vessels was also significantly lower (decrease of 
99%) in comparison with the native specimen (3.7 ± 2.4ng DNA/mg fresh scaffold 
versus 0.36 ± 0.08$g DNA/mg of native tissue) (Table 12).  
 
 
Fig. 21 DNA quantities in control ileum and tissue de-cellularised using optimal protocol. Lanes 1-3: 
DNA in native ileum, 4-6: DNA in native mesenteric vessel, 7-9: DNA in de-cellularised ileum, 10-12: 
DNA in de-cellularised mesenteric vessel. M- molecular marker.  
 
Table 12 Quantification of residual in de-cellularised specimen DNA and GAG’s in comparison to 
native tissues.  
Specimen 
DNA (STDEV*) 
[$g/mg] 
GAG’s (STDEV) 
[!g/g] 
Native ileum 
Native blood vessel 
De-cellularised ileum 
De-cellularised blood vessel 
0.74 (0.17) 
0.36 (0.08) 
0.005 (0.002) 
0.004 (0.002) 
3.1 (0.05) 
2.9 (0.03) 
1.1 (0.005) 
0.9 (0.03) 
*STDEV – standard deviation 
3.3.1.4.2. GAG’s  
The amount of GAG’s remaining after de-cellularisation and in control tissue 
was measured using spectrophotometric detection of sulphated GAG’s fresh 
specimen, and expressed as $g of GAG’s in a gram of fresh tissue (Table 12). The 
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quantity of GAG’s present in normal tissue ranged between 3 and 3.2 $g/g fresh 
weight (mean: 3.1 $g/g; ±SEM= 0.07 $g/g). Mean concentration of GAG’s in the 
scaffolds produced in our laboratory came to 1.3 $g/g (with minimum of 1.2 $g/g, 
and maximum of 1.35 $g/g; ±SEM=0.06 $g/g). There was a significant drop in the 
quantity of GAG’s remaining after the decellularisation. The GAG’s remaining after 
the de-cellularisation constituted 42% of GAG’s found in native tissue. 
 
3.4. Discussion 
“Bench-to bedside” translation has been widely discussed since the first 
implantations of bioengineered organs and tissues (123). The creation of specific 
constructs for specific clinical settings which are not only non-immunogenic and bio-
compatible, but also provide immediate functionality and contain internal vascular 
network, are believed to fulfil the patients’ needs (124). There are few well-
researched strategies to increase the rate of vascularisation. However, most of them 
rely on in vivo ingrowth of host vessels that can last few weeks (125), with the threat 
of ischemia and necrosis (126). At this stage of development of regenerative therapies 
and scaffold fabrication, only constructs which can be surgically or microsurgically 
connected into to the patient vasculature have chance for quick translation into clinics.  
According to Rowkema el al. (125) there are four strategies to improve neo-
vascularisation of tissue-engineered grafts: scaffold design, angiogenic factor 
delivery, in vivo pre-vascularisation and in vitro pre-vascularisation. The problems 
encountered when creating a model which would address the need for large, pre-
vascularised constructs is one of the reasons why investigation into construction of an 
artificial ileum has been a long process. Our scaffold was obtained in a way that 
allows improvement in terms of its application via integrating all four strategies and 
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creating the opportunity to direct the creation of intestinal/vascular construct. The 
structure of the scaffold enables the incorporation of two different tissues, the use of 
ECM provides the necessary cellular cross-talk molecules and immediately after 
implantation all parts of the scaffold are supplied with blood.  
Scaffolds with a preserved vascular network that have been de-cellularised via 
their vascular tree create a viable opportunity of obtaining off-the-shelf organs, which 
are ready to implant. This technique has been used to de-cellularise liver (127), kidney 
(128), pancreas (128), intestine (128), lungs (129), placenta (130), and heart (131). 
They all resulted in preserving perfusable vascular architecture and the organ 
geometry.  
Our presented scaffold also resulted in the 3D structure and molecular 
composition bein preserved using individually tailored vascular and intestinal part de-
cellularisation protocols, and at the same time removed cellular and nuclear content of 
the tissues. Although others have already reported the results of de-cellularisation of 
intestinal tissue, and use of vascular tree for delivery of de-cellularising agents, none 
of the existing protocols separated the process for the tissue of interest and its 
vasculature. What is more, none of the published results investigate in detail the state 
of the de-cellularised vascular tree of the scaffolds. The scaffold contains a perfusable 
acellular feeding artery, a draining vein and microvascular connections, which were 
analysed with the same emphasis as the ileum. The de-cellularisation of a more fragile 
vasculature was achieved quicker than the thicker and more complex ileum, that is 
why the process was divided into cycles and the amount of cycles applied to vessels 
was lower than the one introduced via a second, intestinal circuit. All segments of 
ileum and mesenteric arcade with the main pedicle were cell-free. The use of enzyme-
detergent cycles and the perfusion was a major advantage over standard water bath 
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process, which failed to remove all cells (132). The final perfusion with Evans blue 
solution proved that all the conduits within the specimen were competent following 
the de-cellularisation. The dye-experiment demonstrated that the injected fluid was 
perfusing through the intact vascular network and slowly moved from larger vessels 
to smaller capillaries. The technique presented can be applied to segments of intestine 
long enough to create viable treatment for SBS patients.  
The perfusion de-cellularisation system has several technical and practical 
advantages. It is compact in size (does not take much bench space), has a low 
perfusion volume (one litre of solution per change), little production costs, and is easy 
to handle. In comparison to other time-consuming processes this one is reasonably 
short (130). The scaffolds sterility could be achieved using simple incubation of the 
scaffold in 0.1% solution of PA and no expensive apparatuses for irradiation or 
ethylene oxide exposure are needed.  
What is more, modifications of the model could easily be used in perfusion 
and de-cellularisation of other tissues and organs. Nonetheless, one of the biggest 
advantages of this scaffold is the fact that it can be used to culture two different cell 
lines, facilitating a new level of complexity for cellular interactions and organization. 
So far this has been an unmet need in bio-engineering of intestinal tissue. 
The distinctive differences in using different de-cellularising agents emerged 
while optimising the process. Many combinations of the detergent solutions as well as 
enzymes were less successful in the removal of cells (trypsin, Triton X-100, SDX), 
nuclear content (trypsin, Triton X-100, SDX), or preserving ECM structure. Some of 
the applied methods were better in terms of preservation of the collagen and elastin; 
however, they failed to remove the nuclear or cellular components of the tissue 
(Triton X-100).  
                                           Chapter 3: De-cellularisation of porcine intestine! 
 
 118 
The use of SDS gave better results than any other detergent or trypsin 
digestion on its own. De-cellularising reagents used in the optimal protocol removed 
cellular components as well as the majority of DNA while preserving functional ECM 
proteins and structure. SDS or combined methods of SDS and enzymes have been 
reported to show excellent cell removal (133). However it was also shown that the 
treatment with SDS results in disintegration of the collagen (134) as well as 
fragmentation and swelling of the fibres (135). The influence on ECM state varies 
depending on detergent concentration, duration of treatment, presence of protease 
inhibitors and differences in tissue morphology or age (136). The separation of the 
two circuits within the scaffold was done to avoid overexposure of more fragile parts, 
and the resultant negative side effects of SDS. 
Trypsin is a serine protease commonly used as an enzymatic de-cellularisation 
agent. However, ECM proteins such as collagen have limited resistance to trypsin 
cleavage (137). Removal of cells and ECM constituents by trypsin is time-dependant, 
and complete de-cellularisation of intestinal tissue by trypsin alone would take days. 
Thus, tissue exposure to trypsin was used with caution and other agents were added in 
order to shorten the time of tissue exposure to the enzyme. In comparison to SDS, 
trypsin is more disruptive to elastin and collagen and slower to remove cells but 
shows better preservation of GAGs (134).   
Chelating agents such as EDTA aid in cell dissociation from ECM proteins by 
sequestering metal ions (138;139). EDTA alone is insufficient for cell removal, and is 
therefore typically used in combination with enzymes such as trypsin (140).  
DNase I is a nuclease that cleaves nucleic acids sequences and can therefore 
aid in removal of nucleotides after cell lyses in tissue (141). 
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The de-cullarisation process may never reach the theoretically possible 100% 
(142), but a virtually complete de-cellularised intestinal/vascular matrix was shown by 
the analysis of DNA. The DNA remaining in the scaffold constituted less than 1% of 
native tissue (both ileum and blood vessels), which is comparable to the amounts of 
DNA found in commercially available ECM used in clinical applications (143), and 
often is much less than the nuclear content found in acellular scaffolds under pre-
clinical investigation (144). Gilbert et al. (51) described the impossibility of any 
combination of de-cellularising agents to remove 100% of cellular and nuclear 
components. It was concluded that methods which remove most or all of the visible 
cellular material result in most of the cases in biologic scaffold materials that are safe 
for implantation. Crapo et al. (145) goes even further with this estimation and points 
out that the scaffolds containing less than 50ng of double stranded DNA per mg of dry 
weight of ECM, less than 200 base pairs-long DNA fragments, and no DAPI staining 
are safe to implant. DNA remaining in the presented scaffold ranged from 4-5ng/mg 
of ECM.  
While optimizing the de-cellularisation protocol care was taken in order to 
maintain the 3D integrity of the functional and structural proteins. Vascular and 
lymphatic structures, nerves and the tissue specific cells should easily find the cues 
for ingrowth and differentiation within the preserved ECM. Collagen content, status 
and distribution within the scaffold was shown to be very similar to these of native 
tissue. The thickness of intestinal layers within the ECM scaffold was lower; however 
this is unavoidable while removing the cellular components of the tissue.  
In this experimental model the existence of internal elastin within the de-
cellularised vasculature was of high importance. It is not only crucial in the process of 
re-endothialisation (and secondary in preventing blood from interacting with the 
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highly thrombogenic collagen) but also provides the elasticity to the vessels which 
prevents them from breakage while stretching under the load, and it also prevents 
fibrocellular pathology (146).   
GAG’s are important attachment and information highway molecules within 
the ECM. They are highly functionalised, linear, and negatively charged 
polysaccharides present in animal tissue, which are covalently bound to a protein core 
in macromolecular assemblies known as proteoglycans (147). A reduction in 
sulphated GAG content is observed after any de-cellularisation procedure. A 
considerable removal of GAGs from the ECM can affect the bioactivity of the 
scaffold (148). Significant amount of GAG’s (42%) was preserved, and this result is 
comparable to 15-60% range reported by others (149). What is more, the assay 
measured the sulphated GAG’s, and the de-cellularisation process may have affected 
the amount of sulphated residues of ECM.   
The host tissue response following in vivo implantation of ECM scaffolds is 
dependant upon efficacy of cells and their remnants removal, therefore adequate 
application of the appropriate de-cellularising agents, is critical. The balanced 
protocol provided little of the cellular and DNA components as possible, without huge 
compromises on the amount of functional proteins, structure of collagen and elastin 
within all parts of the scaffold.  
The use of porcine intestine as a biologically-based scaffold offers several 
potential advantages. Tissue is easy to harvest even in large quantities, in size it is 
appropriate for transplant procedure, human and porcine intestine show anatomical 
and physiological similarities, and porcine ECM surface has strong cellular adhesive 
properties (150). Moreover, this 3D supporting matrix includes vasculature which 
would allow the survival of cells that thanks to important ECM proteins such as 
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collagen, elastin and GAGs migrate into and repopulate these scaffolds. All this is 
missed in polymeric materials, which have been previously used in small intestine 
tissue engineering.  
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Chapter 4. 
Biocompatibility tests in the rodent model 
 
4.1. Background and aims   
 Since the immune response induced by bio-engineered products can decide 
their fate, it is extremely important to evaluate the implant’s biocompatibility before 
incorporating it into further studies. Animal studies provide an understanding of how 
the body responds to the scaffold, its evaluation, as well how to estimate long-term 
outcomes. Since most of the products are designed to be surgically implanted for the 
patient’s entire life, the duration of the study should extend the time when final 
clinical outcome is achieved (20). However, the biocompatibility tests should state the 
first line of reaction towards the device and therefore the time of the in vivo studies at 
this stage usually extend the transition period from the acute to chronic immune 
response. The model presented in this chapter was used to check if the acellular 
scaffold produces any immediate negative outcome in mammals, and thus it was used 
as a negative control rather than an immediately translatable into human or even 
porcine outcome. The aim was to show that the scaffold did not induce any adverse 
clinical reaction in rats, which would be linked with probability of positive outcome 
in other in vivo models. However, if the scaffold would appear to be toxic or reject 
acutely it could suggest that the same pattern could be expected in all other mammals. 
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 It is clear that species differences exist in the structure and function of the 
immune system and that these differences need to be kept in mind when designing 
experiments with the goal of extrapolating the data to humans. Taking into account 
the experiments presented in this chapter it was also necessary to identify which 
differences would be relevant for the endpoint that was considered. Therefore the rat 
model was chosen, as it is the best described one across the field of tissue engineering, 
and has been used in many biocompatibility studies (166).  The abundant data on the 
characteristics of the cell-mediated immunity in rodent models is readily available for 
comparison. The humoral immune response can be enhanced in rats in comparison to 
humans, however strain-differences exist (213). On the other hand, cellular responses 
and induction of foreign-body granulomatous inflammation (main concerns when 
considering tissue-engineered implants) have been proven to develop more severely in 
rats than in humans (213). Thus, this model makes it a good negative control for 
hyperacute and acute rejections and toxicity.  
Pig model used in Chapter 6 is not very well characterised for the immune 
responses in tissue-engineering scenarios. However, pigs in contrast to rodents are 
proven to produce Pulmunary Intravascular Macrophages (213), which is an 
additional reason (except the fact that it was crucial to check scaffold performance 
under systemic perfusion using appropriately sized animal) for conducting vascular 
anastomosis in porcine model.  
The differences between both (rat and pig) responses and human immunity 
exist, but it is important to check in vivo performance of a scaffold before 
incorporating it into further investigation. The use of animal model is sometimes more 
beneficial than use of in vitro human cultures, but one should not exclude the other 
during the scientific process.  
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 To evaluate biocompatibility in vivo, the scaffolds described in the previous 
chapter were implanted subcutaneously into nine adult male Sprague Dawley rats 
(three rats per time point; two pieces of scaffold per animal resulting in six explants 
per time point) for two, four and eight weeks. After each time point a macroscopic, 
histological and IHC analysis was conducted in order to estimate long-term outcome 
of the grafts, and assess if the acellular matrix would result in scar tissue formation or 
smart remodelling.  
 These studies were designed in a way that allowed testing of the acellular 
scaffold for its toxicity and biocompatibility, based on promoting cellular ingrowth 
and neovascularisation, and not for its regenerative potencies.  
 
4.2. Methodology  
4.2.1. Materials 
 The list of materials and equipment used in experiments described in this 
chapter is presented in Appendix 4.  
 
4.2.2. Animal husbandry 
All animals were maintained and handled similarly to the procedure presented 
in Chapter 2 (2.2.2). 
 
4.2.3. Subcutaneous implantation into rat recipients  
1cm2 squares of porcine acellular scaffold (intestinal part) were implanted 
subcutaneously into adult male Sprague-Dawley rats. All rats were weighed prior to 
surgery and later on the termination day. Weight controls, were conducted every week 
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to monitor the animals’ well-being and general health. Following a midline incision 
and creation of subcutaneous pouch, corners of two trimmed intestinal scaffolds were 
attached using 5-0 Prolene sutures to the abdominal muscle (Fig. 22). Skin was closed 
with 3-0 Vicryl (horizontal mattress suture). At two, four and eight weeks post-
surgery tissue was harvested from the animals after termination by lethal injection of 
sodium pentobarbitone. 
 
Fig. 22 Subcutaneous implantation of the trimmed porcine scaffold (arrow) into a rat recipient (day 0). 
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4.2.4. Evaluation of the grafts  
4.2.4.1. Macroscopic 
At the time of harvesting grafts were photographed, measured and their 
general appearance recorded (Fig. 23). Moreover, the surrounding tissue was checked 
for any obvious macroscopic signs of inflammation (e.g. redness, extensive fibrosis).  
 
4.2.4.2. Histological  
Tissue was processed and prepared for histological staining in the way 
described in sub-chapter 3.2.6.2. 
Full thickness of the abdominal muscle together with the sutured scaffold was 
analysed. H&E staining was performed to assess basic tissue, cell morphology and 
cell distribution within the grafts. Picro Sirius red staining was used to visualise 
collagen fibres and comparatively estimate their thickness (the relation between 
collagen thickness and the colour of Picro Sirius red stained tissue viewed using 
biofringed light is described in methods of Chapter 3). The presence of aggregates of 
dense thick (red) collagen fibres could suggest the secretion of new ECM by re-
populating cells. The implants were expected to contain green, thin fibres mostly in 
the periphery, which would mean that the ECM is undergoing biodegradation at the 
same time. Miller’s elastin staining was incorporated to visualise the presence of neo-
vessels within the grafts.  
 
4.2.4.3. Immunohistochemical  
 IHC was performed to visualise: epithelial cells (cytokeratin 8: CK8), 
proliferating cells (Ki67), neural progenitors (S-100), smooth muscle actin (!SMA), 
endothelium of the blood vessels (Factor VIII: FVIII), VEGF, and its receptors 
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(VEGF-R) in the grafts harvested at each time-point. Expression of VEGF was also 
checked in the scaffold prior-implantation. The staining was performed in a way 
described in sub-chapter 3.2.6.3. Specific IHC protocols are summarised in Table 8 
(Appendix 9).  
 
4.3. Results  
 All rats survived the operation. The scaffolds could be easily sutured onto the 
abdominal muscle. Two scaffolds were implanted into one recipient (either sides of 
the midline opening).  
 Eight out of nine rats survived the planned study period. One animal had to be 
euthanised three days before (at day 25 post-surgery) the planned termination date due 
to problems not associated with implantation. Eight out of nine animals were feeding 
well, and gained weight post-surgery (Table 13). Three rats were terminated two 
weeks after scaffold implantation, two four weeks post-surgery (and one after three 
weeks and four days) and three rats eight weeks after operation. 
 
Table 13 Weight changes of the rats with subcutaneous implants of porcine de-cellularised ileum.  
Animal Number Time of 
explantation 
Weight of the 
animal at the day 
of surgery [g] 
Weight of the 
animal at the day 
of termination [g] 
" weight 
[g] 
1. 2 weeks 409 410 +1 
2. 2 weeks 407 422 +15 
3. 2 weeks 439 462 +23 
4. 3 weeks and 4 
days 
517 407 -110 
5. 4 weeks 480 513 +33 
6. 4 weeks 572 579 +7 
7. 8 weeks 515 630 +115 
8. 8 weeks 502 557 +55 
9. 8 weeks 538 598 +60 
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4.3.1. Evaluation of the grafts  
4.3.1.1. Macroscopic 
All the grafts could be easily identified post-mortem and were still attached to 
the abdominal muscle when harvested from the animals. Sutures at the corners of the 
grafts kept them in position throughout the duration of the experiment. Macroscopic 
examination showed no major adhesions to the skin or fibrotic encapsulation of the 
grafts at any time-point.  Graft shrinkage was minimal and occurring only in the 
implants harvested eight weeks post-surgery (Fig 23).  
 
Fig. 23 Gross appearance of the grafts (arrows) harvested eight weeks after subcutaneous implantation. 
The length of the implants was oscillating around one centimetre. 
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4.3.1.2. Histological  
4.3.1.2.1. H&E staining 
H&E staining showed that as early as two weeks post-implantation all the 
grafts were evenly infiltrated with cells (mostly polymorphic, inflammatory cells) 
(Fig. 24). Signs of early neo-vascularisation were mostly visible in the parts of the 
scaffold adjoining the abdominal muscle.  
 
Fig. 24 H&E staining of the scaffold harvested two weeks after implantation showing intense cellular 
infiltration. Yellow bar indicates the scale of the image. 
 
 
H&E staining of the specimen harvested four weeks after implantation showed 
that the grafts remodelling continued, and no chronic inflammation could be seen 
within the scaffold or adjoining muscle. Cells were repopulating the whole volume of 
the grafts, and most of them no longer showed characteristics of inflammatory cells. 
Moreover, the neo-vessels could be seen in all parts of the grafts and throughout the 
Scaffold  
Abdominal 
muscle  
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whole thickness (Fig. 25). Nevertheless, most of the vasculature was still present in 
the muscle-adjoining part of the scaffold.  
 
Fig. 25 H&E staining of scaffold harvested four weeks after implantation. Black arrows indicate 
possible, newly-created blood vessels. Yellow bar indicates the scale of the image. 
 
H&E staining of the grafts harvested from the rat that did not survive till the 
planned end-point showed no extensive inflammation or immune reaction. As in the 
case of all the other grafts harvested four weeks post-implantation the cellular 
infiltration was extensive and there were signs of rapid angiogenesis (Fig. 26).  
Scaffold 
Abdominal muscle  
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Fig. 26 H&E staining of the scaffold harvested during the fourth week after the implantation, from a rat 
that had to be terminated prior to the planned time-point of four weeks, showing even cellular 
infiltration. Yellow bar indicates the scale of the image. 
 
Eight weeks post-implantation the cells were also present within the grafts. No 
‘empty-spaces’ could be seen in any part of the scaffolds. Even though the graft 
surface seemed to be smaller on macroscopic examination at the harvest time, no 
significant reduction in thickness of the scaffolds was visible. Inflammatory cells 
were mostly gathered around the big blood vessels or sutures. Intense 
neovascularisation occurred over two months, and from week four vessels developed 
full circumferential lining of lumen with endothelial cells surrounded with well 
distinguishable smooth muscles layers. What is more, acellular nerves within the 
scaffolds were re-populated with cells (Fig. 27). No signs of fibrotic encapsulation, or 
scar tissue formation within the muscles or grafts were seen.  
 
Scaffold 
Abdominal 
muscle 
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Fig. 27 H&E staining of the scaffold harvested four weeks post-implantation. A: black arrows - blood 
vessels within the graft with endothelial lining and vascular wall of smooth muscle cells, yellow arrow 
- acellular nerve infiltrated with cells resembling native neural layout, black arrow heads – 
inflammatory cells around big vessels within the graft; B: inflammatory cells around the sutures. 
Yellow bar indicates the scale of the image. 
 
A 
Suture 
Inflammatory 
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4.3.1.2.2. Picro Sirius red/Miller’s elastin staining 
 Picro Sirius red staining showed well preserved collagen within the scaffold. 
The fibres were green, green-to-yellow, yellow, and yellow-to-orange when viewed 
under polarised light. Two weeks post-implantation thin green fibres were 
predominant at the edges of the scaffold. Some green fibres were also found between 
orange fibres in central parts of the grafts (Fig. 28A). Faint elastin staining was also 
seen in two-week old grafts (Fig. 28B).  
 
 
Fig. 28 Picro Sirius red and Miller’s elastin staining of the scaffold harvested two weeks after 
implantation. A: white arrows – thin green collagen fibres at the edges and in some central parts of the 
cross section; B: black arrows – blue, elastin staining. Yellow bar indicate the scale of the images. 
A 
B 
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The distribution and state of the collagen fibres at four weeks post-
implantation were also the same as in acellular scaffold. However, grafts harvested 
eight weeks post-surgery showed abundant amount of thick, orange and red fibres, 
especially in close proximity of the blood vessels (Fig. 29 A). Green fibres were still 
present mostly at the edges of cross sections of the specimen. Elastin was easily 
identifiable in many newly created blood vessels (Fig. 29 B). 
 
 
 
Fig. 28 Picro Sirius red and Miller’s elastin staining of the scaffold harvested four weeks after 
implantation. A: white arrows – thin green collagen fibres at the edges of the cross section, green 
arrows – thick red and bright orange collagen fibres around the new blood vessels; B: black arrows – 
blue, elastin staining of the blood vessels. Yellow bar indicate the scale of the images 
 
A 
B 
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4.3.1.3. Immunohistochemical  
 IHC staining proved that cells residing in the grafts obtained at all three time 
points expressed the proliferation marker (Ki67). However, up to two months post-
implantation there were no cells that had differentiated towards either intestinal 
epithelium (CK8), or nerve tissue (S-100) in the specimen. Encouragingly, as early as 
two weeks after implantation of scaffolds, neo-vessels were positive for !SMA. After 
the first two weeks in vivo some cells in the walls of bigger veins and arteries were 
expressing !SMA (Fig. 30 A). By the end of the fourth week post implantation most 
of the newly created vessels were positive for !SMA (Fig. 30 B), and at the end of the 
experiment bigger vessels had well differentiated !SMA-positive, thick, muscular 
walls (Fig. 30 C).  
 
 
 
 
 
 
                                    Chapter 4: Biocompatibility tests in the rodent model! 
 
 136 
 
 
 
Fig. 30 IHC staining of !SMA in grafts harvested two weeks (A), four weeks (B), and eight weeks (C) 
post-implantation; black arrows – brown-stained smooth muscle cells in neo-vessels, blue arrows – 
smooth muscle cells of arteries, yellow arrows – smooth muscle cells of veins. Yellow bar indicates the 
scale of the images.  
A 
B 
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As soon as two weeks post-implantation some of the cells lining the 
circumference of the neo-vessels were FVIII-positive. However, only eight-week old 
grafts expressed endothelial marker within full circumference of the vessels (Fig. 31).  
 
 
 
Fig. 31 IHC staining of FVIII in grafts harvested two (A), four (B), and eight (C) weeks post-
implantation; black arrows – brown-stained endothelial cells in neo-vessels. Yellow bar indicates the 
scale of the images. 
A 
B 
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 Analyses of VEGF expression indicate that it is retained in the de-cellularised 
intestine (Fig. 32). It has been shown in the grafts harvested at each time point with a 
visible time-related increase in staining intensity (Fig. 33).  What is more, the section 
of the grafts harvested two weeks after surgery show expression of VEGF that is not 
restricted to angiogenic activity (newly created, small vessels).   
 
Fig. 32 IHC staining of VEGF within de-cellularised intestinal blood vessels (arrows). Yellow bar 
indicates the scale of the image. 
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Fig. 33 IHC staining of VEGF in grafts harvested two weeks (A), four weeks (B), and eight weeks (C) 
post-implantation; black arrows – brown-stained VEGF within neo-vessels. Yellow bar indicates scale 
of the images. 
 
A 
B 
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 There were very few VEGF-R-positive cells in the grafts harvested two weeks   
after implantation. Their amount gradually increased with time. Four weeks post-
surgery positive cells were randomly repopulating the scaffold. Some cells expressing 
the receptor were located on the lumenal surface of the blood vessels. After eight 
weeks, considerably high amounts of VEGF-R- positive cells were present mostly in 
the close proximity of the blood vessels, with some lining possible places of previous 
blood vessels (Fig. 34).  
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Fig. 34 IHC staining of VEGF-R in grafts harvested two weeks (A), four weeks (B), and eight weeks 
(C) post-implantation; black arrows –VEGF-R -positive cells not associated with blood vessels, yellow 
arrows – VEGF-R-positive cells lining pre-existing vessels. Yellow bar indicates the scale of the 
images. 
A 
Possible pre-existing 
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4.4. Discussion  
ECM scaffolds are commonly used for reconstructive and regenerative 
applications in clinical and pre-clinical studies (62). Acellular intestinal matrix has 
been proven to provide smart remodelling which is an important prerequisite for 
tissue maturation and regeneration (151). When de-cellularised scaffold is implanted 
as a naturally occurring biopolymer, it stimulates angiogenesis, growth and 
differentiation of connective and epithelial tissue, as well as deposition, organization, 
and maturation of ECM components, which results in blocking cell-mediated 
contraction of the site and induces remodelling towards tissue in its natural 
physiological state (152).  
Biocompatibility tests performed in rat model proved to induce angiogenesis, 
cellular infiltration and secretion of new ECM without inducing chronic immune 
response. This proved the possibility of using de-cellularised ileum as a potential 
scaffold in tissue engineering.  It appeared to be non-immunogenic and served as a 
good matrix for cellular ingrowth. Implants were well tolerated and they induced 
much lower levels of  inflammation or immune response than the implants presented 
in Chapter 2. As early as two weeks post-surgery all the implants were infiltrated with 
cells, which were distributed evenly within the implants (no ‘empty’ spaces could be 
seen) in all of the grafts at any time. H&E staining showed re-populating cells initially 
having characteristics of inflammatory cells (polymorphonuclear), but failed to induce 
chronic inflammation. Moreover, lack of fibrotic encapsulation or scar tissue 
formation suggests that any foreign body reaction had resolved. The above result 
proves that even though the scaffold contained traces of DNA material, its amount 
was below the threshold needed to stimulate a foreign body reaction, or DNA was 
degraded during first two weeks post-implantation.  
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Non-cross-linked ECM-scaffolds were described as completely absorbable 
(153), however the graft could be well-distinguished from surrounding tissue up to 
two months post-implantation. The collagen analysis showed that collagen at the 
edges of the grafts (thin green fibres) undergoes gradual degradation. However, its 
rate gives the re-populating cells enough time to produce new ECM, indicated by 
depositions of thin, green collagen in the centre of the two-week-old grafts. New 
fibres gradually mature, which is shown by bright orange-to-red colours of Picro 
Sirius stained collagen at eight weeks post-implantation.  
Most of the cells were proliferating, and some of them started to appear within 
acellular nerves or ganglions. Their morphology resembled that of nervous tissue; 
however, they were not positive neural markers (S-100). In explants harvested at each 
time point spontaneous angiogenesis was taking place, which could have been a factor 
that limited the immune reaction. Within a few weeks most of the new vessels 
developed endothelial lining (positive for F VIII), and a well-defined vascular wall 
containing elastin and expressing smooth muscle markers (!SMA). Analysis of VEGF 
showed that de-cellularised matrix retained VEGF, which could be one of the reasons 
why remodelled material promotes such rapid angiogenic ingrowth. VEGF expression 
in the grafts harvested at the two-week time point was not associated with the existing 
blood vessels and there were hardly any VEGF-R-positive cells. It could indicate that 
‘unrelated’ staining was in fact residual VEGF remaining in the tissue after de-
cellularisation. Moreover, some of the VEGF and VEGF-R expression was centred at 
the possible pre-existing vessels of the scaffold, which may suggest that internal cues 
and retained functional proteins directed the neo-vascularisation of the grafts. There is 
a positive correlation between the amount of retained ECM GAG’s and VEGF 
expressed in a scaffold (154). Therefore, the presence of VEGF expression within the 
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de-cellularised ileum proves that the method of de-cellularisation described in the 
previous chapter allows retention of the sufficient amounts of GAG’s to guarantee 
some of the bioactive function of the ECM. VEGF is crucial for neo-vascularisation 
of grafts. Post-implantation blood vessels permeability to cells and macromolecules 
within the scaffold increases. This causes coagulation, enabling platelets to 
disintegrate and shed their contents, among which are several inflammatory mediators 
such as VEGF. In response to this chemotactic factors neutrophils, followed by 
macrophages migrate towards the site of angiogenesis. At the same time, angiogenic 
factors that were released by platelets and secreted by attracted cells stimulate local 
vascularisation. However, if the scaffold is not supplied with VEGF in the first place 
that initial attraction by the cells and macromolecules does not take place. Therefore, 
biomaterials that do not express growth factors are often less compatible and do not 
promote cellularisation and angiogenesis as efficiently as the biological matrices 
(155). The fact that the de-cellularisation process preserved VEGF in the scaffold is 
the reason of immediate blood vessel penetration of the matrix. Time-related increase 
in VEGF expression was caused by intensive platelet deposition and infiltration of 
cells expressing VEGF-R (endothelial cells, fibroblasts, keratinocytes, macrophages, 
mast cells, platelet and polymorphic neutrophils), first in the part of the grafts 
adjoining native muscle and later in other parts. In synthetic scaffolds loaded with 
VEGF, the expression of the growth factors is difficult to control. This is because too 
much VEGF alone leads to immature, leaky vessels (156). This problem is non-
existent when ECM scaffolds are used, where release of molecules is gradual and 
occurs in the same manner as in native tissues.  
In vivo routes and origin of new vessels within the acellular tissues will never 
be described, unless a method of permanent labelling of the de-cellularised blood 
                                    Chapter 4: Biocompatibility tests in the rodent model! 
 
 145 
vessels is discovered. Nevertheless, careful histological examination can promote 
some ideas. The above studies seem to show that most of the neo-vascularisation 
happens in the close proximity of the recipient tissue, with adjoining vessels growing 
into the scaffold.  However, there are some cells that line the pre-existing conduits. 
Examination of these cells is most exciting as it proves that the concept of using ECM 
scaffolds extends far beyond them being only natural, non-toxic biopolymers with 
pre-loaded biomolecules. The fact that the direction and differentiation of the cells re-
populating ECM scaffolds can be directed towards the tissue of origin is very exciting 
in the field of bio-engineering, but yet it remains to be proven.  
Biocompatibility within human body of acellular ileum can not directly be 
assured by the above results (namely the immunologic differences between human 
and rat). However, the method presented in the previous chapter show that it is 
possible to produce scaffold that is well tolerated in rat model and promotes smart 
remodelling in contrast to being immunologically rejected. These properties are key 
factors and requirements when designing a scaffold for tissue engineering application.  
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Chapter 5. 
Stereological analysis of scaffold performance 
in vivo 
 
5.1. Background and aims   
 A stereological approach can provide an objective unbiased assessment of 
structural changes in biological systems. In this chapter stereological analysis was 
incorporated to assess time related changes of biological activity within the implanted 
scaffold. The focus was on host tissue infiltration, immunological active cell numbers 
and changes of the volume of porcine de-cellularised ileum implanted subcutaneously 
into the rat recipients. As research in the field of tissue engineering progresses, and 
new scaffolds continue to be manufactured it is essential to develop an unbiased 
analytical method of in vivo performance.  
 
5.1.1. Concept of unbiased stereology  
 Stereology was developed to describe the methodologies that allowed access 
to 3D information about biological (or other geometrical) structures based upon 
observation made on 2D sections (157). In stereology, quantification is considered the 
objective method to describe a structure, compare two structures, study structural 
change and relate the structure to the function. Stereological probes such as the 
dissector can provide unbiased estimates of numerical density and if volume is known 
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estimates of total numbers within an object. A stereology-compatible sample must be 
representative of the entire structure (158). Unbiased sampling procedures must also 
be applied uniformly at every stage of tissue processing, sectioning and selecting of 
fields of view.  A test-system needs to be superimposed onto an image before 
counting, so that a stereological formula can be subsequently applied (159). Thus, 
unbiased samples (sections) were mounted on the histological slides and analysed 
using stereological parameters.  
Subsequently, the challenge faced is determining which stereological 
parameter is relevant to the particular question being asked. The stereological 
parameters fall into two categories. These are absolute: volume, surface area, length 
and number (e.g. number of neurons in rat brain) or relative: volume density, surface 
density and number density (e.g. number of neurons per cubic millimetre) (160).  
 
5.1.1.1. Absolute volume  
The ‘safest’ (allowing the best interpretation of the results) method that could 
be applied for the analysis of the porcine scaffolds implanted subcutaneously into rats 
(explants described in chapter 4) was estimation of absolute numbers of certain cells 
per implant. The absolute volume was measured to check if the implanted ECM 
scaffolds shrank within eight weeks post-surgery, as well as to obtain a reference 
parameter for absolute number analysis.  
The absolute volume of an explant can be calculated by weight and specific 
gravity or by liquid displacement using the Archimedes’ Principle (161). However 
this method cannot be applied to tissues that can not displace water after immersion 
(lungs), are too small (blood capillaries) or are trapped/attached to other structures 
(brain cortex). In such cases, volume can be estimated using Cavalieri’s Principle, 
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which states: “the volume of an arbitrary shaped object can be estimated in an 
unbiased manner from the product of the distance between planes and the sum of the 
areas on systematic random parallel sections through the object” (162). This means 
that the scaffold needed to be serially sectioned at known distances (T), parallel to an 
originally randomly chosen section (in an interval 0-T) plane (Fig. 35). Only one face 
of each section can be measured and the areas (Ai) are determined by point counting 
(161).  
Fig. 35 Cavalieri’s Principle; The absolute volume can be calculated by the product of the distance 
between planes (T) and the sum of the areas (Ai) on systematic random sections through the object.  
 
The volume of the object is estimated by summing the areas and multiplying by the 
slice thickness:  
 
 
 
T 
1 2 3 4 
Section number 
3 
Area of the third transect 
(A3) 
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In point counting, a suitable test system is placed on the image and the area 
occupied by the object is measured by counting the points that fall onto the object (P). 
Given random positioning of the array, the total number of points, which falls on the 
profiles (slices of the scaffold) provides an unbiased estimate of their total area. The 
exact relation is:  
 
    
where a(p) is the area equivalent of one test point (area associated with the point). 
Therefore the absolute volume of an object can be calculated: 
 
 
 
The application of the above equation will give an unbiased estimation of the 
scaffold’s absolute volume, irrespective of the shape and of cutting direction (161). 
Only four to eight systematic sections can guarantee a coefficient error of the estimate 
of about 5-10% when using the Cavalieri’s estimator (163). 
 
5.1.1.2. Number density   
 Number is a dimensionless entity. Thus, when counting objects, the smallest 
unique feature that is readily identifiable (e.g. nucleus when counting Eucaryota cells) 
should be used (164). However, that object could be present in more than one section 
if the sections are thin enough (160). Conventional object counting of each slide will 
result in an overestimation. Stereology provides the solutions to the problem. One of 
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them is the optical brick method which was used to perform analysis of the implanted 
scaffolds.  
 
5.1.1.2.1. The optical brick    
 The optical brick has been created to prevent overestimation of particle 
counting. It relies on the optical section ‘scanning’ method which increases the 
practical efficiency of counting object numbers. Using light microscopy, ‘optical 
sections’ can be continuously scanned, which provides a direct count (160). In 
practice, the microscopical plane of focus is moved up and down within one thick 
section (15-30 $m) of the object. The microscope used for number analysis should be 
fitted with the microcator, which is used to measure depth in the z direction (the 
optical axis of the microscope) by the microscope stage. In light microscopy, the 
highest numerical aperture lens should be used as this provides the thinnest possible 
optical section. A depth of focus of approximately 0.5$m can be achieved using oil 
immersion lens (x 100) and a condenser. When applied to a thick histological section 
only a thin slice of the section is in focus, which in practice means that the objects 
appear and disappear as the section is focused through (160). 
  
5.1.1.2.2. Unbiased counting rule    
 The objects are counted on the basis of the unbiased counting rule, using an 
unbiased ‘brick’, rather than by a 2D unbiased counting frame. The unbiased brick is 
generated be moving an unbiased counting frame through the thick histological 
section of an object. It consists of three acceptance planes and five forbidden surfaces 
(Fig. 36). The particles (e.g. nuclei) are counted if they are within the counting frame 
and do not intersect any of the forbidden planes (Fig. 37) (160).   
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Fig. 36 A schematic illustration of the unbiased brick. The brick consists of the central volume, 
bounded by three acceptance surfaces (green), and five forbidden planes (red). 
http://www.stereology.info/optical-disector-unbiased-brick/ 
 
 
 
Fig. 37 A schematic illustration of the unbiased counting rule. The unbiased counting frame consists of 
a red forbidden and green acceptance line. Objects falling inside the frame or intersect the acceptance 
line are counted (green ticks). Particles touching the forbidden lines are not counted (red crosses). 
http://www.stereology.info/criteria-for-counting-cells 
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 In practice, the unbiased counting brick is superimposed onto a thick section 
and the microcator is set to zero. The section is scanned downwards at a defined 
distance (optical dissector height). It is important to count the objects only within the 
unbiased counting brick when they are in their maximal focus. Only then they are 
recorded as ‘new events’ and counted.  
 Numerical density (Nv) can be estimated by dividing the total number of 
objects counted (!Q) by the number of the dissector (!P) multiplied by the dissector 
volume. The dissector volume is obtained by multiplying the area of the unbiased 
counting brick (Af) by the optical dissector height (h). Thus, a number per unit volume 
is obtained:   
 
 
 
5.1.1.3. Absolute number   
The absolute number of objects (NTOT) within the reference parameter (e.g. 
absolute volume) can be estimated by multiplying numerical density (Nv) by the 
absolute volume (V) of the object of interest (e.g. scaffold).  
 
 
 
5.1.1.4. Coefficient of Error   
 The efficiency of the stereological methods incorporated into analysis of an 
object can be defined by calculating the Coefficient of Error (CE) for each step 
(volume estimation and density estimation).  
Volume CE is obtained:  
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where Pi stands for the number of points within the object.  
Numerical density CE is obtained:  
 
 
 
where n is the number of section of an object, P is the total number of dissectors 
within the object and Q is the total number of the particles counted per object (160). 
 
5.1.2. Macrophage phenotype as a determinant of biologic 
scaffold remodeling.  
 Quantification of inflammatory cells in terms of presence/absence and time 
frame of occurrence indicates the nature of inflammatory reaction and scaffold 
integration (164).  Macrophages are critical antigen presenting cells that play pivotal 
roles in host responses to biomaterial implants. The control of macrophage phenotypic 
balance from proinflammatory M1 to reparative M2 (described in Chapter 1) is a goal 
of investigators to optimize the host response to scaffolds for tissue engineering 
purposes (165). The processing method used during the manufacturing of a biologic 
scaffold, tissue source and species of origin can have a profound influence upon the 
macrophage phenotype profile and downstream remodeling events (166). 
Biomaterials directly influence innate and adaptive immune cell adhesion, reactive 
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oxygen intermediate production, cytokine secretion, nuclear factor-kappa B nuclear 
translocation, gene expression, and cell surface markers, all of which are likely to 
affect allogeneic rejection or acceptance responses (167). Routine histological 
examination alone is inadequate to determine the phenotype of mononuclear cells that 
participate in the host response to the scaffold.  
 The presence of large numbers of macrophages in the tissue and their 
multinucleate giant-cells counterpart is one of the hallmarks of chronic inflammation. 
Typically, the host inflammatory response to an implanted biomaterial followed a 
predictable sequence of events, which resulted in foreign body reaction and fibrosis. 
That was before phenotypic and functional polarization of the mononuclear phagocyte 
cell population was described (59). The M1 (pro-inflammatory) and M2 
(immunoregulatory) phenotypes of macrophages gave a new insight into immune 
activity in the acute phase of host response to biomaterials. Further investigations 
proved that although morphologically indistinguishable, mononuclear macrophages 
from these two pathways can be identified and differentiated according to their cell 
surface markers and their cytokine and gene expression profiles (60).  
 Macrophages are a plastic cell population capable of changing sequentially 
their polarization in response to local stimuli during the process of wound healing 
(168). These stimuli can originate from other cells infiltrating the scaffold, microbial 
or toxic agents, biomaterial epitopes and its degradation products (169). The effects of 
macrophage phenotype upon the tissue-remodeling outcome following the 
implantation of a biomaterial are largely unknown, but recognition of the predominant 
phenotypic profile may provide a tool by which a constructive and functional tissue 
remodeling outcome can be predicted and/or promoted.  
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 The objective of the experiments presented in this chapter was to examine the 
changes of the macrophage phenotype within the first eight weeks post-implantation 
of a porcine de-cellularised scaffold into a rat recipient. Moreover, using stereological 
analysis it was possible to quantify the cellular infiltration of the implants with not 
only macrophages but also other cells. The changes of ratio of M1 and M2 
macrophages within implanted scaffold in a time related manner have been proven to 
predict the biomaterial’s fate in vivo (166). The objective of this chapter was to show 
this changes of M2/M1 ratio, which in case of significant increase could suggest that 
there is a documented somewhere else chance for smart remodelling and positive 
long-term outcome. The aim was to show if the de-cellularised intestine can induce 
better than described negative controls (cross-linked matrices inducing long-term 
rejection) and show similar pattern of residual macrophages populations to positive 
control (autologous tissue) in vivo. Quantitative data in existing reports is based on 
straightforward counting in 2D of M1 and M2 macrophages within fields of 
microscopical view, which is linked to assumptions which are highly biased and 
therefore difficult to interpret.  
 
5.2. Methodology  
5.2.1. Materials 
 The list of materials and equipment used in experiments described in this 
chapter is presented in Appendix 4.  
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5.2.2. Animal husbandry 
All animals were maintained and handled similarly to the procedure presented 
in Chapter 2 (2.2.2). 
 
5.2.3. Tissue slides preparation  
 The blocks of tissue harvested two, four and eight weeks post-implantation 
(Chapter 4) were measured and cut into four equal segments (Fig. 37).  Tissue was 
processed and prepared for histological staining in the way described in sub-chapter 
3.2.6.2. The blocks embedded in wax were cut into 15 $m (sections undergoing 
staining for chemokine receptor 7: CCR7 antigens) or 25$m (sections undergoing 
staining for CD68 and CD163 antigens) thick histological sections and mounted onto 
5% APTS-covered slides.  
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 Fig. 38 A schematic illustration of the scaffold explantation eight weeks post-surgery and preparation 
of sections for stereological analysis. The scaffold was resected with underlying abdominal muscle and 
the blocks of tissue were cut into four equal segments, each measuring ~2.5mm (length) and 10 mm 
(width). The segments were embedded in wax facing longer (10mm) side.  
 
5.2.4. Immunohistochemistry 
 The staining was performed in a way described in sub-chapter 3.2.6.3. 
IHC-staining was optimized using first the control tissue (rat spleen) and then 5$m 
thick sections of the test tissue (explants). The optimal protocols used for IHC 
staining are described in Appendix 9, Table 8. Sections were stained with CD68 (pan 
macrophage marker), CCR7 (M1 profile marker) and CD163 (M2 profile marker). 
The optimal protocol for CCR7-labelling involved the use of harsh antigen retrieval 
treatment. 25$m thick sections were not resistant to high temperature exposure and 
the sections did not remain attached to the slide. Thus, thinner (15 $m) sections were 
cut and stained with CCR7 antibodies.  
Explant 
section on 
histology 
slide 
Scaffold 
Abdominal 
muscle 
15-25!m  
10 mm 
Scaffold 
Abdominal muscle 
T = 2.5 mm 
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 Prior to stereological quantification each section was analysed for its precise 
thickness using microcator, the antibody penetration of its whole thickness and length. 
Sections with average thickness less than 15$m, which showed incomplete 
penetration of the antibodies or any damage of the stained tissue were re-cut and re-
stained.  
 
5.2.5. Stereological quantification of changes of scaffold 
volumes in vivo 
 The volume of the scaffold pre-implantation was calculated based on their 
measurements. The volumes of the scaffolds harvested at each time point were 
estimated according to Cavalieri’s principle. The areas were estimated using 
microfiche reader superimposed with a grid of quadratic points calibrated using a 
microscopic grid, and a(p) was calculated. Ai of each explant were estimated in single 
H&E stained sections of each segment of each subdivided into four scaffolds (T = 2.5 
mm), counting and summing the points interposed on each of them (Pi). The absolute 
volumes of explanted scaffolds were then calculated considering their total length of 
10mm. CE of the estimates was calculated.  
 
5.2.6. Stereological quantification of cellular infiltration, 
macrophages content and M1/M2 ratio within scaffold 
implanted into rat recipients 
 The numerical densities of cells infiltrating the scaffold, staining positively for 
CD68, CD163 and CCR7 were estimated using a 3D stereological technique. Sections 
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counting frame (60% of the image total area) generated by a digital software package 
(Kinetic Imaging Stereology 5.0) was projected onto IHC-stained image. Each image 
was brought into maximum focus of the first nucleus and the microcator was zeroed. 
The unbiased optical brick technique was used for the estimation of positive and 
negative for the appropriate macrophage marker cell densities. All nuclei seen in 
maximum focus at their largest diameter and contained within unbiased counting 
frame and defined brick depth of 15 $m were counted, starting at the top left corner 
and following a tessellating pattern of 3mm (optimized in pilot study). For each slide 
13 optical bricks were sampled and the number of negative and positive for each 
marker cells was recorded. This ensured that for a single scaffold 52 unbiased optical 
bricks were sampled.  
 Total number of negative CD68+, CD163+ and CCR7+ cells within each 
scaffold was estimated by multiplying the volume of each scaffold with the numerical 
density.  M2/M1 ratio changes in time post-implantation were also estimated.  
  
5.2.6. Statistical analysis 
All continuous data was expressed as the mean ± Standard Error of the Mean 
(SEM) and p<0.05 was taken as significant. p values were estimated using two-way 
ANOVA with post hoc Tukey intergroup comparison, and all computations were 
performed using GraphPad Prism 4 and Microsoft Office Excel software.  
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5.3. Results 
5.3.1. Stereological quantification of changes of scaffold 
volumes in vivo 
The volumes of scaffold pre-implantation are as follows [mm3]: 720, 680, 600, 
590, 600, 640, 650, 650, 670, 800, 550, 570, 600, 640, 580, 680, 700 and 600. This 
gave mean volume of 640 mm3 (STDEV=62.02 mm3). The estimated volumes of each 
explanted scaffold along with CE values are shown in Table 14 (Appendix 13). 
Pooled data from each of the three harvests (two, four and eight weeks after 
subcutaneous implantation) are shown in Table 15.  
 
Table 15. Estimated average volumes of the scaffolds explanted at each time point post-
implantation. 
Time post-implantation 
[week] 
Mean Volume 
[mm3] 
STDEV 
2 561.6 120.5 
4 632.3 137.3 
8 659.7 97.28 
  
Statistical analysis showed no significant changes (p>0.05) in scaffold volume 
at any time point (Fig. 39). There was no implant shrinkage even after eight weeks 
post-surgery, with mean volume oscillating around value of 600mm3 (640, 561.6, 
632.3 and 659.7 mm3) at any given time.  
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Fig. 39 Estimated volumes of scaffolds pre-implantation (week 0) and at 2, 4, and 8 weeks post-
implantation into rodent recipient. No significant difference could be seen between any of the columns.  
 
5.3.2. Stereological quantification of cellular infiltration, 
macrophages content and M1/M2 ratio within scaffold 
implanted into rat recipients 
 The densities of negative, and positive CD68, CD163 and CCR7 cells were 
estimated. Along with CE are presented in Table 16 (Appendix 14).  The total 
numbers of negative and positive for CD68, CD163 and CCR7 cells within each of 
the scaffold are presented in Table 17 (Appendix 15). Pooled data from each of the 
three harvests (two, four and eight weeks after subcutaneous implantation) are shown 
in Table 18.  
  
 
 
Table 18. Average total number of cells, pan, M1 and M2 macrophages within the scaffolds 
explanted at each time point post-implantation. 
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Time post-
implantation 
[week] 
Mean 
Total 
Cells 
NTOT 
STDEV 
 
Mean 
CD68 
NTOT 
STDEV 
Mean 
CD163 
NTOT 
STDEV 
Mean 
CCR7 
NTOT 
STDEV 
2 9.69 E-10 
2.37 
E-10 
3.92 
E-10 
1.00 
E-10 
1.29 
E-10 
4.22 
E-11 
1.36 
E-10 
4.44 
E-11 
4 8.15 E-10 
1.36 
E-10 
3.3 
E-10 
1.1 
E-10 
9.88 
E-11 
2.82 
E-11 
9.03 
E-11 
1.86 
E-11 
8 8.56 E-10 
1.08 
E-10 
3.19 
E-10 
3.38 
E-11 
1.35 
E-10 
1.24 
E-11 
4.25 
E-11 
2.36 
E-12 
 
 
 Two-way ANOVA analysis proved there was no significant difference at two, 
four or eight weeks post-implantation (p>0.05) in the total numbers of cells 
infiltrating the scaffold, number of pan macrophages or M2 macrophages within the 
scaffold (Fig. 40).  However, the total number of CCR7+ cells decreased significantly 
after four (p<0.05) and eight (p<0.001) weeks comparing to the number of CCR7+ 
cells within the scaffold at two weeks post-implantation. There was also statistically 
significant drop in total number of CCR7+ macrophages within the scaffold between 
fourth and eight week in vivo (p<0.05) The total number of CD163+ showed some 
trend towards increase, but this was not statistically significant difference.  
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Fig. 40 Estimated total numbers of cells within explanted scaffolds at 2, 4, and 8 weeks post-
implantation into rodent recipient. No significant difference could be seen between total numbers of 
cells infiltrating the scaffolds, pan and M2 macrophages at any given time point. There was a 
significant drop in total number of M1 macrophages both at four (*) and eight (**) weeks post-
implantation.  
 
At every time point there was a significant difference (p<0.001) between 
number of total cells having infiltrated the scaffold and CD68+ cells, CD163+ cells  
and CCR7+ cells. There was also significant difference between the number of pan 
macrophages and CD163+ cells at two and four (p<0.001) as well as eight weeks 
post-implantation (p<0.01). p value < 0.001 was constant for difference in the number 
of pan macrophages and CCR7+ cells at all three time points. There was no 
significant difference in the number of CCR7+ and CD163+ macrophages at two and 
four weeks in vivo (p>0.05). However, at eight weeks post-implantation the number 
of CCR+ cells was significantly lower (p<0.05) than the number of CD163+ cells 
within the scaffold (Fig. 41).  
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Fig. 41 Estimated total numbers of cells within explanted scaffolds at 2, 4, and 8 weeks post-
implantation into rodent recipient. Significant difference could be seen between total numbers of cells 
infiltrating the scaffolds and CD68+ (a-c vice a*-c*), CD163+ and CCR7+ (a-c vice a**-c**) cells at 
any given time point. There was also a significant difference between number of pan and M1 or M2 
macrophages at any given time (a-c* vice a-c**). There was no significant difference in number of 
CD163+ and CCR7+ cells at two or four weeks (a**-b**). However, there was a significant drop of 
CCR7+ in relation to CD163+ cells at eight weeks post-implantation (c** vice c***).  
 
 The changes of ratio of M2/M1 macrophages confirmed that the switch from 
pro-inflammatory to pro-remodeling phenotype occurred eight weeks post-
implantation when ratio of M1/M2 total numbers significantly increased (p<0.01) 
from 1.1 to 3.2 (Fig. 42).  
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Fig. 42 Changes of M2/M1 macrophages ratio, showing significant (p<0.01) increase at eight weeks 
post implantation into rat recipient showing switch from pro-rejection to pro-acceptance response.  
 
 
 
 40% of cells re-populating the scaffolds at two and four weeks post-
implantation were macrophages stained positively for CD68. That percentage 
decreased slightly at the time of the last harvest (Fig. 43). CD 163+ cells constituted 
to 13, 12 and 16% of total number of cells infiltrating the scaffolds, which was equal 
to 32, 30 and 43% of pan macrophages at two, four and eight weeks respectively (Fig. 
43 and 44). The number of CCR7+ cells decreased from 14% of total cells infiltrating 
the implant at two weeks in vivo to 11% at four weeks and 5% at eight weeks. They 
represented 35% of the pan macrophages at first harvest, 28% at second and 14% at 
third (Fig. 43 and 44).   
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Fig. 43 Pie chart of total number of cells infiltrating the scaffolds at two (A), four (B) and eight (c) 
weeks post-implantation into rodent recipient.  
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Fig. 44 Pie chart of total number of macrophages infiltrating the scaffolds at two (A), four (B) and 
eight (c) weeks post-implantation into rodent recipient.  
M2 
32% 
M1 
35% 
2 WEEKS 
Non-differentiated 
33% 
H!
4 WEEKS
Non-
differentiated
42%
M2
30%
M1
28%
M2 
43% 
M1 
14% 
8 WEEKS 
@ 
H 
< 
Non-differentiated 
43% 
                                                                   Chapter 5: Stereological analysis! 
 
 168 
5.4. Discussion  
 In a recent study that compared the host tissue response to five biologic 
scaffold materials currently marketed for orthopaedic applications, it was shown that 
an intense mononuclear macrophage response in the early post-implantation period 
was common to all five products. However, the long-term remodeling outcome 
differed greatly between the scaffold materials. The tissue showed chronic 
inflammation, fibrosis, scarring, and encapsulation with some materials and the 
formation of organized, site-appropriate tissue for other materials (170). The presence 
of a cell population that is typically associated with cytotoxicity and inflammation 
was not necessary predictive of the long term remodeling outcome. Following studies 
showed that the phenotype of mononuclear macrophages that participate in the host 
response to biologic scaffold materials can differ markedly and that the method of 
material processing was an important variable (166). The surface topology and 
molecular organization of a scaffold was shown to affect macrophages, and cell-
surface interactions, which in turn can change the quantity and identity of secreted 
pro-inflammatory cytokines and chemokines, the gene expression pattern, and 
downstream remodeling events (171). For example, Badylak et al. (166) showed that 
chemical cross-linking of SIS resulted in a switch from an M2-dominant profile (pro-
acceptance) to a M1-dominant one (pro-rejection) and a change in the long term (16 
weeks) remodeling outcome from constructive remodeling to chronic inflammation. 
M1 cells are crucial in matrix destruction and tissue reorganisation at injured tissues 
via the production of a variety of enzymes such as matrix metalloproteinase, 
collagenase, elastase, and hyaluronidase (165). This allows them to quickly migrate 
through the injured tissues to clear pathogens and debris. However, prolonged 
activation of M1 macrophages can lead to tissue injury. Therefore, mechanisms have 
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evolved to replace the inflammatory profiles with reparative or alternatively activated 
(beneficial for tissue engineered constructs) M2 macrophages at later stages of 
inflammation to facilitate tissue remodeling. The extent of plasticity of macrophages 
in changing their phenotype is yet to be determined. It is known though that a variety 
of absorbed proteins including fibronectin, vitronectin, albumin, fibrinogen, and VWF 
play a pivotal role in the response of macrophages to biomaterial (165). As shown in 
Chapter 4 some of these factors have been preserved in intestinal scaffold, which may 
suggest possibility of polarisation towards M2 phenotype. The M2 response is 
associated with an organized, site-appropriate tissue-remodeling outcome and an 
absence of persistent inflammation. However, the specific ligand-receptor interaction 
between macrophages and the scaffold surfaces are yet to be discovered.  
 Mononuclear cells are commonly observed and are expected participants in 
the host response to biomaterials, including those that are used as scaffold for tissue 
reconstruction. “The term mononuclear cell is a generic morphologic description for a 
population of cells with a single nucleus, a round or oblong shape, and variable 
amounts of cytoplasm.” In tissue they are usually considered to have phagocytic or 
macrophage capability (166).  
The proposed earlier paradigm for M1 and M2 differentiation is based upon 
observations of differential cytokine expression profiles and cell surface markers. M1 
phenotype expresses CD68, CD80, and CCR7 cell surface markers in rats, and M2 
phenotype expresses CD68 and CD163 surface markers in rats (species differences 
exist). This chapter presents the changes of macrophages accumulations within the 
implants, which could possibly be translated into predictions of the viability of the 
implant (166). In addition to the fact that rat and mouse are the only animal models 
characterised for M1/M2 markers, the rationale for the model choice should be 
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confirmed by the fact that rats pan macrophages demonstrate the highest degree of 
chemotaxis in response to complement-activating chemoattractants. This makes them 
the most robust and safest from the clinical translation point of view model for 
investigation of macrophage-based responses (213).  
 Previous reports characterizing the macrophage population that participated in 
the remodeling responses as a function of the M1 and M2 polarization schemes in rat 
model were based on counting cells stained with IHC markers within microscopical 
fields of view. This is very biased method and only a stereological approach could 
definitely prove or disprove it. Stereology is powerful because it provides 3D data 
which makes the interpretation of results more effective. Stereological estimates have 
two important statistical qualities: they are unbiased in general and they are efficient. 
Moreover, wherever 3D information is required from slice images, stereology should 
be the method of choice (161). It has been applied successfully in other disciplines of 
biology. However its potential has not been realized in the evaluation of tissue 
response to bio-engineered scaffolds. Stereological methods can be successfully 
employed in order to understand the dynamics and complexity of tissue-scaffold 
interactions in an objective quantitative manner. The state of the art is now such that 
there is no excuse for confining measurement to the planar areas like in other studies 
investigating M1 and M2 profiles in the tissue, which could be accused of less 
effective in, repeatability, groups’ comparison, efficiency and what follows 
interpretation of scaffold behaviour in vivo.  
 An important aim in designing a research animal experiment is to obtain 
statistically relevant results with the use of a minimal number of animals (163). It was 
suggested that a conservative starting point is five specimens per experimental group 
(n=5). The reason being that “if something is found to increase (or decrease) in all 
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five cases, the probability that this is due to chance is p=(1/2)n=5<0.005, and the 
experiment could be conclusive” (172). In stereology the same number can be applied 
to the number of blocks per animal, sections per block or fields per slide to obtain 
statistically relevant data. In this study we used six cases per time point, four blocks 
per case and 13 fields of view per block, which in total gave 52 optical bricks per 
case, 104 per animal and 312 counts per time point for each of the markers. Thus, the 
statistical and stereological relevance of the analysis was achieved.  
Estimates of the absolute volume of the scaffolds implanted subcutaneously 
into rat recipients for two, four and eight weeks showed no significant difference at 
any given time point. This also corresponds with the macroscopic observations of the 
scaffolds at the explantation time. This indicates that there was no significant matrix 
shrinkage between two, four and eight weeks. What is more, there is a trend indicating 
increase in absolute volume of the scaffolds in time, which may suggest that 
infiltrating cells secrete new structural ECM proteins. This corresponds with the 
results of Picro Sirius red staining of the explants showing new, thin, green collagen 
fibres in the populated by the cells parts of the scaffold (Chapter 4). However, this 
trend was not statistically significant. The efficiency of the Cavalieri’s Principle 
incorporated into absolute volume analysis over other planimetric methods is well 
documented (163). The CE should ideally be around 5%. Most of the CE values were 
around 10% with only couple of counts reaching 13 and 15%. This was due to the 
restricted grid size (the smallest available used) and the count of four slides per case.  
There was also no significant difference in the total number of cells within the 
scaffold. The total number of CD68+ remained statistically unchanged over the 
duration of the study. Furthermore, there was no significant difference in the total 
number of CD163+ cells at any time point in vivo. The amount of M2-profiled 
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macrophages seemed to remain the same up to two months post-implantation. On the 
other hand, there was a significant drop in the total number of CCR7+ cells after four, 
and then again after eight weeks post-implantation. This strongly suggests that the 
presence of M1-profiled macrophages in the scaffold implanted in vivo was negatively 
correlated with the time. This was confirmed by the analysis of macrophages ratios 
that showed significant switch towards M2-pro-acceptance profile. This in terms of 
M2/M1 time related switch placed the scaffold closer to the positive control rate than 
the negative one presented by others (169). This implies that: M1 macrophages were 
either migrating out of the scaffold or trans-differentiating into pan or M2 
macrophages over time. The percentage analysis suggests that it was the former, as 
the percentage of the pan macrophages remained almost the same during eight weeks 
in vivo with only small (3%) drop at eight weeks. At the same time the percentage of 
M1 profile dropped from 14% to 5% of pan macrophages during the same time. 
Simultaneously the percentage of M2 macrophages within the population of CD68+ 
cells increased from 30% to 43%. Said differently there was a 9% drop in M1 
phenotype, and increase of 13% M2 phenotype within the population of 
undifferentiated macrophages, which amount stayed almost unchanged over the 
period of study.  
Two-way ANOVA analysis proved as well that the ratio of M1 and M2 
macrophages remained the same at two and four weeks post-implantation. However, 
after eight weeks in vivo there were significantly less pro-inflammatory macrophages 
than macrophages inducing constructive remodeling. It is hypothesised that the ratio 
of M1:M2 cells may be more important than the total number of cells, as there is 
clearly a correlation of the M1:M2 ratio to remodeling outcome (169). Thus, the 
analyses of two-way ANOVA were performed, and the switch from M1 to M2 profile 
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could be established on the time scale at four weeks post-implantation. Other studies 
investigating M1:M2 ratio in acellular scaffolds showed that this switch can be 
achieved as soon as one week post-implantation. Nevertheless, these observations 
were based on a biased and unreliable planimetric method of counting positive cells in 
the fields of microscopic view (169). Interestingly, the same authors state that any 
cellular (even autologus) material elicits a predominantly M1 type of response and 
results in deposition of dense connective tissue and scarring, which is contradictive 
with many tissue-engineering reports showing smart remodeling using seeded with 
autologus cells matrices (173). Nevertheless, this study suggests that the involvement 
of a cellular component can alter the ultimate response against the implant, but the 
underlying mechanism is not clear. It is possible that dendritic cells may contribute to 
the preferentially M1 response in the presence of cellular components by uptaking the 
codelivered cells near the implant site and becoming activated. They may also 
respond to maturation-inducing danger signals released by the transplanted cells from 
the construct. The maturation of the dendritic cells and the subsequent adaptive 
immune response may cross-talk with macrophages and result in M1 phenotype (165). 
Nevertheless, these results are based on biased methods and only thorough 
investigation using more effective and reliable methods, such as stereology could shed 
some light on the above hypothesis.  
The sum of M1 and M2 immunopositive cells’ numbers did not always equal 
the number of CD68+ cells, which is similar to what others reported using non-
stereological methods (166). It could mean that CD68+ macrophages that were not yet 
determined to be an M1 or M2 phenotype would remain negative for the CD163 or 
CCR7 marker. It is unknown whether macrophages that were not committed to the 
M1 or M2 phenotype were recruited to the site of scaffold remodeling and then 
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stimulated to differentiate locally or whether phenotype-committed macrophages were 
selectively recruited to the site of remodeling depending upon the antigens or 
substrates that were present (166).  
The analysis of cellular densities were characterised by CE values of 10-20%. 
Normally they should oscillate around 10%. Nevertheless, the counts were performed 
on 52 optical bricks per case which makes the results reliable and statistically 
relevant.  
 There were a couple of limitations in this study. First, the control group was 
not analysed for inflammation or constructive remodeling, and therefore the ultimate 
fate of the graft could not be predicted with certainty. Nevertheless, the quantitative 
data of M1 and M2 phenotypes in the control and test groups using a rat model was 
described by others (166). Therefore, the relative changes in the macrophages sub-
population within the same range of time using the same animal model can be 
compared to this existing data suggesting link between M2 response and a favourable 
remodelling of the scaffold. Some of the other studies checked the expression of 
cytokines in the implants. However, using the stereological approach in this case it 
was crucial to preserve the whole explants (as they were relatively small pieces of 
tissue) for unbiased sampling. Thus, no material could be sacrificed to perform 
additional measurements. Nevertheless, the quantitative method employed is the best 
existing one in obtaining reliable and efficient results.  
 Work presented in this chapter highlights the method of predicting the fate of 
biomaterials using short-term and simple in vivo studies. This technique can be easily 
applied to any other tissue-engineered graft or implant. It proves it is important to 
consider not only the simple presence of macrophages (which number has not 
significantly changed over two months in vivo) at the site of remodeling, but also the 
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phenotype of this important cell population when attempting to predict downstream 
remodeling outcomes. The scaffold that was obtained by the method presented in 
Chapter 5 proved to provoke M2 response as soon as four weeks post-implantation. 
Even though the switch towards pro-remodeling phenotype took place later than in 
studies reported by others, it was very significant and proved using an advanced and 
considerably superior method.  
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Chapter 6. 
In vivo evaluation of scaffold biocompatibility in 
the porcine model 
 
6.1. Background and aims   
One of the most limiting aspects of the existing approaches to tissue 
engineering of complex tissues and organs is the ability to provide for a functional 
circulatory system when in vivo studies are performed. The method of obtaining a 
scaffold with an intact acellular vasculature described in chapter 3 could possibly 
eliminate this obstacle. Every de-cellularisation process changes the properties of 
ECM and what follows, mechanobiological properties of the tissue (145). The 
ultimate test for bio-engineered tissues and organs, containing their vascular tree, is 
the introduction of systemic perfusion in order to test their potential in vivo (174). 
Performing scaffold implantations it was possible to test the behaviour of the vascular 
and intestinal part of the scaffold under physiological loading of systemic perfusion. 
Because the scaffold is composed of a vascular and intestinal part, characterised by 
significant differences in their ECM structure, it was crucial to test the behaviour of 
both. The biocompatibility test of the scaffold described in chapter 4 was the first step 
in estimating its in vivo behaviour. To verify the conceptual assumption that the 
presented scaffold could provide an immediate blood-supply post-implantation and to 
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check if the vessels’ lumens remain open and their walls resistant to rupture, a 
vascular anastomosis between acellular scaffold and donor porcine renal pedicle were 
performed. The place of implantation was chosen primarly due to the vessels size 
compatibility. Moreover, nephroctomy is one of the least invasive procedures and 
linked with high recovery rate. An additional advantage was the fact that implanted 
scaffold, onced left in vivo for longer than one-hour, could rest in the kidney cavity. 
 The ultimate goal is to use the scaffold described in chapter 3 to create an in 
vitro system where the vascular tree could be seeded with endothelial cells and 
acellular ileum with intestinal stem cells, and then the whole construct could be used 
as an in vitro model or transplanted into a recipient. Blood vessels seeded with 
endothelium are less prone to induce blood coagulation and the resulting thrombosis. 
However, bare collagen is highly thrombogenic (175), and therefore the 
anticoagulation protocols had to be applied in the presented here, preliminary in vivo 
studies.   
 The first procedure was planned to last one hour, which was enough for the 
full re-perfusion of the scaffold. The aim of this implantation was to check if the 
concept resulting in de-cellularising the intestine with intact mesentery granted 
immediate blood distribution within the whole graft post-implantation.  As the 
experiment finished with a success the next objective was to check if the viable blood 
perfusion within the graft can be obtained for periods longer than one-hour. The 
scaffold has been implanted for one week, and the animal was kept under mild 
anticoagulation. This was estimated to be long enough to characterise cellular 
compatibility of the matrix post-implantation within the porcine model. Poor results 
promoted further investigation into variables impacting on grafts survival.  It was 
obvious that before advancement into longer studies the one-hour-long implantations 
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needed to be repeated and the satisfactory outcome replicated in three separate 
experiments. This also allowed finding denominator for the successful perfusion of 
the graft with blood over prolonged periods of time and resulted in advancement 
towards recovery studies. This time the understanding of the perfusion 
biocompatibility of the scaffold was greater.  
The behaviour of the scaffold exposed to systemic perfusion is crucial when 
planning transition into more complex models. Thus, the investigation of the de-
cellularised scaffold was described in detail, including all, even unsuccessful 
transplantations. The chronology of the experiments was also preserved. 
 
6.2. Methodology  
6.2.1. Materials 
 The list of materials and equipment used in experiments described in this 
chapter is presented in Appendix 4.  
 
6.2.2. Animal husbandry 
All animals were maintained and handled similarly to the process presented in 
Chapter 3 (3.2.2).   
 Animals that underwent recovery studies received post-operatively analgesia 
using intravenous Carprofen (4mg/kg body weight) and Cefuroxime (14mg/kg) to 
prevent post-operative sepsis.  
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6.2.3. Acellular scaffold implantation into porcine recipient 
A Large White Landrace crossbreed pig (55-75kg) underwent a right sided 
nephrectomy via a midline incision. The vascular part (main artery and vein of ileal 
pedicle) of de-cellularised and sterilized scaffold construct was anastomosed in an 
end-to-end fashion to the appropriately renal artery and vein using 8-0 Ethicon, 
Prolene suture. The anastomosis site as well as the mesenteric vasculature of 
implanted scaffold construct was checked for any bleeding and Mersilk ties were put 
in places of excess blood loss. Once the blood perfusion within the graft was obtained 
the implant was placed into the kidney cavity for one hour before explantation of the 
graft and termination of the animal by lethal injection of sodium pentobarbitone 
(100mg/kg). If signs of severe clotting were seen, the graft was immediately removed 
and the animal was terminated.  
 After the first successful procedure (terminal), the vascular tree of the scaffold 
was implanted for seven days into a porcine recipient (first recovery studies). 
Following three successful one hour implantations (terminal procedures) into the 
porcine recipient the scaffold-construct was implanted for 24 hours (second recovery 
studies). The implant was placed into the kidney cavity and the abdominal muscle 
layers were closed using intramuscular suture (3.0 Vicryl) and skin using horizontal 
mattress suture (3.0 Mersilk). Post-operatively, the animal received analgesia using 
intravenous Carprofen (4mg/kg body weight). Following the grafts’ explantation the 
animals were terminated.  
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6.2.4. Development of anti-coagulation protocol 
The anti-coagulation protocol used was composed of pre-treatment with anti-
thrombotic drugs prior and during surgical procedure, as well as pre-conditioning the 
vascular part of the implant by injecting it with either neat or dissolved solution of 
heparin sodium in saline (Table 19).  The pig that underwent the first recovery study 
received additional treatment of Aspirin post-implantation.  
 
Table 19 Anticoagulation protocols used while implanting acellular constructs. 
Animal 
Number 
Type of 
procedure 
(terminal/recover
y) 
Weight 
of the 
pig  
[kg] 
Heparin 
sodium 
administrated 
systemically 
during 
implantation 
[U] 
Heparin 
sodium 
applied into 
the scaffold 
prior to 
implantation 
[U] 
Total 
heparin  
sodium 
received by 
an 
animal/kg/h 
of surgical 
procedure 
 
Additional 
anti-
coagulative 
/platelet-
formation 
drugs 
received by 
an animal 
[U/kg/h] 
 
1.11 
1. Terminal 55 
 
1. Post-incision: 
7.000 
2. Prior to 
releasing the 
vascular clamps: 
1.000 
 
1.000 55 - 
2. Recovery (7 days) 55 
 
1. Post-incision: 
7.000 
2. Prior to 
releasing the 
vascular clamps: 
1.000 
3. Prior to 
placing the 
implant into 
kidney cavity: 
1.000 
4. 1h after 
placing the 
implant in the 
kidney cavity: 
2.000 
 
1.000 82 
1. Aspirin 
40mg/day, 
post-surgically 
 
3. Terminal 60 
 
1. Post-incision: 
7.000 
2. Prior to 
releasing the 
vascular clamps: 
2.000 
 
1.000 51 - 
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4. Terminal 73 
 
1. Post-incision: 
7.000 
2. Prior to 
releasing the 
vascular clamps: 
2.000 
3. Administrated 
into graft’s 
feeding artery: 
2.000 
 
1.000 82 
1. Warfarin: 
12mg/day 
starting 3 days 
prior to 
surgery 
 
5. Terminal 70 
1. Post-incision: 
10.000 
2. Prior to 
releasing the 
vascular clamps: 
10.000 
30.000 260 
 
1. Warfarin: 
12mg/day 
starting 3 days 
prior to 
surgery 
 
 
6. Terminal 70 
1. Post-incision: 
10.000 
2. Prior to 
releasing the 
vascular clamps: 
10.000 
30.000 260 
 
1. Warfarin: 
12mg/day 
starting 3 days 
prior to 
surgery 
 
 
7. Terminal 75 
1. Post-incision: 
10.000 
2. Prior to 
releasing the 
vascular clamps: 
10.000 
35.000 298 
 
1. Warfarin: 
12mg/day 
starting 2 days 
prior to 
surgery 
2. Clexane: 
120mg on the 
day of surgery 
 
 
8. 
Recovery 
(24 hours) 55 
1. Post-incision: 
10.000 
2. Prior to 
releasing the 
vascular clamps: 
2.000 
30.000 255 
 
1. Warfarin: 
12mg/day 
starting 3 days 
prior to 
surgery 
 
 
6.2.5. Histological analysis of the grafts  
The explants were first fixed in 10% neutral buffered formalin solution for 
48h, and then intestinal part of the grafts was open longitudinally and histology 
samples were taken in a uniform matter (Fig. 45).  
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Fig. 45 Layout of the sampling sites for the histological analysis of porcine grafts (animals:1, 3-8) fixed 
in 10% formalin solution. A, B two sides of the explant; A: white rectangles indicate places of the 
sampling within the main artery and vein (cross sections) and their anastomotic sites (longitudinal 
sections); red brackets include the cross sections of the upper (A1-A7) and lower (C1-C5) mesenteric 
arcade; green rectangle shows site of longitudinal sections of mesenteric vessels; yellow ovals present 
places of sampling for “flat embedding” of the bowel segments (D1-D8). B: sequential cross sections 
of the bowel in two different directions (direction E and F).  
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The sampling pattern enabled progressive analysis of the blood perfusion 
within the vascular and intestinal part of the scaffold-construct. Starting from the 
arterial side, longitudinal sections of the arterial anastomosis were prepared for 
histological analysis.  Moving with the direction of the blood flow, serial sections of 
the main artery as well as the mesenteric arcade were taken. Moreover, longitudinal 
section of mesenteric arcade was analysed. Longitudinal sections of the venous 
anastomosis and cross sections of vein were also prepared. The bowel part of the 
scaffold was cut along and samples from one side were embedded flat in order to 
longitudinally analyse the vessels within the bowel (Fig. 46). The other side was used 
to produce cross sections of the bowel in two different orientations (Fig. 45B).  
 
 
Fig. 46 Flat embedding of intestinal part of the scaffold-construct. 
 
 The sampling of the graft harvested seven days post-implantation was dictated 
by its appearance and is presented in Fig. 47.  
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Fig. 47 Layout of sampling sites for histological analysis in porcine graft harvested 1 week post-
implantation (animal number 2), and fixed in 10% formalin solution. Letters A-L show 
morphologically different regions of the graft. Six sequential sections were harvested from each region. 
Red cubes show orientation of the samples.   
 
 Tissue was processed and prepared for histological staining in the way 
described in subchapter 3.2.6.2. Samples of grafts underwent H&E and Picro Sirius 
red/Miller’s elastin staining.  
 
6.2.6. Immunohistochemical analysis of the grafts  
IHC staining was incorporated in order to visualize endothelial and endothelial 
progenitor cells, smooth muscle actin, macrophages and VWF within the grafts. Some 
sections of interest (based on H&E results) were chosen and stained with different 
markers: CD133 for endothelial progenitor cells (all grafts), CD68 for macrophages 
(grafts harvested 1 and 24 hours post-implantation), VWF (grafts harvested 1 and 24 
hours post-implantation, scaffold-construct as a reference tissue) for blood vessels and 
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! smooth muscle actin (!SMA; grafts harvested 1 and 24 hours post-implantation) 
and endothelial cells (CD31; grafts harvested 7 days post-implantation). Protocols 
were initially tested on porcine control tissue. The staining was performed in a way 
described in sub-chapter 3.2.6.3. Specific IHC protocols are summarised in Table 8 
(Appendix 9).  
 
6.3. Results 
6.3.1. Acellular scaffold implantation into porcine recipient 
All procedures resulted in successful end-to-end anastomosis of the de-
cellularised feeding artery and draining vein to the appropriate renal artery and vein of 
the recipient animal. Releasing the arterial clamps resulted in partial re-perfusion of 
the grafts, which was followed by positioning the scaffold into the kidney cavity.  
In six out of eight scaffolds complete blood re-perfusion was obtained within one hour 
from implantation. Five grafts remained perfused for the time of the experiment 
(animals number: 1, 5-8); macroscopically no blood coagulation could be 
characterised (Table 20).  
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Table 20 Outcome of the implantations of the scaffold-constructs into porcine recipients.  
Animal 
number 
Outcome of the implantation 
Successful 
anastomosis 
Re-perfusion 
with blood 
Clot 
formation 
Excessive 
bleeding 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
+ 
+ 
+ 
+ 
- 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
+++ 
+ 
 
 
All parts of the scaffold-construct (including vascular micro-connections 
within the de-cellularised bowel) were uniformly re-perfused and maintained blood 
flow for the duration of the experiment (Fig. 48), which was confirmed by the 
microscopically observed blood perfusion in vivo. Three grafts re-perfused within ten 
minutes, and other two had to be placed into the kidney cavity to allow the completion 
of the process.  
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Fig. 48 Completely and evenly re-perfused with systemic blood scaffold one hour post implantation A - 
arrow heads – clot-free mesenteric vessels, B - arrows – intestinal micro-connections with 
distinguishable de-cellularised vessels: wider veins and  narrower arteries. 
 
A 
B 
Vein 
Artery 
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Two of the procedures resulted in a complete loss of the vessels perfusability 
caused by the blood coagulation as early as ten minutes after introducing the systemic 
perfusion and failed to completely re-perfuse with blood (animal number 3 and 4) 
(Fig. 49). Within one of the re-perfused grafts excessive bleeding occurred (animal 
number 7), and the planned recovery study could not be carried on.  
 
 
 
Fig. 49 Porcine graft implanted for one hour (animal number 3) and fixed in 10% formalin solution for 
24 hours, both sides (A, B). A - Mesenteric arcade with coagulated blood, what was confirmed by the 
incision across the mesenteric vessels. Black arrows – non-perfused parts of the graft.  
 
A 
Incision 
across the 
mesenteric 
vessels  
B 
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In all the grafts some bleeding from the de-cellularised vessels into the spaces 
underneath the serous membrane was observed. Even though blood filled the spaces 
between the serosa and the submucosa in the intestinal part, and between two serous 
layers of mesenteric arcade of the grafts in animals: 1, 5-8 (Fig. 50), striping off the 
serosal layer and closer examination showed an undisturbed rate of the perfusion. 
Within a few minutes of removing the serosal layer, the extravascular leakage 
stopped, and all five grafts were fully perfused with circulating blood till the end of 
the experiments.  
 
 Fig. 50 Porcine graft implanted for one hour (animal number 5) showing extravascular bleeding in 
between serous membranes. Black arrows – blood gathering under intestinal serosa and within 
mesentery. 
 
The lumens of the vessels of the graft left in vivo for 24 hours were perfused at 
the time of explantation (Fig. 51). There was some bleeding from the implant into the 
abdomen, however there were no adverse clinical signs during the time of the 
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experiment. There was no excess blood within the intestinal lumen of any of the 
grafts.  
 
Fig. 51 Intestinal scaffold at 24 hours post-implantation, arrow heads - clot-free mesenteric and 
intestinal vessels showing good blood flow. 
 
The animal that underwent the seven-day-long recovery study survived till the 
planned termination date without showing any signs of systemic infection or other 
alerting symptoms. Over the study period the animal was feeding well, gained 5kg of 
body weight and as soon as 1 day post-surgery passed urine.  
While the graft could not be recognized easily at first sight on explantation, after a 
more thorough examination it was found where implanted. Excessive adhesions to 
surrounding tissues and fibrosis were identified. However, post implantation the 
scaffolds structure and all its parts (including sutures) could be named and visualized 
(Fig. 52).  
 Feeding pedicle 
Mesenteric 
arcade 
De-cellularised 
intestine 
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Fig. 52 Porcine graft harvested 1 week post-implantation, and fixed in 10% formalin solution. White 
arrows show parts of the scaffold-construct that could be identified at the time of explantation.  
 
6.3.2. Development of anti-coagulation protocol 
The re-perfusion of the grafts with systemic blood was obtained in five out of 
eight cases. The unsuccessful re-circulations were caused by clotting of the 
mesenteric vessels, which took place shortly after introducing systemic blood to the 
scaffold-construct. The most successful protocols combined oral pre-medication of 
the animals with 12mg/day of Warfarin, pre-conditioning of the scaffold construct 
with 30.000U of neat sodium heparin and intravenous infusion of 12 000 – 20 000U 
of  sodium heparin. The animals where the total heparin intake (calculated based on 
the weight of the animals and the length of the surgical procedure) was 255-
260U/kg/h were anticoagulated most sufficiently. Nevertheless, the procedure 
performed on the animal that received only 55U/kg/h also had a satisfactory outcome 
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with complete re-perfusion of the de-cellularised vessels (Table 20). It appeared that 
the additional variable was the length of the de-cellularised feeding artery and 
draining vein (Table 21). The outcome of the implantations of shorter vessels was 
more successful and the grafts, which had the highest intake of heparin per body 
weight, per time of the study and per length of the donor pedicle, were mostly clot-
free. The grafts with the lowest heparin intake considering the length of the pedicle 
developed clots at the early stages of the experiments.  
 
Table 21 Total heparin received by an animal in regards to the lengths of the de-cellularised feeding 
artery and draining vein of the scaffold-construct.  
 
Animal 
number 
Length of the 
pedicle 
[cm] 
Average length 
of implanted 
vessels 
Total heparin received by an 
animal regarding length of the 
implanted vessels 
[U/kg/h/cm] Artery Vein 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
1 
3.0 
3.5 
3 
2 
1.9 
1.95 
2 
0.5 
2.5 
2.5 
2.35 
1.95 
1.9 
1.95 
1.85 
0.75 
2.75 
3 
2.675 
1.975 
1.9 
1.95 
1.925 
73 
30 
17 
30 
131 
137 
153 
132 
 
Three successful implantations (animals number: 1, 5 and 6) confirmed good 
mechano-biological behaviour of the scaffold-construct, and plans regarding the next 
step involved recovery studies (animal number 7). Due to unrelated experimental 
circumstances the recipient animal could not receive three but only two doses of 
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Warfarin (2x12mg/day). With regards to properly anti-coagulating the animal, an 
extra dose (120mg=12 000U) of low molecular heparin (Clexane) was injected 
subcutaneously prior to making the midline incision. There was no reduction in the 
amount of heparin sodium injected during the surgical procedure, which in total gave 
298U/kg/h of heparin received by the animal. This protocol appeared to be too strong 
as the animal lost a considerable amount of blood and could not be expected to 
perform satisfactorily in recovery studies (Fig. 53). Therefore four hours after 
implantation the decision was made to remove the graft and terminate the recipient 
animal. 
 
 
Fig. 53 Porcine graft during implantation into porcine recipient (animal number 7); excessive bleeding 
from mesenteric arcade caused the termination of the recipient animal.  
 
The anticoagulation of the graft implanted in the first recovery study was most 
probably insufficient, which caused complete lost of lumen’s perfusion. However, the 
outcome of the second recovery study was successful and the vessels within the graft 
stayed open. There were no signs of severe anti-coagulative activity even in the 
micro-vasculature up to 24 hours post-implantation.  
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The anticoagulation protocol incorporated into the animal studies influenced 
greatly the outcome of the implantations. The biologic activity of blood within the 
grafts was confirmed by the histological findings.  
   
6.3.3. Histological analysis of the grafts  
H&E staining was performed mostly in order to check the uniformity and rate 
of grafts’ re-perfusion with blood and visualize the lack or presence of coagulative 
activity within the de-cellularised vessels. Blood vessels were considered clotted 
when the entire lumen or its majority was filled with a blood clot. A clot is 
characterized by changes of red blood cells morphology (single cells can not be 
distinguished) and uneven distribution of white blood cells (they are usually gathering 
to disintegrate the coagulated blood). Implanted scaffold-constructs were also 
examined for the character and extensity of infiltration with the host cells.    
 
6.3.3.1. Histological analysis of the grafts harvested one hour post-
implantation 
Histological findings showed that all the parts of the explants harvested from 
animals number: 1, 5-8 were fully perfused with blood. Only the smallest vessels in 
the intestinal parts of the grafts showed minimal anticoagulative activity, with 
majority of lumen containing morphologically unchanged erythrocytes.  
H&E staining of anastomotic sites and main pedicle just above the suture line showed 
no signs of clotting (animals number: 1, 5-7) (Fig. 54).  
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Fig. 54 H&E stained cross sections of the anastomotic sites of the graft harvested one hour post-
implantation (animal number 5): A – arterial anastomotic site with no clot formation; B – venous 
anastomotic site with no clot formation. Blue arrow heads indicate the suture. Yellow bars indicate the 
scale of the images. 
 
White blood cells were distributed evenly throughout the lumen and the 
morphology of the red blood cells was unchanged with no indication towards their 
phagocytosis and autolysis within the main pedicle and most of the mesenteric vessels 
(animal number 1, 5-7)  (Fig. 55). Furthermore, small vessels within the intestinal part 
of the scaffold were also clot-free. 
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Fig. 55 H&E analysis of mesenteric arcade of the scaffold implanted for one hour into porcine recipient 
(animal number 6). A- cross section of the mesentery with no signs of clotting,; B- longitudinal section 
of mesenteric vein and artery with clot-free lumens. Yellow bars indicate the scale of the images. 
The majority of the intestinal vessels were evenly and fully filled with blood. 
Moreover most of them contained no blood clots with only few showing minimal 
coagulative activity (Fig. 56).   
 
Mesenteric 
vessel 
A 
White blood 
cell 
Red 
blood 
cells 
Clot-
free 
lumen 
B 
Vein Artery 
                           Chapter 6: Scaffold’s biocompatibility in the porcine model! 
 
 197 
 
 
 
Fig. 56 H&E stained cross section of de-cellularised bowel of the graft implanted for one hour into 
porcine recipient (animal number 1). A- blood-perfused, clot-free intestinal vessels; B- intestinal 
vessels showing minimal blood clot-formation (arrow). Yellow bars indicate the scale of the images. 
 
 
Miller’s elastin staining proved that clotting within the grafts harvested from 
animals number 1, 5-7 was mostly triggered in places where the vascular wall or 
internal elastin was interrupted (Fig. 57). 
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Fig. 57 Picro Sirius red/Miller’s elastin stained section of the small-diameter vessel within intestinal 
part of the graft one hour post-implantation; interrupted elastin (blue staining) causing coagulation of 
the blood (arrow). Yellow bar indicates the scale of the image.  
 
 Histological analysis of the vasculature of the grafts that showed macroscopic 
signs of clotting during the surgical procedure (animal numbers: 3 and 4) proved 
partial or complete loss of ability to perfuse caused by blood-clot formation in many 
places. Major clot formation could already be seen in longitudinal sections of 
anastomotic sites (Fig. 58). 
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Fig. 58 H&E stained longitudinal section of arterial anastomotic site of the graft harvested one hour 
post-implantation (animal number 4): A - blood coagulation within the lumen of the de-cellularised 
donor artery, no blood coagulation in the recipient tissue, blood could still flow through the graft but 
the diameter of the donor vessel was drastically reduced; B – magnified place of anastomosis with 
visible clotting only within the recipient vessel. Yellow bars indicate the scale of the images. 
 
  Similarly, the majority of the mesenteric and intestinal vessels were filled with 
blood at some stage of coagulation or non-perfused at all (Fig. 59).  
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Fig. 59 H&E stained sections of the graft harvested one hour post-implantation (animal number 4): A – 
anastomosed artery with early signs of blood clotting in the central and peripheral part of the lumen; B 
– mesenteric vessels showing signs of blood-coagulation; C – cross section of the intestinal part of the 
graft with non-perfused with the blood intestinal vessels. Yellow bars indicate the scale of the images. 
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As soon as one hour post-implantation, recipient cells were present in the 
anastomosed acellular vessels (Fig. 60).  
 
Fig. 60 H&E stained longitudinal section of the arterial anastomotic site of the graft harvested one hour 
post-implantation from porcine recipient (animal number 1): arrows – host cells infiltrating de-
cellularised superior mesenteric artery. Yellow bar indicates the scale of the image. 
 
6.3.3.2. Histological analysis of the graft harvested one week post-
implantation 
H&E-stained samples obtained from the region of anastomosis and the graft’s 
main pedicle showed a clotted major part of the main artery, with visible signs of 
calcification and fibrotic capsule around the pedicle (Fig. 61). However, some 
thrombus and clot-free sections of the main pedicle could also be identified (Fig. 62).  
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Fig. 61 H&E stained cross section of the graft harvested one week after the implantation (animal 
number 2) showing thrombosed and partially calcified feeding artery. Yellow bar indicates the scale of 
the image. 
 
Fig. 62 H&E stained cross section of the graft harvested one week after the implantation (animal 
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number 2) showing some places where clots were not formed, and the vessels were perfusing. Yellow 
bar indicates the scale of the image. 
 
 Most of the graft’s mesenteric vessels were not open at the time of explantation. 
Infiltration with cells was restricted to the scaffold-constructs external parts, where 
there was evidence of intensive neo-vascularisation (Fig. 63). Fibroblasts aggregation 
could be seen at the outer parts of the mesenteric arcade.  
 
 
A 
                           Chapter 6: Scaffold’s biocompatibility in the porcine model! 
 
 204 
 
Fig.  63 H&E stained cross section of the mesentery of the graft harvested one week post-implantation 
(animal number 2). A- non-infiltrated with the cells middle part of the explant (bracket), and neo-
vascularisation (arrows) in the external, populated with the cells part of the graft; B- non-perfused 
mesenteric vessel. Yellow bars indicate the scale of the images. 
 
 Huge amounts of inflammatory polymorphonuclear cells could be found in 
places of graft re-population (Fig. 64).  
B 
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Fig. 64 H&E staining of intestinal section of the graft harvested one week post-implantation showing 
abundance of polymorphonuclear cells (arrows). Yellow bar indicates the scale of the image. 
 
 
 Furthermore, most of the intestinal parts of the graft were filled with loose, 
spongy ECM fibres. Histology confirmed that the periphery of the graft was fibrotic. 
The only exception was the part of the bowel in region F in Fig. 36. H&E analysis 
showed that at this specific region all the acellular intestinal layers (villi, 
submucosa/muscularis externa and serosa) still could be identified post one week in 
vivo, and no fibrotic reaction or extensive polymorph infiltration was present (Fig. 
65). This was the only part of the bowel where there were signs of functional, blood-
perfusing vessels.  
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Fig. 65 H&E staining of the intestinal part of the graft (region F in Fig. 36) harvested one week post-
implantation.  Arrows – blood-filled vessels within the graft. Yellow bar indicates the scale of the 
image. 
   
6.3.3.3. Histological analysis of the graft harvested 24 hours post-
implantation  
The last scaffold-construct was implanted for 24 hours. The histological 
analysis showed that all of its sections were perfused with blood and most of the de-
cellularised vessels were clot-free. The rate of the cellular infiltration was 
significantly higher than in the grafts implanted for one hour.  The wall of the vein 
was evenly infiltrated with cells some of which were fibroblast-like cells (Fig. 66).  
 
 
Submucosa 
Villi 
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Fig. 66 H&E stained cross sections of the main vein of the graft harvested 24 hours post-implantation 
(animal number 8): A – evenly infiltrated with cells wall of the de-cellularised vein showing no signs 
of blood-clotting; B –elongated, fibroblast-like cells situated within the venous wall (arrows). Yellow 
bars indicate the scale of the images. 
 
 
A 
B 
Clot-free lumen 
Vascular wall 
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The graft’s anastomosed artery (proximal and distal parts) was also infiltrated 
with cells. However, throughout the whole length of the vessel the middle section of 
the wall showed no signs of cellular presence (Fig. 67).  
 
 
Fig. 67 H&E stained cross sections of the main artery of the graft harvested 24 hours post-implantation 
(animal number 8): cells infiltrating the wall of the de-cellularised artery with no signs of clotting 
within the lumen, double arrows - non-infiltrated by cells part of the arterial wall within proximal (A), 
and distal (B) end. Yellow bars indicate the scale of the images. 
 
A 
B 
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The mesenteric vessels were also well perfused and showed no blood-
coagulation. The blood released into ECM was restricted to some small intestinal 
vessels, but there was no major bleeding within any part of the graft (Fig. 68). Most of 
the vessels infiltrating the mesenteric and the intestinal part of the graft were the 
polymorphonuclear cells.   
 
Fig. 68 H&E stained cross section of the mesenteric arcade of the graft harvested 24 hours post-
implantation (animal number 8): clot-free vessels (black arrows) and inflammatory cells infiltrating the 
outer parts of the graft (yellow arrows). Yellow bar indicates the scale of the image. 
 
 Moreover, micro-vessels of intestinal part of the graft were fully perfused with 
blood and, even the small ones were free of clots. Nevertheless, not all of the micro-
vessels were clot-free. In some even though perfusion of blood was still present early 
signs of clot formation started to appear (Fig. 69).  
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Fig. 69 H&E stained cross sections of the intestinal part of the graft harvested 24 hours post-
implantation (animal number 8): A – clot-free section (arrow indicates no clot formation within fully 
perfused intestinal vessel), B – early signs of clotting within some of the intestinal vessels (arrows 
indicate small blood clots). Yellow bars indicate the scale of the images. 
 
Villi 
 
Lumen 
A 
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Bleeding from leaking vessels was present in limited amounts in the intestinal 
part of the graft (Fig. 70).  All parts of the graft were infiltrated with inflammatory 
cells.  
Fig. 70 H&E stained cross sections of intestinal part of the graft harvested 24 hours post-implantation 
(animal number 8): black arrows indicate bleeding in between the ECM fibres, blue arrow indicates 
blood-perfused intestinal vessel. Yellow bar indicates the scale of the image. 
 
6.3.4. Immunohistochemical analysis of the grafts  
All sections of the implants were stained with CD68 as a marker of 
macrophages. The CD68-positive (CD68+) cells were present in almost all sections of 
the grafts implanted for one and 24 hours. Even within one hour post-implantation the 
donor de-cellularised tissue was infiltrated with CD68+ cells. On the cross section of 
the anastomotic site, almost all the cells infiltrating the donor arteries and veins were 
CD68+ and almost no CD68+ could be found within the renal arteries or veins of the 
recipients. The infiltration with CD68+ cells was also intense in mesenteric arcade 
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and intestinal parts of the grafts. Many positive cells were involved either in breaking 
down the blood-clots, gathered on the luminal surface of the vessels, or in the close 
proximity (Fig. 71). The infiltration of monocytes was even more intense at 24 hours 
post-implantation.  
 
Fig. 71 Immunohistochemical analysis of the intestinal part of the graft harvested one hour post 
implantation (animal number 6). Red arrow heads indicate elongated CD68+ cells gathering on the 
luminal surface of the de-cellularised vessel; green arrow heads indicate round, mononuclear CD68+ 
macrophages within the lumen of the re-perfused vessel. Yellow bar indicates the scale of the image. 
 
IHC showed that endothelial progenitor cells were present in all of the parts of 
all grafts harvested one and 24 hours post-implantation. Some were lining the lumen 
and some could be found in the wall of the vessels. Most of the endothelial progenitor 
cells (CD133+) lining the lumens of the de-cellularised vessels were of elongated 
shape. No CD133+ cells could be seen within the recipient vessels. The distal end of 
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the anastomosed vessels was less populated with CD133+ cells.  There were also 
places where endothelial progenitor cells could not be found (Fig. 72).  
 
 
 
Fig. 72 Immunohistochemical analysis of the anastomosis of the graft harvested one hour after 
implantation (animal number 6). A – CD133+ cells line the lumen of the graft’s proximal artery (blue 
arrows); no positive cells could be found in the wall of recipient renal artery; B – magnified de-
cellularised artery: CD133+ cells present in the wall of the vessel (red arrow); C – distal end of the 
anastomosis with no CD133+ cells. Yellow bars indicate the scale of the images. 
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The sections of the graft harvested 24 hours post-implantation showed more 
intense infiltration with CD133+ cells, which were present in the feeding pedicle, 
mesenteric vessels and intestinal micro-vessels. Especially in larger vessels the 
progenitor cells were located mostly on the luminal surface (Fig. 73).  
 
Fig. 73 Immunohistochemical analysis of the anastomosis of the graft harvested 24 hours after 
implantation (animal number 8). Arrows - CD133+ cells lining lumen of the donor de-cellularised 
artery. Yellow bar indicates the scale of the image. 
 
 There were some CD133+ cells spread within some parts of the graft 
harvested one week post-implantation (animal number 2). However, little staining was 
seen in pre-existing vascular conduits, but was seen at the peripheral parts of the graft 
where neo-vascularisation was taking place.  
Von Willebrand Factor is a glycoprotein present in endothelium and 
subendothelial connective tissue. All sections of grafts harvested one and 24 hours 
Lumen 
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post-implantation were marked with anti-VWF antibodies.  For comparison non-
implanted sections of the scaffold-construct were negative for VWF.  
As soon as one hour post-implantation the luminal surface of the graft’s de-
cellularised vessels was positive for VWF (VWF+). Sections of anastomotic site 
showed similar amount of VWF+ staining in donor and recipient main pedicle. 
However, no staining was detected when non-implanted de-cellularised main artery 
and vein were analysed. Vessels that collapsed or were clotted during the period of the 
experiment were not positive for VWF. WVF positivity was found only on clot-free 
surfaces.  No VWF+ could be detected within non-implanted mesenteric arcade (Fig. 
74). Blood vessels of the graft implanted for 24 hours were also VWF+. 
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Fig. 74 IHC analysis of VWF: A - the cross section of the mesentery of the graft harvested one hour 
after implantation (animal number 1): VWF+ present in perfusable vessels without blood clotting 
(black arrow) and absent in clotted vessels (red arrows); B – the cross section of mesenteric vessel 
partly clotted: the VWF+ restricted to non-clotted parts of it (blue arrows); C – the cross section of  the 
mesentery of a scaffold prior-to-implantation showing no VWF+ staining within its vessels. Yellow bar 
indicates scale of the images. 
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The staining of the graft harvested one week after implantation expressed 
endothelial cells’ marker (CD31) only in functioning vessels. No smooth muscle cells 
were detected in any of the scaffolds implanted for either one or 24 hours.  
 
6.4. Discussion  
Orthotopic implantation of de-cellularised organs is increasingly considered as 
a more relevant test of mechano-biological properties of the de-cellularised (through 
the vasculature) tissues and organs than any ex vivo experiments (174). These 
matrices should have the requisite strength and properties to enable them to function 
adequately under physiological loading. Vascularised scaffolds need to be not only 
biocompatible, but also minimally thromboreactive, which is the greatest immediate 
concern. It is well established that platelet activation occurs when platelets come in 
contact with collagen. Platelets directly adhere by binding platelet collagen receptor to 
integrins on collagen, and the intrinsic clotting cascade is initiated when prekallikrein, 
kininogen, factor XI and XII are exposed to collagen (175). Lack of an endothelial 
lining can make the anastomosed vessels highly thrombogenic, and too gentle an 
anticoagulation protocol can cause blood clot development in the early stages of 
surgical procedures. 
At the moment, there is no commercially available system that could be 
successfully incorporated into in vitro models of small intestine bio-engineering using 
de-cellularised porcine ileum. Therefore, the only way to test a scaffold’s 
biomechanical behaviour was introduction of the systemic perfusion in vivo. Ongoing 
studies are focused on pre-seeding vascular and intestinal parts of the scaffold with 
different cell types (endothelial and organoid units) which in future will be tested in 
vivo. Seeding anti-thrombogenic precursors or heparin lining of capillaries may avoid 
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coagulation while implanting the scaffold-constructs. However, at present none of the 
above techniques are ready to be incorporated in the studies and thus, the application 
of anticoagulants was necessary.  
Coagulation of blood and consequential loss of vessels un-clotted was a worry 
while performing implantations into porcine recipients. Pigs have the most reactive 
blood coagulation mechanism, clotting the fastest and lysing the slowest (176). This 
makes them both: perfect to check scenarios of grafts perfusion-ability, and at the 
same time extremely difficult in terms of obtaining positive outcomes. While no 
anticoagulation protocol must be applied in studies of ECM-scaffolds under high-
sheer and high-pressure (142) when implanting small-diameter, acellular grafts in 
positions with lower flow velocity and pressure values anticoagulation treatment is 
necessary (177).  
The presented results show that the mechano-biological features of the developed 
scaffold made it easy to implant and re-perfuse with blood. The developed 
anticoagulation protocol was sufficient to keep implants perfused for the duration of 
experiment, without causing excessive bleeding. When other acellular scaffolds 
composed of vascular tree were implanted, lack of anticoagulation activated 
thrombosis within 30 minutes post-anastomosis. The only way to eliminate this 
negative outcome would have been to pre-seed and culturing the vasculature of the 
scaffold with endothelial cells or progenitors (178). Nevertheless, even in this group 
preliminary studies involved implantation of seven un-seeded scaffolds into porcine 
recipient. Moreover, all seven implants resulted in immediate and excessive bleeding 
from the vasculature, suggesting, that the applied process of de-cellularisation 
damaged the structure of ECM, especially elastin of the scaffolds vascular tree. As 
collagen fibres are highly thrombogenic, places of disrupted tunica interna and 
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internal elastin were inducing clot formation in grafts implanted for one hour. 
Therefore, it was of high importance to design the de-cellularisation process to 
preserve these features of ECM and at the same time remove antigenic epitopes. 
When heparin was used as an anti-coagulative agent the outcome of the implantations 
was much more positive (174). 
The preliminary outcome of the first anastomosis showed great potential, and 
therefore the decision to conduct a first recovery study was taken. Inefficient 
anticoagulation and rapid loss of vessels ability to get perfused post-implantation were 
the cause of the grafts negative outcome. Nevertheless, even these seemingly 
unsuccessful experiment proved that in places where perfusion was present for the 
whole time, were well infiltrated with cells, and did not show extensive inflammation 
or fibrosis. However, it was obvious that the mechanism of this primary perfusion 
needs to be well established before committing to longer than one hour studies.  
The series of following procedures proved that the outcome of testing 
biological products/scaffolds can very often depend on the donor animals and their 
anatomical and physiological variability. Therefore, the methods incorporated into the 
experimental model needed optimizing for a range of biological differences that could 
contribute to the general outcome of the study. It appeared that while implanting the 
de-cellularised scaffold the first successful procedure could not be repeated without 
optimizing anticoagulation protocol. Moreover, additional criteria such as recipient 
blood pressure, or the length of grafted vessels were the reason for the negative 
outcome of the graft. Nevertheless, four similar and satisfactory outcomes in the 
terminal procedures (one hour implantations) could be achieved. What is more, a 
recovery study using the same protocol resulted in very promising data.  
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Two short term operations were unsuccessful. The main reason of the failure 
of the first one was early clotting within the mesenteric arcade. The second implant 
was unsuccessful largely due to the hypotension within the recipient renal vessels, 
which in combination with unsatisfactory heparinisation caused early vascular 
obstruction.  
Surprisingly, the length of the anastomosed donor capillaries appeared to be an 
additional variable, which influenced the outcome of the implantations. Distal parts of 
the grafts with longer pedicles were characterised with lower blood pressure, which 
triggered blood clotting within smaller vessels. Taking into consideration all the 
variables it was possible to optimize dosage of heparin/Warfarin that had to be 
introduced into the system (through the recipient and the scaffold) to prevent blood 
clots formation. Some authors suggest that anticoagulation is not recommended for 
SBS patients, especially children (179), however at this stage of the project it was 
more important to check the graft’s biomechanical behaviours, to prove the concept 
that it can be re-perfused immediately after implantation, rather then design a viable 
clinical protocol.  
Only when heparin intake was increased to 250-260U/kg/h the anticoagulation 
was strong enough to prevent clot formation even in intestinal micro-vessels. On the 
other hand, too harsh an anticoagulation protocol caused excessive bleeding from the 
graft (animal number 7), and recovery studies could not be continued. Dose of heparin 
oscillating around 250-260U/kg/h with addition of 12mg/day of Warfarin for three 
days prior to surgery appeared to be a mostly reliable and an optimal protocol which 
prevented clotting, but did not cause excessive bleeding within the graft. Even after 24 
hours the vasculature was unobstructed and only few vessels contained small blood-
clots. At the time of harvest there was small amount of blood within the kidney cavity, 
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which suggested that the leakage was originating from the graft. Such a state in longer 
studies (e.g. few days or weeks) could induce overt clinical symptoms. The bleeding 
could have been caused by the animal placing too much physiological tension on the 
fragile de-cellularised vessels while moving. Moreover, high doses of the 
anticoagulative drugs would prevent blood from clotting and naturally strengthening 
the acellular vessels. In future it would be advisable to separate fragile scaffold from 
abdominal content by use of surgical bowel bags.  
There was some leakage from the vascular channels into the matrix. However 
most of the fluid was exiting via the venous outflow. Most of the blood was gathered 
underneath the serosa. Similar problems were encountered when Peterson et al. 
performed in vivo studies of de-cellularised lung tissue in rat model (180). 
Nevertheless, the bleeding from the intestinal scaffold was significantly limited after 
24 hours post-implantation. In long term studies while vessels are re-cellularised, new 
ECM is being produced and there is less leakage from the loose collagen fibres of 
micro-vessels (181). Moreover, as the endothelium is being formed, or vessels are 
seeded prior to implantation the need for anticoagulation is lower.  
Little information is available on the re-cellularisation of plain de-cellularised 
biological scaffolds in the systemic circulation. This study proves that the ingrowth 
from the host tissue happens immediately after implantation, but the deposition of the 
progenitor cells and macrophages from the blood stream is also possible. All the 
successfully integrated grafts proved to be highly biocompatible and as soon as one 
hour post-implantation the proximal ends of anastomosed vessels were re-populated 
with the host cells. It has been shown that the majority of the cells residual in the 
tissue engineered grafts come from host tissue rather than the seeding process (182).   
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Comparing the histological sections of the scaffolds that stopped perfusing 
blood within the first half hour in vivo, with the ones that stayed clot-free, the rate of 
the scaffold infiltration with host cells was lower. Many more cells were always 
visible within the anastomotic site than in other parts of the implants, which indicated 
that cells were coming from direct tissue-tissue rather than blood-tissue contact. Yet, 
cells were also visible in distal parts of the grafts, in the vicinity of open, blood 
perfusing vessels. The cells infiltrating the scaffold-construct within first hour post-
implantation are mainly polymorphonuclear cells and macrophages. 
Immunohistochemical analysis proved that majority of the cells repopulating grafts 
implanted for one and 24 hours into porcine recipient were macrophages and 
monocytes. Recently, as stated in the previous chapter it has been identified that 
macrophages’ activity is very important in constructive remodelling of the graft and 
as well inducing rejection of the implant it also can promote regeneration or site 
specific tissue formation (183). Moreover, macrophages are very plastic cells and are 
responsive to cell-cell and cell-matrix cross-talk: in vivo that monocytes and 
macrophages can have the propensity for endothelial trans-differentiation (184). 
Moreover, 24 hours post-implantation endothelial progenitor cells could be found on 
luminal surfaces. In grafts explanted after one hour CD68+ cells were found in 
abundance. As a result of exposure to higher sheer-stress levels endothelial 
progenitors and macrophages were mobilized, which was confirmed by differences in 
re-population with CD133+ and CD68+ cells within arterial and venous anastomotic 
sites. More endothelial progenitors were present in proximal parts of the acellular 
vessels. However, some were delivered with systemic perfusion into distal, smaller 
mesenteric vessels, as one of the roots for re-endothelialisation (185). 
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Absent in non-implanted scaffolds VWF+ staining was found on clot-free 
luminal surfaces of vessels within the grafts implanted for one and 24 hours. This 
means that the staining is indicating the dynamic surface of the blood activity rather 
than subendothelial proteins. VWF is blood glycoprotein involved in haemostasis, and 
its expression within the vasculature of the implants was a consequence of its 
interaction to collagen and not indication of endothelial activity. Moreover, the 
implants showed infiltration with progenitor cells which over time could possibly 
become mature endothelium with all the trans-membranous proteins, but this 
differentiation has been reported to last at least two weeks (175).  
All parts of the graft were infiltrated with cells 24 hours post-implantation. 
Some of the ones present on the lumenal surface and within the vascular wall had 
elongated shape, similar to endothelial and fibroblast-like cells. However, except 
some randomly placed cells on the periphery of the vascular wall no other !SMA+ 
staining was detected.  
Interestingly, there was one part of the graft that did not get re-populated with any 
cells. It was the media (central part of the vascular wall) of grafted main artery (Fig. 
67). The cells were lining the lumen and re-populating the outer part of the wall. 
However, not even one cell was seen in middle section. That kind of selective 
infiltration pattern was reported when other de-cellularised vessels were tested in vivo 
(186). One explanation could be the fact that highly organised ECM of central part of 
the vascular wall is more resistant to cellular infiltration. It is possible that this 
organisation of fibres is very specific to smooth muscle-like cells.  
The 24 hours old graft was infiltrated with inflammatory cells, but no severe immune 
response could be seen in any of its parts. Nevertheless, the period of experiment was 
too short to definitely say that no chronic reaction was expected. 
                           Chapter 6: Scaffold’s biocompatibility in the porcine model! 
 
 224 
After 24 hours in vivo there was less macrophages within the arterial 
anastomotic site than within the venous one. On the other hand, high numbers of 
CD133+ cells were still present in the arterial anastomotic site and not many CD133+ 
cells were seen within the grafted vein. It could suggest that in the first instance the 
macrophages re-populate de-cellularised tissue and induce ECM remodelling which 
then attracts progenitor cells. The rate of infiltration with host cells of arterial 
anastomotic site was higher than the venous one in all the grafts (181).  
 Taking everything into account it was demonstrated that the de-cellularised 
tissue was easy to implant and re-perfuse (using adequate anticoagulation protocol) 
and trigger cellular infiltration and possible differentiation towards functional 
endothelium. It is a satisfying initial phase of constructing complex tissue constructs. 
It could be a good proof of principle for incorporating the scaffold into in vitro phase, 
where vasculature and intestinal segment can be separately and simultaneously seeded 
and cultured in a bioreactor.  
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Chapter 7. 
Isolation and characterisation of porcine 
organoid units and endothelial cells 
 
7.1. Background and aims   
 The epithelial lining of the gastrointestinal tract is the most rapidly 
proliferating tissue in the body. As described in Chapter 1 this constant state of 
renewal of differentiated epithelial cells is sustained by a continual supply of progeny 
from multipotent progenitors that originate from stem cells located within the 
intestinal crypts. In addition to supporting normal epithelial homeostasis, intestinal 
stem cells are thought to play an important role in the rapid expansion of the gut 
during development, tissue regeneration following injury or surgical loss, and 
malignancy (187).   
The above caused a tremendous increase in the study of stem cells in both 
homeostatic and disease states in the past decade. Our understanding of intestinal 
adult stem cell biology and (how stem cells fit into a niche, and how that niche 
influences them) has significantly increased. However, this knowledge results largely 
from indirect measurements of their behaviour, as very little is known about the 
specific markers that could be used to isolate and characterise intestinal stem cells. 
Furthermore, their specific location and function within a well-established intestinal 
stem cells niche makes it difficult to culture them in vitro. Thus, growing of intestinal 
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epithelium containing stem cells has many limitations. Established cell lines are 
predominantly fetal or transformed and bear little resemblance to normal adult 
intestine in terms of growth factor responses, susceptibility to apoptosis, gene 
expression, and differentiation (116).  Currently the only method to isolate intestinal 
stem cells, and preserve their ability to proliferate and differentiate into adult 
intestinal epithelium has been described by Evans et al. (73). As mentioned before 
intestinal OU isolated from neonatal rats (73) or juvenile pigs (80) with preserved 
intact stem cells and their niche have been shown to generate mature tissue in vivo 
(116). 
The recent description of several potential markers and the use of transgenic 
mice and advances in neomucosa creation have provided a tremendous advancement 
in current understanding of these cells. The first such marker identified in the small 
intestine, Musashi-1 (Msi-1), is expressed within a broad region of the stem cell zone 
of the crypt (187). Lgr5 was initially identified as a Wnt target gene expressed in 
colon cancer, and is the first marker to identify the cells between the Paneth cells 
(188). Lgr5-positive cells were shown to be active in the cell cycle, dividing once 
approximately every 24 hours. Lineage tracing experiments showed that Lgr5- 
positive cells were capable of generating the entire villus epithelium (187).  Recently 
doublecortin and CaM kinase-like-1 (DCAMKL-1), a microtubule associated kinase 
in postmitotic neurons, has been shown to colocalize with Msi-1 staining, however 
with a more restricted expression (189).  
The aim of the experiments presented in this chapter was to establish the 
method of isolation of porcine intestinal organoid units, and using available stem cell 
markers to localise them within isolated clusters. Organoid units were isolated from 
juvenile and adult donors. The obtained populations could be used in future 
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experiments for seeding de-cellularised intestine to promote neomucosa creation, 
which would be a completely novel approach in targeting small intestine tissue 
engineering. The method of isolation adult, porcine, intestinal organoid units has not 
been described before.  
Moreover, the isolation, and in vitro propagation of endothelial cells was 
characterised with the aim of incorporating them into future experiments for seeding 
the vascular part of the scaffold presented in chapter 3.  
The experiments presented in this chapter characterise the structure, but the 
functionality of isolated OU and cells is yet to be proven.  
 
7.2. Methodology  
This chapter describes the method of isolating porcine OU from a piglet and three 
adults, characterization of their yield and IHC labelling of intestinal stem cells.  
The isolation of endothelial cells was carried out once as the methods of obtaining 
relevant amounts of endothelial cells are well described in literature. Nevertheless, it 
was important to optimise and make ready the protocols for harvesting and 
characterising cells prior to the seeding experiments.  
 
7.2.1. Materials 
 The list of materials and equipment used in experiments described in this 
chapter is presented in Appendix 4.  
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7.2.2. Animal husbandry 
All animals were maintained and handled similarly to the process presented in 
Chapter 3 (3.2.2).   
 
7.2.3. Solutions 
 Solutions used in experiments presented in this chapter are described in 
Appendix 16.  
 
7.2.4. Isolation and characterisation of porcine intestinal 
organoid units 
 
7.2.4.1. Isolation of porcine organoid units 
Under sterile conditions 10 cm of jejunum (n=1) was resected from a 6 weeks 
old piglet (11 kg), 10 cm of jejunum (n=3) and ileum (n=3) from an adult White 
Crossbred pig. First, the lumens were flushed with room temperature saline solution 
and then with cold Hank’s Balanced Salt Solution (HBSS) to clean the luminal 
content. The specimens were then cut into 1mm2 squares using a tissue cutter. These 
were washed three times with 4ºC HBSS, sedimenting for at least 1 minute between 
washes. Subsequently the specimen was digested with enzyme solution on an orbital 
shaker at 37 ºC for 30 minutes (piglet) or 2.5 hours (adult pig). The digestion was 
immediately stopped with three washes of a 4ºC Dulbecco's Modified Eagle's 
Medium (DMEM) solution. The organoid units were centrifuged between washes at 
150 rpm for 5 minutes, discarding the supernatant. Finally the organoid units were 
reconstituted in DMEM solution and their yield was checked and histological smears 
were prepared.  
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7.2.4.2. Characterization of the yield of porcine intestinal organoid units 
To establish the yield of the isolation process, OU were counted in the 
haemocytometer and their viability was checked. Immediately after isolation, 100$l of 
organoid units’ solution was spun down and the pellet was re-suspended in PBS. 
Trypan blue solution was added to the suspension to obtain 1:1 dilution. The pellet 
was broken down by pippeting up and down and 10$l of the prepared solution was 
placed in a haemocytometer. The number of intestinal organoids seen in five separate 
grid squares was recorded. The organoid units’ viability was checked by counting 
units, which did not stain with the dye against the dead ones that appeared blue.  Each 
grid square measured 1mm x 1mm with a depth of 0.1mm corresponding to a volume 
of 0.1µm. Since the total volume of resulting OU suspension was known, the yield 
was calculated per 10cm of intestine.  
 
7.2.4.3. Immunohistochemical visualization of intestinal stem cells within 
the porcine organoid units 
Organoid units reconstituted in DMEM were spun down and re-suspended in 
PBS. Subsequently smears of cell clusters were prepared on APTS slides by placing 
40$l (one drop) of solution onto the slide. The liquid was gently spread out using a 
pipette tip on a slide surface and left to dry overnight. The following day the slides 
were fixed in 1:1 solution of ice-cold acetone and methanol for 2 minutes at 4 ºC and 
left to dry at room temperature overnight.  
Fixed slides underwent IHC staining of intestinal stem cells within the 
organoid units using DCAMKL-1 antibody (Table 8, Appendix 9). The staining was 
performed in a way described in sub-chapter 3.2.6.3.  
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7.2.5. Isolation and culture of porcine endothelial cells and 
their characterisation  
 
7.2.5.1. Preparation of gelatin-coated glass coverslips 
 Gelatin solution was autoclaved and cooled down to room temperature. Glass 
coverslips were heated in nitric acid solution, and rinsed under running distilled water. 
Then they were transferred to a conical tube containing 70%EtOH solution and stored 
till the day of the experiment. Two hours prior to the cells isolation coverslips were 
placed in the wells of the culture plates and rinsed twice with sterile distilled water. 
The culture surfaces of the coverslips were coated with gelatin solution (10µl/cm2) 
and allowed to dry at least for two hours (with lid partially open) under the laminar 
flow, before introducing cells and medium.  
 
7.2.5.2. Isolation of porcine endothelial cells  
 Under sterile conditions a 5cm segment of jugular vein was resected from an 
adult White Crossbred pig. First it was flushed with Dulbecco’s PBS (D-PBS) and 
filled with Collagenase F solution. The vein was then incubated at 37°C (gassed with 
5% CO2 at 100% humidity) for 15 minutes. The endothelial cells solution was placed 
in centrifugation tubes, and the collagenase activity was stopped by adding 
supplemented standard medium. After centrifugation at 1000rpm for 5 min, the 
supernatant was discarded and the pellet resuspended in PBS. This procedure was 
repeated twice before the pellet was suspended in endothelial cell growth medium. 
Cells were seeded onto 6-well-plates supplemented with gelatin-coated coverslips and 
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cultured at 37°C  (gassed with 5% CO2 at 100% humidity) for two weeks. The culture 
was passaged twice (day 5 and 10), and the medium was changed every second day. 
 
7.2.5.3. Yield and viability analysis of harvested and cultured endothelial 
cells  
Harvesting of cells from gelatin-coated coverslips was performed by 
incubation for 5 minutes in 37°C trypsin solution. Trypsin was inactivated by adding 
supplemented standard medium to wells. Following trypsin solution treatment cells 
were centrifuged and washed in PBS. Their yield and viability were checked on day 0, 
5, 10 and 14 using haemocytometer in a similar matter as described above.  
At the end of the experiment the coverslips were removed, washed in PBS, 
fixed in ice cold acetone and methanol (1:1) for 10 minutes at -20°C, and air dried. 
 
7.2.5.4. Immunocytochemical characterisation of cultured endothelial 
cells  
The cells identity was confirmed performing immunocytochemical staining 
(ICC) using anti-Factor VIII antibody (A0082). First cells were washed three times in 
PBS and immobilized for 10 minutes using Triton X solution. Then coverslips were 
washed 3 x 3min in PBS and non-specific staining was blocked with Dako Protein 
Block for 30 min. The primary antibodies were applied in dilution of 1:200 overnight. 
On the following day the coverslips were washed 3 x 3 min in PBS and incubated 
with Anti-mouse ImmPRESS kit for 30 min. Following three washes in PBS (3 x 
3min) coverslips were incubated with chromogen (DAB) for 3 minutes and washed 
with distilled water. Coverslips were then counterstained with Harri’s haematoxylin 
and mounted onto histological slides.     
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7.3. Results  
7.3.1. Isolation of porcine intestinal organoid units 
The process of isolating the organoid units from jejunum of a piglet was 
successful, however the digestion of the tissue needed to be harsher and longer when 
using small intestine of an adult animal. The isolated organoid units were clusters of 
mesenchymal and epithelial cells of different size (Fig. 75). Some were very similar 
in appearance to rat organoid units (Fig. 75 A) measuring 50 (width) -200 (length) 
$m, others appeared to be as big as single intestinal crypt/villi. Their lengths exceeded 
350 $m (Fig. 75 B). Nevertheless they were always composed of a mesenchymal core 
and external epithelial layer.  
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Fig. 75 Intestinal organoid units isolated from an adult pig, containing mesenchymal cells in the centre 
and epithelial layer on the periphery: A – small units measuring 50-200$m; B – large, crypt-size units 
measuring more then 350 $m in length (for comparison of crypts morphology see Fig. 1). Bars indicate 
the scale of the images.  
 Final suspensions of OU obtained from adult intestines contained much more 
cellular components (both epithelial and mesenchymal), as well as some unbroken 
sections of muscularis mucosae.  
 
7.3.2. Characterization of the yield of porcine intestinal 
organoid units 
Using a more gentle protocol the amount of organoid units isolated from piglet 
jejunum was comparable with the amount of OU harvested from the ileum of an adult 
animal. It was possible to obtain 250 000 OU per ml of PBS which was equal to 5 000 
000 OU isolated from 10cm-long segment of jejunum. The average amount of the 
intestinal OU isolated from ileum of an adult pig was 263 333 OU/ml which was 
equal to 5 266 667 OU per 10cm of ileum (Table 22). On average much less organoid 
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units could be obtained using the same protocol from jejunum of an adult pig (170 
000 OU/ml = 3 400 000 OU/10cm of jejunum). However, high standard deviation 
values showed high variation within that group, with one procedure resulting in 
isolating 280 000 OU/ml (5 600 000 OU/10cm of jejunum) whilst another as little as 
80 000 OU/ml (1 600 000 OU/10cm of jejunum).  
 
Table 22 Yield analysis of intestinal organoid units isolated from adult pigs; STDEV – standard deviation. 
Tissue 
Animal 
weight 
[kg] 
Organoid 
units/ml  
of PBS 
[OU/ml] 
Average 
OU/ml  
(STDEV) 
Total 
organoid  
units in 
10cm  
of small 
intestine 
Average 
OU/10cm of 
small intestine 
(STDEV) 
Ileum 
55 270 000 
263 333 
(11 547) 
5 400 000 
5 266 667 
(230 940) 
65 250 000 5 000 000 
62 270 000 5 400 000 
Jejunum 
50 280 000 
170 000 
(101 489) 
5 600 000 
3 400 000 
(2 029 778) 
65 80 000 1 600 000 
60 150 000 3 000 000 
 
 Viability tests showed that isolated OU were intact and contained a majority of 
viable cells, although some of the epithelial cells of the isolated OU were not viable - 
which is to be expected with this type of isolation (Fig. 76). Nevertheless none of the 
analyzed organoid units were composed of only dead cells. Most of the mesenchymal 
and epithelial cells had intact cytomembrane and did not show any trypan blue intake. 
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Fig. 76 Trypan blue-stained intestinal organoid units isolated from an adult pig, some dead (blue) cells 
can be seen on the periphery of the cluster (arrows), however most of the cells within the unit stayed 
alive. Bar indicates the scale of the image.  
 
7.3.3. Immunohistochemical visualization of intestinal stem 
cells within the porcine organoid units 
The intestinal stem cells were successfully identified in both small intestine 
and intestinal organoid units (Fig. 77, 78). The DCAMKL-1+ cells were present in 
OU isolated from both: piglets and adult animals. However, not all OU contained 
DCAMKL-1+ cells. Some organoids had the morphology of the OU but contained no 
stem cells (Fig. 79). The DCAMKL-1+ cells found in the small intestine were mostly 
restricted to the intestinal crypts. Nevertheless, some odd cells could be also seen 
towards the villi (Fig. 78).  
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Fig. 77 IHC analysis of the intestinal stem cells within the isolated from an adult pig intestinal organoid 
unit. A – large, crypt-like units; B – smaller OU. Arrows indicate brown, positively stained with anti-
DCAMKL-1antibodies cells within the OU. Bars indicate the scale of the images. 
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Fig. 78 IHC analysis of intestinal stem cells within the ileum of an adult pig. A- low magnification; B – 
high magnification. Arrows indicate brown, positively stained with anti-DCAMKL-1antibodies cells. 
Bar indicates the scale of the image. 
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Fig. 79 IHC analysis of intestinal stem cells within the isolated from an adult pig, intestinal organoid 
units. No brown, positively stained with anti-DCAMKL-1antibodies cells within some of the OU. Bar 
indicates scale of the image. 
 
7.3.4. Isolation of endothelial cells and their characterisation 
 The process of isolation of endothelial cells from a 5 cm long segment of 
porcine jugular vein was conducted once and resulted in the yield of 240 000 cells and 
high viability (Table 23). Endothelial cells were successfully seeded onto gelatin-
coated glass coverslips and maintained in the culture for two weeks. Their yield was 
checked while passaging on day 5 and 10 and at the end of experiment. The six-fold 
increase in the yield of the endothelial cells was recorded two weeks into the culture. 
The cells viability remained high (83-95%) throughout the experiment (Table 23).  
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Table 23 The yield and viability of endothelial cells cultured in a monolayer on a gelatin-coated glass 
coverslips. 
Day of culture Yield [CN*] 
Viability 
[%] 
0 (isolation) 240 000 83 
5 (1st passage) 950 300 95 
10 (2nd passage) 1 102 000 90 
14 (final harvest and end of the experiment) 1 124 500 91 
*CN- total cell number originating from 5cm long segment of porcine jugular vein 
 
The cultured cells remained in their differentiated state throughout the 
experiment, which was confirmed performing ICC labelling of endothelial marker 
(Fig. 80).  
 
Fig. 80 ICC analysis of porcine endothelial cells cultured in monolayer for two weeks. All the cells 
remained in their differentiated state expressing FVIII (brown staining). Bar indicates the scale of the 
image. 
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7.4. Discussion  
The intestinal epithelium is a continuously replacing tissue. The cells 
responsible for this replacement are the stem cells located towards the base of the 
small intestinal crypt or at the very base of a colonic crypt (116).  
As described before, OU are multicellular clusters, originating from 
gastrointestinal tissue, predominantly containing epithelial cells based around a 
mesenchymal core. When seeded on an appropriate scaffold, either in a rodent (190) 
or pig (80) model they have been reported to form neo-tissue which replicates the 
architecture of the native organ (stomach and intestine).  
The secret of success of OU in their proliferating capacities is the preservation 
of mesenchyme-epithelial integrity. Beyond fetal development, balanced gut 
maturation depends on that cross-talk (191). Only the preservation of intestinal stem 
cell niche and support of mesenchymal-derived cells is crucial for preservation of the 
balance between the high rate of production and apoptosis of intestinal cells and the 
regulation of their proliferation and differentiation. This interaction is vital for 
maintaining crypts and villi morphology and therefore the gut functionality (192). 
Pericryptal mesoderm is composed of fibroblasts, which are key cells supporting the 
intestinal stem cells. Characteristically they form a protective fenestrated sheath 
around the stem cell compartment, creating the stem cell niche – the optimal 
environment for stem cells to renew themselves and to give rise to differentiated 
progeny (191). Thus, the mesenchymal core of OU is a major source of instructive 
signalling to the intestinal epithelium. Growth factors and cytokines secreted by it 
promote epithelial restitution and proliferation (192). Mesenchymal derived cells are 
required for long-term culture of intestinal stem cells. Intact Wnt and Notch 
signalling, which are active in the niche, were confirmed to be necessary in vitro 
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(193). This key feature of OU was granted by gentle isolation, which results in 
preservation of the niche containing stem cells.  
It was possible to isolate the OU whilst preserving the stem cell niche from 
both: piglet and an adult animal. The age of the piglet was chosen as it corresponds (in 
terms of establishing all cell lines of the small intestine) to the age of suckling rats 
used by Evans and colleagues (73) and the age of pigs used by Sala et al. (80). The 
obtained clusters resembled in their appearance OU reported by Sala et al. (80).  They 
were also similar in their structure to OU isolated from rodents (190). There was 
neither noticeable difference in the appearance of the clusters isolated from a piglet 
and adult animals, nor between OU obtained from jejunum and ileum. The 
dissimilarity among jejunal and ileal tissue appeared in the yield of the isolation 
procedure. Use of the same protocol resulted in a much lower yield of OU isolated 
from jejunum. However, the high standard deviation values suggest the result could 
not be interpreted into a firm conclusion. Two out of three variables within that group 
are similar to the values of the OU isolated from the ileum, and exclusion of the 
lowest number would bring these assessments to equilibrium. The average yield of 
OU isolated from a six weeks old piglet by Sala et al. (80) was similar to the one 
obtained here (5 845 000 vice 5 000 000). It was also comparable to the yield of OU 
harvested from an adult ileum (5 266 667). 
Even though the isolation process of OU from an adult gut was significantly longer 
than any other previously reported, there was no compromise on OU viability.  
The isolation procedures were similar to that reported in the other study (80), 
however the time and the concentration of enzymatic agents had to be drastically 
increased while isolating clusters from the adult animals (for both: ileum and 
jejunum). Even though Evans et al. (73) reported large numbers of mesenchymal cells 
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from the lamina priopria of a suckling rat, which were present as single cells and 
smaller clusters, it appeared that while harvesting OU from adult intestine the 
contamination with mesenchymal and epithelial cells is much higher. This was caused 
by the fact that porcine intestine harvested from an adult contains much thicker 
mucosal, submucosal and muscular layers which are more resistant to the gentle 
digestion by collagenase/dispase cocktail. Higher enzyme concentrations and longer 
digestion time allowed OU to be obtained in the desired cluster-form, but some 
superficial cells, exposed to these high doses were easily disconnected from main core 
of the tissue. Moreover, big undigested sections of muscularis mucosae were still 
present in the supernatant of the OU solution. While isolating OU from the rodents all 
the non-OU debris can be eliminated by simple sedimentation. This technique worked 
well in case of the piglet intestine but when using adult guts the supernatant still 
contained non-OU tissue sections and large amounts of cells. All of the intestinal 
tissue engineering studies to date have isolated OU from either neonatal rat intestine 
which contained small blunt villi but no well-developed crypts, or piglets intestine 
with much thinner than in adults tissue intestinal layers (80).  
No other report investigates the isolation of OU from adult animals, and the 
presented protocol is the optimum method while preserving the stem cells niche and 
organoids morphology without incorporating complex and time consuming steps. 
However, it is not known if the function of the intestinal stem cells within isolated OU 
is preserved. The fetus and newborns have significant regenerative capability different 
from adults (194). Therefore, the activity of the adult intestinal stem cells within 
isolated OU may not be as efficient in generating intestinal epithelium as the reported 
neonatal tissue. Furthermore, the in vitro or in vivo role of ‘contaminating’ cells and 
mesenchymal sections remains to be tested.   
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In many reports describing generation of neo-intestine when using OU in 
rodent models it was uncertain whether any functional stem cells survived the 
isolation procedures or the subsequent culture period (116). It was not until recently 
that a putative molecular maker for intestinal epithelial stem cells in situ within intact 
tissue sections was suggested. Msh-1 was reported as that candidate. It is a neural 
RNA-binding protein that controls Drosophila external sensory organ development by 
regulating target genes post-transcriptionally and controls asymmetric cell division 
(195). The expression pattern of Msh-1 has been examined in mouse small intestine 
using IHC and in situ hybridization. The Msh-1 positive cells were located not only 
within the expected stem cell niche but also above the theoretical location, which 
suggest that some daughter cells also express the epitope (196). Moreover, the Msh-1 
expression could not be examined ex situ and only small amounts of Msh-1 are 
normally found in gut (197). The only way to identify these cells was to localize them 
in a very selective expected place of residence. The improvement in the field of 
antibodies used for visualization of specific antigens within the tissue is much slower 
in the field of pre-clinical than clinical studies. Antibodies specific for animals and 
especially for rodents (huge cross-reactivity) take longer to be tested for specific 
applications and introduced to the market. Working on a rat tissue it was impossible to 
use Msh-1 to visualize intestinal stem cells within OU isolated even from suckling 
pups. However, moving towards large animal models it was achievable using a 
different, better tested marker. It appeared that intestinal stem cells identified by the 
putative stem cell marker - DCAMKL-1, are one of the major components of an intact 
intestinal stem cell niche. First to characterize this microtubule associated kinase, 
expressed in post-mitotic neurons as an intestinal stem cell marker were May et al. 
(198). This chapter characterises the expression of this marker in either: the native 
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small intestine (of a piglet and an adult) and within isolated OU (piglet and an adult). 
DCAMKL-1 expression in colon has been restricted to a single cell within the crypt. 
However, in the small intestine it was reported in more than one location of intestinal 
crypt, and even within crypt/villus junction (189). Multicenter staining of DCAMKL-
1+ cells was also reported by Sala et al. (80). This unspecific to stem cell niche 
staining was also observed in this experiment. Nevertheless, not all of the isolated 
units contained positive DCAMKL-1 cells. Each individual OU may consist of a 
mixture or one type of the proliferating cell populations, stem cells or differentiated 
cells (199) which explains why some of the OU were negative for DCAMKL-1.  
 The method presented in this chapter for isolation and in vitro propagation of 
endothelial cells has been previously described by Mall et al. (200). The ultimate goal 
of the project focuses on constructing a cellular implant that could be generated in 
vitro for in vivo application. As future work will mostly be focused on engineering a 
bioreactor and seeding the scaffold, it was important to optimize methods of isolation 
and characterise both types of cells needed for seeding a scaffold that has intact 
vascular conduits. The presented method may not be ideal for clinical use but at this 
stage it was more important to create a reliable method of obtaining endothelial cells 
rather than an applicable method of their harvesting from the patients. SBS patients 
very often lack the vessels that could be used as source of endothelial cells due to the 
PN-dependency. There are well-described techniques of differentiating bone marrow 
stem cells into functional endothelium (9), however pulsatile stimulation of seeded 
vessels is an unavoidable requirement. Thus, it cannot be achieved without more 
complex equipment.  
 The yield of isolated and cultured cells was high and it was proved that it is 
possible to culture these cells without compromising their differentiated state for at 
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least two weeks. Moreover, the six-fold increase in the yield from a single isolation 
procedure is a very satisfactory result (200).  
The presented technique of OU isolation is a broad variation first presented by 
Evans et al. (73), however it was possible to adjust the process to obtain a 
morphological equivalent of intestinal OU in an adult porcine model. OU seeded on 
appropriate scaffold, that could be also vascularised in vitro would be an alternative 
option to existing therapies of SBS. There are still many problems yet to be resolved 
before small intestine tissue engineering finds its way into clinical applications. 
Unless sources of autologus epithelial cells, or stems that give rise to them, can be 
harvested from the patients, standard SBS treatments will remain necessary. 
Harvesting a sufficient amount of these cells can be difficult in patients with diseased 
or damaged intestine that has led to massive resection. It may be possible to harvest 
small amounts of OU from the remnant small intestine over a period of time that 
could then be expanded in vitro. None of the existing studies have ever reported the 
construction of lengths bigger than 1cm, which would be clinically beneficial for SBS 
patients. Therefore the methods used today will not be applicable when treating 
humans, unless ways can be found to expand either the number of OU or isolate stem 
cells that can differentiate into intestinal epithelium capable of producing mucosa. Up 
to this point researchers experienced difficulties with expanding OU in the culture as 
their proliferative and differential capacities depend on the competence of each OU 
separately as well as an appropriate 3D environment (201).  
The method presented here for isolating OU from adult animals allows 
preservation of intestinal stem cells and in the future it will hopefully be used as an 
additional tool in investigating yield and the regenerative capacities of mature tissue, 
which is much easier to obtain in a clinical situation.  
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Nonetheless, the in vitro culturing conditions of OU harvested from a pig are not 
optimized yet. Rat OU has been reported to survive under flow conditions (96). 
Nevertheless, the method of simultaneous culture of OU and endothelial cells remains 
to be validated. Progressing to an adult, large animal model has undoubtedly many 
advantages. Unanswered questions, like establishing long-term stability and 
functionality of the tissue-engineered constructs with autologus-cells, as well as 
regulation of molecular turnover responsible for the occurrence of the disease in the 
first place could be tested in a model that resembles morphologically and 
physiologically of human patients. Such construct could also find it applications in 
studying pathogenic states in vitro or screening of therapeutic agents (202).  
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Chapter 8. 
General  conclusions and discussion 
 8.1. Conclusions  
 There is an abundance of evidence in the bioengineering field in the 
advantages in using de-cellularised structures as natural scaffolds to replace failing 
organs and tissues. Small intestinal tissue engineering is a fledgling technology, which 
may in the future provide an adjunct to medical and surgical therapies for intestinal 
failure resulting from small bowel syndrome. The experiments described in this thesis 
confirm that: 
• it is possible to de-cellularise porcine ileum with intact mesenteric arcade 
while preserving the structural and functional integrity of the ECM, 
• the presented de-cellularisation process results in biocompatible and non-toxic 
matrix, that upon implantation triggers cellular infiltration and angiogenesis, 
without inducing foreign body reaction and fibrosis, 
• de-cellularised scaffold primarily induces pro-remodelling type of 
mononuclear response, 
• intestinal organoid units can be harvested from adult and neonatal porcine 
donors with reproducible yield, 
• intestinal stem cells can be characterised within isolated neonatal and adult 
porcine organoid units. 
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8.2. Discussion  
 This chapter will initially describe the models used in investigating the 
bioengineering of the small intestine and the reasons behind the transition from rodent 
to porcine preclinical model presented in this thesis. Then it will discuss the progress 
made in the development of a biological, ready-to-vascularise scaffold for 
applications in large animal models, as well as simultaneous biocompatibility and 
toxicity studies. Finally the conclusions of the presented work will be specified and 
the future developments, that will be required before the techniques can be progressed 
further, discussed.  
 
8.1.1. In vivo and in vitro models in development of 
bioengineered small bowel  
 Tissue engineering is a rapidly emerging field that combines the established 
disciplines of engineering, biology and medicine with the goal of fabricating viable 
tissues and organs. Although initially targeted for applications in regenerative 
medicine, a novel application of this technology has been to generate experimental 
model systems for studying biological mechanism and testing the efficacy of potential 
therapies. Nevertheless, the ultimate goal of the field is the development of vital 
tissues and organs that can be used to restore, maintain, or improve diseased or worn-
out native counterparts (16). To date, numerous organ prototypes have been bio-
engineered, including heart valves, blood vessels, nerves, skin, cartilage, bone, 
cornea, liver, pancreas, bladder and gastrointestinal tract.  
 The most prevalent biological model systems incorporated into tissue 
engineering include those based on cultured cells, tissues and organs, and on whole 
animals. A chief advantage associated with reductionist models based on cultured 
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cells is the ability to precisely control the microenvironment to which the cells are 
exposed. In intestinal physiology, for example, cultured monolayer of Caco-2 cells 
have been used extensively as models of intestinal absorptive and secretory 
epithelium (203).  Much of the current understanding of intracellular signals 
transduction mechanisms regulating intestinal epithelial transport is derived from 
studies based on these and related models. However, it is important to remember that 
reductionist models rely on immortalised or transformed cells residing in an artificial 
microenvironment, each of which bear little resemblance to their normal counterparts. 
Thus, the behaviour of this Caco-2 line can not be extrapolated to those of normal 
enterocytes residing in a complex, 3D and multicellular milieu (202).  
 The isolation of organoid units was a considerable step towards creation of 
intestinal replacement. However, the early excitement was extinguished by the 
difficulties in establishing long-term culture of the viable intestinal epithelium. 
Therefore, most of the researches focused on in vivo studies.  
Ex vivo models of tissue and organ culture allow preservation of normal tissue 
architecture and still make it possible to control a local environment but they have 
limited throughput and viability compared to simple in vitro models. However, this is 
a step in the right direction towards bioengineering of a gastrointestinal tract, which 
has not yet been described or clarified.  
 On the other hand, in vivo models can allow for long-term studies of complex 
processes under physiological relevant conditions. In intestinal physiology, models 
based on intestinal intubation or cannulation, isolated intestinal loops, and gross 
nutrient balances have been used to study absorption (204). In many cases, studies 
conducted under physiological relevance using these models yielded findings that are 
dramatically opposed to those based on non-physiological models (202). At present, 
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the experience of small intestine tissue engineering remains limited to experiments 
using animal models, principally small rodents, such as those described in Chapter 2. 
As mentioned in Chapter 1 there are two approaches to generate neointestinal tissue. 
First, the use of scaffolds (mostly SIS and other acellular matrices) as interposition 
grafts, second, the transplantation of intestinal organoid units onto implanted scaffold 
or denuded bowel. Both techniques have advantages and disadvantages, which have 
been highlighted before. Nevertheless, in general it has become clear that 
development of more complex, multi-layered tissues, such as intestine may be 
promoted and achieved quicker using biologically derived scaffolds. ECM structure of 
acellular tissues was suggested to facilitate the growth of correctly orientated mucosa, 
smooth muscle and serosal layers, while allowing the development of adequate 
vasculature and lymphatic tissue (105). 
 The development of a tissue-engineered construct requires the performance of 
several preclinical studies prior to an evaluation in human subject. Some preclinical 
studies can function as a proof of concept and are usually followed by expanded 
studies that are designed to evaluate efficacy in a relevant or well-accepted model. 
Usually, parallel studies are also performed to evaluate safety (205). An experimental 
model of intestinal regeneration using organoid units harvested from a neonatal rat 
has been previously achieved and served as a proof of concept for the work presented 
in this thesis (94). Following a new trend of de-cellularised native organs as tissue-
specific scaffolds promoted the use of an in vivo model using a de-cellularised rat 
intestine seeded with organoid units. However, the intestine-derived scaffold was 
mechanically weak and therefore it failed to provide neomucosa development when 
seeded with organoid units and implanted subcutaneously. Further advancement of the 
experimental model described in Chapter 2 required strengthening of the ECM 
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scaffold. This could be achieved by creating a hybrid scaffold done by coating the 
acellular intestine with a porous polymer. Preliminary studies of this design were less 
than encouraging as the polymer showed unusual stiffness and did not provide 
adequate permeability for cellular infiltration. As a result the scaffold appeared non-
biocompatible and the seeded organoid units did not survive and generate neomucosa. 
At this point it was crucial to estimate future perspectives of the project balancing 
technical difficulties and progress towards viable replacement therapy for intestinal 
failure.  
 For many tissue-engineered constructs, the pivotal preclinical studies designed 
to demonstrate efficacy involve a transition from the use of small animals to large-
animal models. The need for large animals may be dependant on a need to evaluate 
responses to the construct under conditions that better simulate a physiologic match 
with the human clinical condition. Thus, a decision was made to place the emphasis 
on the development of porcine model, where the mechanical weakness of the scaffold 
was less likely to be an issue. As a result a biologically derived, ready-to-vascularise 
porcine scaffold, described in Chapter 3 has been developed.  
 In contrast, the safety and biocompatibility studies are focused on evaluating 
toxicity, either locally or systemically, and sometimes they also can provide 
assessment of the effects of storage or sterilisation on the properties of the construct 
(205). Therefore, at this stage simultaneously a small animal model described in 
Chapters 4 and 5 was incorporated into biocompatibility and toxicity studies of 
porcine de-cellularised ileum. The relevance of the results described in these chapters 
are summarised below.  
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8.1.2. Possibilities and advantages of using capillarised, 
biological, acellular scaffold for small intestine tissue 
engineering 
 The field of tissue engineering is constantly evolving putting hope into 
alternative to transplantations methods of treatment for end-stage tissue and organ 
failures. Ideally, surgeons would replace defective tissues with identical ones, 
recapitulating completely their structure and function. Nevertheless, when building 
biological structures from scratch, such an advance may become unachievable.  The 
approach adopted in this thesis was to regenerate and then replace damaged tissue 
with an information rich scaffold into which adjacent cells migrate to create a 
replacement bowel. This material, ideally, should closely recapitulate the structure 
and function of the defective tissue while providing a safe, biocompatible material for 
tissue replacement (206). The information rich environment of the ECM was proved 
to provide the key signals and cues needed to restore damaged tissues to their natural 
state (207). However, this approach quickly evolved into the necessity of 
incorporating ex vivo seeding of reconstructive matrices with appropriate cells. ECM 
scaffolds started to be used not only as prosthetic and repair materials, but created a 
whole new source of scaffolds for the generation of off-the-shelf tissues and organs. 
As soon as the difficulties with in vivo incorporation of created ex vivo structures 
started to emerge, researchers reached for biomaterials that could contribute to 
scaffold turnover in vivo, preserving viability of seeded cells and at the same time 
actively directing the local cells to migrate and proliferate to where they are needed. It 
became obvious that the integration of the host tissues with the implanted construct is 
an important milestone in creating viable clinically treatment options not only for SBS 
patients, but for everyone with end-stage organ failure.  
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An ideal material for soft tissue reconstruction must be strong, easy to handle 
and biocompatible while supporting the growth of the new tissue. Natural ECM of the 
intestine provides the components necessary to direct the healing response allow for 
the proliferation of new, healthy tissue and restore tissue integrity to the damaged site. 
The 3D organization of these extracellular components distinguishes them from 
synthetic materials and is associated with constructive remodeling instead of scar 
tissue formation. Common features of this ECM-assisted tissue remodeling include 
angiogenesis, recruitment of inflammatory and circulating progenitor cells and 
constructive remodeling of damaged tissue structures (40). Therefore, ECM scaffolds 
have started to be widely used to create replacement tissues and organs using both in 
vitro and in vivo models. Thanks to the technique of de-cellularisation even complex 
tissues can be generated using this relatively simple approach. Even though this 
simple strategy does not offer a universal regenerative solution, it has resulted in 
many significant advancements across the field. One of the first of these was the de-
cellularisation of the whole rat heart, and in vitro regeneration of its contractile 
function by seeding the ECM with cardiac or endothelial cells (133). In February 
2011 the BBC broadcasted a program entitled: “Horizon – How to Mend a Broken 
Heart” featuring the de-cellularising of a whole human heart in order to repeat the 
approach originally tested on an animal model. Dr. Doris Taylor explained how a 
prepared ‘ghost-heart’ could help patients which are at risk of dying whilst waiting for 
the available donor organs.  Furthermore, three years ago, Claudia Castillo, a 30-year-
old mother of two became the first person to receive a transplant organ created from 
autologus stem cells seeded onto a de-cellularised cadaveric trachea. This was 
followed by performing a similar implantation in ten-year-old Kieran at Great 
Ormond Street Hospital in London. In contrast with traditional transplant surgery, the 
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de-cellularisation protocol solved the problem of tissue rejection by removing 
virtually all traces of human leukocyte antigens, meaning the patients required no 
immunosuppressive drugs. As well as immediately restoring airway function, the 
constructs facilitated rapid development of an internal cellular lining and blood vessel 
network (62).  
Although so far the focus within the field of intestinal tissue engineering was 
on scaffolds designed and assembled in ‘bottom-up’ mode from synthetic polymers, 
de-cellularised tissue offered distinct and important benefits in recreating neomucosal 
function. In addition to the fact that ECM materials compared to synthetic scaffolds 
have advantageous characteristics for cellular migration and differentiation upon 
implantation, they also provide the vital intestinal layered 3D structure important for 
recreation. The scaffold introduced in Chapter 3 has one more, very unique benefit. It 
contains intact vascular conduits, which were preserved by a customised de-
cellularisation protocol. The implantation of de-cellularised vasculature of this 
scaffold described in Chapter 6 proved to provide immediate blood supply to all parts 
of the matrix. What is more, even without recreating vascular morphology but using 
pharmacological agents it was possible to maintain the ability to re-perfuse of de-
cellularised vessels for up to at least 24 hours post-implantation. At that time most of 
the scaffold was infiltrated with the inflammatory and progenitor cells. The majority 
of the migrating cells originated from systemic perfusion, which showed how 
important it was to keep even the smallest vessels within the scaffolds unobstructed.  
The use of the rodent model described in Chapter 4 and 5 allowed 
investigation of the behaviour of the de-cellularised ileum in vivo for periods of time 
longer than 24 hours. Simple subcutaneous implantations proved that antigens and the 
agents used for de-cellularisation were removed from the ileum and the scaffold 
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proved to be safe, non-toxic, and most importantly biocompatible. This meant that 
biomolecules crucial for constructive remodelling were preserved whilst de-
cellularisation and they actively promoted cell-cell and cell-matrix interactions in 
vivo. Most of these functional molecules have a short half-life in the circulation (208) 
hence the need for them to be delivered through the biomaterial and released at low 
concentrations on a timescale of weeks. This was confirmed by some of the 
quantitative and qualitative analysis of the scaffolds structural and functional elements 
presented in Chapter 4.  
Chapter 5 confirmed the switch of pro-inflammatory to pro-remodelling 
immunological phenotype as soon as four weeks post-implantation. The incorporation 
of a stereological unbiased quantitative tool into the model can result in more reliable 
way to predict in vivo fate of the tissue-engineered constructs. This quantitative and 
reproducible functional assay is pivotal in the preclinical stage and cannot be 
underestimated, especially when it can be used as a mean to reduce animal use in 
tissue-engineering without compromising efficacy of the studies (205).  
The results discussed herein demonstrate the importance of the ECM 
environment in determining cell behaviour, and highlight the need for regenerative 
materials to provide cells with not only biological cues but also supply them with 
nutrients immediately after implantation. In light of the above mentioned clinical 
applications, the development of intelligent materials is often guided in the first 
instance by the surgical applicability and potential of improving the outcome for the 
patient. Thus, the scaffold presented here partially targets the biggest obstacle in the 
development of viable therapy for SBS by enabling production of 20-30cm long 
constructs, which can be easily implanted and immediately supplied with blood. Even 
though, the generation of thick and heterogeneous intestinal tissue will require further 
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innovations, the scaffold described in this thesis presents a possible platform for 
further development of the tissue-engineered small bowel.   
  
8.1.3. Sources of intestinal regeneration  
 As a result of recent advances in identification and culture of putative stem 
cells, interest in in vitro models of intestinal epithelial cells has been rejuvenated. In 
particular, there is a considerable relevance in the regenerative potential of intestinal 
stem cells and organoid units (116). Identification of factors and pathways involved in 
controlled differentiation of stem/progenitor cells into tissue-specific lineages is 
expected to contribute immensely to effective clinical protocols. However, it is not 
possible to identify intestinal stem cells on the basis of simple histology alone. 
Recently many immunohistochemical and genetic markers have been described in 
literature as selective, putative, intestinal stem cell markers (195). Most of these 
candidates have been characterised in rodent models. There are many species-related 
differences in the expression of surface markers. For example, the focus of many 
recent reports Msh-1 antigen has been identified as an intestinal stem cells marker in 
mouse and rat but not in any other species (195). When porcine specific anti-Msh-1 
antibody was used in IHC analysis of porcine small intestine (data not shown) the 
positive staining could not be described either in a neonate or an adult animal. At the 
same time, the control tissue (cortex) showed expected, positive staining. Sala et al. 
(80) used a putative stem cell marker: DCAMKL-1 while characterising regenerative 
potential of neonatal, porcine, intestinal organoid units in vivo. The antigen proved to 
be present on the surface of a very selective population of proliferating cells at the 
base of the porcine intestinal crypt.  
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The method presented in Chapter 7 for OU isolation was tailored for adult 
porcine tissue. It is believed that this is the first description of intestinal OU that were 
harvested from an adult porcine tissue. Moreover, anti-DCAMKL-1 antibodies were 
successfully used to visualise the intestinal stem cells residual within control intestinal 
tissue of a neonatal and adult pig as well as some of the isolated OU.  
The prospect of isolating OU from adult intestine opens a whole world of 
possibilities for involving autologous OU into tissue-engineered constructs. At the 
moment one of the major obstacles facing the future of intestinal regeneration is the 
issue of yield needed to rebuild neomucosal layer. If it was possible to harvest OU 
from adults, at the time of bowel resection the yield of isolation could be increased. 
OU harvested from only ten centimetres of neonatal, porcine small intestine allowed 
regeneration of 1.5-3cm of bowel. If harvest at the resection technique could be 
employed in clinics, even up to 30cm of autologous bowel could be bioengineered 
from 100cm of resected tissue. Implantation of 30-50 cm long segments of bowel 
could allow SBS patients to be weaned off PN (202).  
The individuals most desperately needing a new alternative to bowel 
transplantations are children. The donor shortage is even more predominant in this 
group. The technique presented in Chapter 7 is adequate for isolating OU from adult 
tissue, however the method of obtaining juvenile OU has been described elsewhere 
(80). The marker used for identification of putative stem cells within the intestinal OU 
has been checked in neonatal and adult tissue. Such specific targeting of intestinal 
stem cells by the antibody can in the future be used to isolate a pure population of 
intestinal stem cells or pure populations of DCAMKL-1+ OU to better understand 
their role in epithelial proliferation and differentiation, as well as conditions important 
for their growth in vitro.  
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As discussed previously it is possible that an alternative to using intestinal 
stem cells will need to be employed in tissue engineering of the small intestine. 
Ultimately, it may become achievable to generate intestinal progenitor cells from 
other autologous pluripotent cell lines such as bone marrow or blood derived stem 
cells.  
  
8.1.4. Limitations of the current concept of small intestine 
tissue engineering – is it possible to create bioengineered 
small intestine?  
Successful tissue engineering begins with a clear and precise definition of the 
clinical demand or problem being addressed. The incidence, prevalence and 
demographics of the SBS indicate the need for successful therapy. Current intestinal 
tissue management either through PN or transplantations do not seem efficient enough 
in 21st century. At the same time it needs to be considered how innovative and 
complex therapy will benefit the SBS patients and if it will be advantageous over the 
existing treatment methods. For example, long-term graft and patient survival needs to 
be considerably higher for implantations of tissue-engineered constructs than for 
intestinal transplantation to turn the novel technique into common and widely 
available practice. The management of patients with severe chronic intestinal failure 
should aim to optimise long-term survival, minimise the incidence of complications 
and maximise the quality of life for the patient. Perhaps tissue engineering will need 
to integrate with existing medical and surgical therapies in order to achieve these 
goals.  
The concept presented in this thesis is based on creating a scaffold that could 
be used to grow long segments of neomucosa. This would be beneficial to SBS 
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patients, however there are many obstacles, which still have to be addressed when 
considering recreation of the anatomical integrity of the small intestine. The major 
hurdle will be the recreation of the intestinal contractibility and subsequently motility. 
The presented here ECM scaffolds has a potential to provide a good environment for 
in vitro propagation of more than one types of tissue. Its biocompatibility has already 
been proven, so it is very probable that it will be a good matrix for ingrowth not only 
porcine and rat cells, but also human ones. The findings presented in this chapter are 
all linked to specific limitations, which are highlighted in the following sub-chapter. 
However, the general concern of transforming animal and in vitro studies into viable 
clinical therapies remains.  
However, recreating the alimentary tract is not a simple task. Successful 
application of tissue-engineered small intestine in humans requires overcoming many 
unique challenges. As a result, clinical application of engineered intestinal tissue still 
remains a number of years away. The understanding of how to optimally harvest 
relevant cell populations and how to expand and culture them in a 3D environment is 
crucial (116). The difficulty of propagating cell lines of normal intestinal epithelium 
has impeded research into the molecular mechanism underlying differentiation of 
stem/progenitor cells into a various intestinal lineages (202). In all the examples 
provided in Chapter 1 there is a lack of long-term epithelial and/or stem cultures of 
intestine. With an expanding role of stem cells in the treatment of degenerative 
disorders, there is a critical need for additional efforts to develop in vitro models of 
well-characterised and marked stem/progenitor epithelial cells of gut or other cells 
that could be differentiated into all lineages of neo-intestine.  
 Several, earlier described studies demonstrated long-term propagation of 
primary epithelial cell and OU cultures derived from rodents (202). Some of them 
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showed long-term replication potential and functional differentiation, suggesting that 
the cultures might have contained stem cell populations, although such 
characterisation was not performed. More recently, intestinal epithelial cells 
expressing certain stem cell markers have been described, but the cells failed to 
develop into cell lines and died after 3-4 passages (116). The difficulty in producing 
stable cell lines most likely relates to imperfect knowledge of tissue dissociation 
methods, culture conditions, inclusion of appropriate structure and third dimension 
into the culture as well as lack of reliable intestinal stem cell markers (202). 
Furthermore, all the in vitro studies of intestinal regeneration have been performed on 
a rodent, mostly neonatal tissue.  
 The yield and methods of expansion of intestinal epithelium or growth of OU 
in vitro also remains an obstacle. It is possible that a better understanding of the inter- 
and extra-cellular interactions within the intestinal crypts may facilitate targeted 
augmentation of in vitro stem cells replication via the use of specific molecules and/or 
scaffolds. Such methods could then be used in conjunction with in vivo techniques to 
increase the volume of neomucosal tissue in artificial bowel-constructs. This may be 
done by the use of highly biocompatible vectors, that can be supplied with nutrients, 
and integrated with the host environment immediately after implantation, and methods 
proved to induce intestinal adaptation such as GLP-2 or growth factors delivery (209).  
 Even though ECM scaffolds used in bioengineering of intestinal tissue have 
only been tested as acellular matrices it is possible that a combined approach in which 
intestinal OU were transplanted onto the sections of de-cellularised ileum, might 
allow for the creation of compatible, long segments of neointestine. The autologous 
OU would allow the cellularisation of the central section of the scaffold in vitro, and 
after implantation tissue could grow inwards from the adjacent healthy jejunum.  
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 It may also be possible to create sections of tissue engineered colonic mucosa 
and implant this in continuity with remnant small intestine. Tissue engineered colonic 
mucosa has been created in rodent models using techniques similar to those used to 
produce tissue engineered small intestine (116). Although bioengineered colonic 
mucosa would not have the same absorptive capacity as small intestinal mucosa, it 
might improve fluid and electrolytes absorption and also provide hormonal stimuli for 
small intestinal adaptation (202).  
 We must also learn how to build intestinal structures composed of a dynamic 
and complex epithelial lining over a fully innervated muscular tube. At the moment 
there are no studies that approach the issue of appropriate gross geometry of 
bioengineered bowel in order to have adequate functional capacity for peristalsis. The 
use of more advanced, de-cellularised materials may be particularly helpful in this 
regard, by providing the cues for all the epithelial, muscular and neural components.  
 Also unknown is a method of delivery and ultimate positioning of segments of 
tissue-engineered small intestine. The muscular and neural regeneration may be very 
slow or even non-existent. Creation of a pouch or use of a de-functional intestinal 
loop rather than straightforward lengthening by interposition may appear a more 
viable option. At the same time it is important to introduce bioengineered grafts to 
intestinal content in order to provoke functional differentiation. However, all the 
studies of interposition of acellular tubular scaffolds longer than few centimetres in 
large animal models resulted in high mortality. Moreover, exposure of the construct to 
the luminal content of the gastrointestinal tract may result in anastomotic leakage or 
partial digestion/damage of the construct. Noteworthy is the question of whether the 
scaffold will be able to withstand the intraluminal pressure of the small intestine?   
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All of this is largely dependant on the scaffold used for intestinal regeneration. The 
de-cellularised ileum presented in this thesis is a good candidate to be considered for 
this purpose. It has been proven to be compatible, which means it would allow 
considerably quick integration with host tissue. It can be obtained in lengths clinically 
viable for SBS patients and provide immediate re-perfusion with the host blood post-
implantation. Finally, intestinal tissue for de-cellularisation can be harvested either 
from cadavers or as xenografts. The first implants of bioengineered tissues are behind 
us, and therefore it is important to provide the regulations of organ and tissue 
donations for not only transplantations but also tissue de-cellularisation and scaffold 
harvesting. The solution may be adoption of the legislation executed in Spain, where 
the government made everyone a potential organ donor. Furthermore, agreement 
needs to be reached such that the organs and tissues which failed to serve as 
transplantation material can serve as de-cellularisation specimen. Even though the 
porcine anatomy is very similar to human, it is crucial to move towards de-
cellularising human tissues and creating ‘ghost-organs’ which could be re-populated 
with patients’ own cells. 
 Ultimately, if tissue engineering is to become a clinically viable therapy in the 
management of intestinal failure secondary to SBS in adults or children, it will be 
essential to combine the techniques described in this thesis with ones existing in the 
literature to produce a section of biologically active tissue.  
 Although the evolution of the technology to a point where it could be used in 
humans appears to be distant, recent reports of successful clinical experiments using 
tissue engineered bladders and tracheas allude to the potential of the technique 
(210;211). 
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8.1.5. Limitations of the studies 
 The preliminary rodent model presented in Chapter 2 highlighted the many 
technical difficulties of creating a biocompatible and non-immunogenic hybrid 
scaffold. Within two weeks post-implantation seeded with organoid units ECM-
polymer scaffolds induced a foreign body reaction and failed to show signs of 
neomucosal creation. The synthetic scaffold was not the only target of inflammatory 
reaction. OU seeded onto control, non-coated with polymer scaffolds also seemed to 
induce a host response. The results of similar experiments, but using inbred OU-donor 
and recipient rats were different with signs of OU survival and neomucosal generation 
(94). To thoroughly test the strength and compatibility of the new hybrid scaffold the 
experiment would have to be repeated using an inbred rodent model, and most 
probably less rigid polymer. However, at the same time the urge to start developing a 
large animal model resulted in rapid advancement in the process of de-cellularisation 
of porcine small intestine. The transition to the porcine model was inevitable and it 
was also linked to there being no-need for strengthening of the scaffold by polymer 
coating.  
 As mentioned previously presented in Chapter 3 ileal scaffolds have many 
advantages over other matrices for intestinal regeneration used so far. It follows the 
trend in the field of tissue engineering of providing vascular conduits, important in the 
development of big constructs and whole organs (lung heart). The tailored de-
cellularisation process resulted in complete removal of cellular components. It also 
removed the majority of DNA, residuals preserving the collagen structure and a 
considerable amount of GAGs. Nevertheless, the collagen analyses were only based 
on qualitative and not quantitative data. The de-cellularisation of the ileum was very 
demanding in terms of adjusting the process for different tissues involved in the 
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process. At the same time numerous scaffolds had to be delicately and carefully 
harvested and prepared in the process of protocol optimisation. It became clear that 
‘ideal’ de-cellularisation would be impossible to achieve. The process had to be based 
on the balance between removing the cells, preserving the ECM and preserving the 
de-cellularised vessels ability to perfuse. It is noteworthy to say that the animal-to-
animal differences were always present and the exact protocol (e.g. pulsatile rate of 
the de-cellularisation pumps) depended greatly on small adjustments that had to be 
made separately for each scaffold. This also means that the reproducibility of the 
result may be highly dependant on the person performing the experiment. This can 
decrease the chance of the technique to be easily transferred into common use when 
treating the patients. However, it can be a starting point for de-cellularising human 
bowels, and human-to-human differences or their management may not be less 
dominant than in the case of the pigs.  
 The obvious limitation of the rodent in vivo studies presented in Chapter 4 and 
6 is the lack of well-defined control groups. Cross-linking the scaffolds prior to the 
implantation could create the negative control group. As stated before, cross-linking 
induces foreign body reaction and fibrosis rather than constructive remodelling in vivo 
(32). At the same time implantation of autologous tissue is regarded as negative 
control in terms of inducing adverse immune response. Nevertheless, the histological 
results were confirmed by an in house pathologist who due to his expertise in the field 
of scaffold cellular responses could confirm the character of the host reaction to the 
implants. Furthermore, as described in Chapter 5, the quantification of different 
populations of macrophages could be compared to results of the studies using 
identical in vivo model and ex vivo staining that had well-described positive and 
negative control groups.  
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 Vascular anastomoses presented in Chapter 6 were performed in eight animals, 
five of which resulted in re-perfusion of the graft and vessels unobstructed state 
throughout the time of the experiment. These results gave good understanding of the 
biomechanical performance of the scaffold, however it is yet to be determined how 
the seeding of the vasculature with endothelial cells characterised in Chapter 7 will 
influence that outcome.  
 The experiments described in Chapter 7 demonstrate that it is possible to 
create porcine intestinal OU in a reproducible fashion. However, the OU yield 
obtained from one harvest of 10cm long segment of adult jejunum needs to be tested 
for its regenerative potential in vivo or in vitro. A better understanding of the 
dynamics of the intestinal crypt will help to identify what role DCAMKL-1+ cells 
play in intestinal OU replication and development. Presented here are early 
experiments that need to be tested in appropriate models. However, they indicate the 
possibility of ‘reusing’ adult resected bowel to generate intestinal OU containing 
putative stem cells.  
 
8.3. Future work 
The work described in this thesis, coupled with the discussion above, 
encourages a number of further studies. The further tests of the de-cellularised tissue 
are needed to estimate scaffold biomechanics, before incorporating it into complex in 
vitro systems. There is the potential for complete in vitro maturation of intestinal 
tissue in bioreactor (202). Not only will in vitro maturation allow for a precise study 
of intestinal tissue development, it will allow for a potentially limitless supply of the 
off-the-shelf intestinal tissues for SBS patients.  OU isolated from neonatal rat have 
been cultured in flow bioreactor for up to three days (96). The next step within the 
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project should focus on designing and manufacturing two circuits (vascular and 
intestinal) pulsatile perfusion bioreactor. Porcine OU described in Chapter 7 could be 
seeded onto the ileal lumen and endothelial cells onto the vascular lumens of the 
porcine acellular scaffold and cultured to obtain optimal seeding growth. It has been 
shown that endothelial cells described in Chapter 7 can grow for up to two weeks. To 
sustain their differentiated state an incorporation of mechanical or electrical stimuli 
would be required. This could be done by seeding the endothelial cells onto the lumen 
of the de-cellularised mesenteric vessels introduced to the pulsatile flow of bioreactor. 
Separation of the two circuits in the bioreactor could allow simultaneous, dynamic 
seeding of two different type of cells, as well as culture using two different (specific 
for given cells) mediums and mechanical preconditioning (different pulse and flow 
rates).  
Such a system could also be used as a tool to optimise minimal yield of the 
cell/OU isolation required for sufficient seeding of the scaffold, without performing 
costly and time-consuming in vivo studies. Depending on the outcome of seeding 
procedures thought needs to be dedicated to eventual improvement in the yield for the 
isolation process.  
 If the efficiency of employing OU units into creating artificial bowel is 
low, then the characterisation of different sources of cells, such as previously 
described mesenchymal stem cells or even embryonic stem cells need to be 
considered.  
Furthermore, there is another important advantage of operating within in vitro 
models. A clinician of the future might apply a tissue-engineered model system to 
facilitate tailoring therapies for individual patients (e.g. the culture of harvested via 
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endoscopy OU could be used for high-throughput screening of the drugs for 
inflammatory bowel disease patients) (96).   
 Possibly one of the most achievable goals within the project, before the in 
vitro models is created, is seeding the lumen of the de-cellularised ileum and 
intraperitoneal implantation of cellular constructs into porcine recipients with and 
without the immunosuppression. Immunosuppressive drugs may alter the regenerative 
potential of seeded OU, but at the same time without them OU isolated from different 
animals may not survive in vivo. Therefore, the role of immunosuppressants needs to 
be validated.  
The perfect solution would involve obtaining autologous sources of cells and 
performing the OU isolation and implantation during one surgical procedure, as done 
by Sala et al. (80). The alternative is the use of immunodeficient porcine recipients of 
tissue-engineered bowel constructs, but this is a very costly requirement.  
 The first steps in obtaining tissue-engineered small intestine using large 
animal model has been achieved. In future using tools developed here (scaffold and 
cellular components) it may be very possible to create the replacement products in 
vitro and ultimately check their biocompetence performing interposition studies in 
porcine recipients. Ultimately the protocols and techniques can be adjusted for clinical 
use.  
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Appendices 
Appendix 1 
De-cellularisation methods used for organs and 
tissues 
 
Table 1. De-cellularisation methods used for organs and tissues  
METHOD ORGAN/TISSUE 
2. Physical 
• Agitation and sonification Liver  
• Mechanical or pressure massage Bladder 
• Freezing and thawing Nerve tissue 
Liver 
• Irradiation Nerve tissue 
2. Chemical 
 
• Acetic acids 
Small intestine 
submucosa 
Bladder 
Liver 
Pericardium 
• Alkaline acids Small intestine 
submucosa 
• Non-ionic detergents 
 
 
! Triton X-100 
Skin 
Liver 
Aortic valve 
Pericardia 
Ligament-Bone  
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! Polyethylene glycol (PEG) Heart 
• Ionic detergents 
 
 
 
 
! SDS 
Vein 
Ligament-Bone 
Bladder 
Heart 
Tendon 
Esophagus 
Ureter 
! Sodium deoxycholate Valve 
Liver 
Muscle 
! Triton X-200 Nerve tissue 
• CHAPS Artery 
• Sulfobetaine-10 and -16 Nerve tissue 
Liver 
• Tri(n-butyl)phosphate Tendon 
 
• Hypotonic and hypertonic 
solutions 
Artery 
Amniotic 
membrane 
Pericardium 
Small intestine 
submucosa 
• Tributyl phosphate (TnBP) Ligament-Bone 
• EDTA and EGTA Small intestine 
submucosa 
3. Biological 
• Trypsin 
! 0.05% Valve 
Liver 
! 0.25% Skin 
! 0.5% Aortic valve 
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• Endo- and exonucleases Valve 
Amniotic 
membrane  
Bladder 
Pericardium 
Muscle 
Esophagus 
• Dispase Skin 
• Collagenase Cartilage 
Pericardium 
• Pronase Cartilage 
* De-cellularisation methods are not specific for the described organs. The table presents most 
commonly used agents to de-cellularise specific tissues. The agents may be the only part of the process 
or a major one in the combined method.   
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Appendix 2  
Preclinical and clinical applications of ECM scaffolds 
 
Table 2 Preclinical and clinical applications of ECM scaffolds in repair and restoration of organs and 
tissues. 
DECELLULARIZED 
ORGAN 
DONOR 
SPECIES 
APPLICATION 
HOST 
SPECIES 
SKIN 
 
Rat 
 
Dermal substitute 
 
Rat 
Full thickness burns 
healing 
Pig 
Full thickness burns 
healing 
Pig 
Diaphragmatic 
prostheses treatment 
Rat 
 
Bovine 
Repair of mucosa 
defect otolaryngology 
 
Human 
 
Human 
Treatment of hallux 
rigidus 
 
Human 
Urethral reconstruction 
SMALL INTESTINE 
SUBMUCOSA 
 
 
 
 
 
 
 
 
Pig 
Achilles tendon 
reconstruction 
Dog 
Hernia repair 
Rabbit 
Human 
Vocal cord 
reconstruction 
Dog 
Intervertebral disc 
regeneration 
Human 
Repair of cecal wound Rat 
Meniscal regeneration Dog 
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Diaphragmatic 
prostheses 
Rat 
Urinary tract repair 
 
Pig 
Peyronie’s disease 
treatment 
Anastomotic dilatation, 
fistula repair, 
urethroplasty, soft 
tissue repair and 
reinforcement, dura 
matter repair, skin 
grafting, vaginal slings 
Human 
NERVE TISSUE Rat Peripheral nerve repair Rat 
 
AMNIOTIC 
MEMBRANE 
 
Rabbit 
Surgical patch with a 
whole range of uses 
(e.g. soft tissue 
replacement, body wall 
repair, cardiovascular 
applications, wound 
dressing) 
Human 
Fetoscopic closure of 
iatrogenic defects in 
fetal membranes 
Rabbit 
DIAPHRAGM Human 
Abdominal wall defect 
repair 
Rabbit 
PERICARDIUM 
Bovine 
Tissue engineering 
/patches for clinical 
application 
 
Mouse 
 
Dog 
Tissue engineering 
/patches for clinical 
application 
 
Rat 
Pulmonary Sheep 
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bioprostheses 
BLADDER Pig 
Full thickness wound 
repair 
Rat 
Hypospadia repair Human 
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Appendix 3 
 Commercially available ECM scaffold materials 
 
Table 3. Commercially available ECM scaffold materials.  
Product Material Use 
AlloDerm Dry sheet of cross-linked 
human skin  
 
Abdominal wall, breast, head 
and neck reconstructions, 
grafting 
 
AlloPatch® Dry sheet of human fascia 
lata  
 
Soft tissue augmentation 
patch 
 
Axis™ dermis Dry sheet of human dermis   
Pelvic organ prolapse 
 
Bard® Dermal Allograft  
Dry sheet of cadaveric 
human dermis  
 
Pelvic organ prolapse 
CuffPatch™  
Hydrated sheet of cross-
linked SIS  
 
Soft tissue reinforcement  
DurADAPT™  
Dry sheet of cross-linked 
horse pericardium  
 
Dura matter repair 
Dura-Guard®  
Hydrated sheet of bovine 
pericardium 
 
Spinal and cranial repair 
Durasis®  
Dry sheet of SIS 
 
Dura matter repair 
Durepair®  
Dry sheet of fetal bovine skin 
 
Cranial or spinal dura repair 
FasLata®  
Dry sheet of cadaveric fascia 
lata 
 
Abdominal repair and vaginal 
prolapse 
Graft Jacket®  
Dry sheet of human skin  
 
Foot ulcers 
Oasis® Dry sheet of SIS  
Partial and full thickness 
wounds, superficial and 
second degree burns grafting 
 
OrthADAPT™  
Dry sheet of cross linked 
 
Soft tissue reinforcement, 
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horse pericardium 
 
repair and reconstruction in 
orthopaedic applications 
 
Pelvicol®  
Hydrated sheet of cross 
linked porcine dermis 
 
Pelvic organ prolapse 
 
Peri-Guard®  
Dry sheet of cross-linked 
bovine pericardium 
 
Pericardial and soft tissue 
repair 
 
Permacol™ (Zimmer 
Collagen Patch in USA) 
 
Hydrated sheet of cross-
linked porcine dermis 
Soft connective tissue repair 
 
PriMatrix™ 
 
Dry sheet of fetal bovine skin Wound management 
Restore™  
Dry sheet of SIS 
 
Soft tissue reinforcement 
 
Stratasis® 
 
Dry sheet of SIS Treatment of urinary 
incontinence  
 
SurgiMend™ 
 
Dry sheet of fetal bovine skin  
Surgical repair of damaged 
or ruptured soft tissue 
membranes 
 
 
Surgisis® 
 
Dry sheet of SIS  
Soft tissue repair and 
reinforcement 
 
 
Suspend™ 
 
Dry sheet of human fascia 
lata 
Urethral sling 
 
TissueMend® 
 
Dry sheet of fetal bovine skin  
Surgical repair and 
reinforcement of soft tissue in 
rotator cuff  
 
 
Vascu-Guard® 
 
 
Dry sheet of cross-linked 
bovine pericardium 
 
Reconstruction of blood 
vessels in neck, legs and 
arms 
Veritas®  
Hydrated sheet of cross-
linked bovine pericardium 
 
Soft tissue repair 
Xenform™  
Dry sheet of fetal bovine skin 
 
 
Repair of colon, rectal, 
urethral, and vaginal 
prolapse, pelvic 
reconstruction, urethral sling 
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Appendix 4 
 Laboratory equipment and reagents 
 
1. Laboratory equipment  
1.1. Tissue preparation and histology 
" Balance-HF-300 (A&D Instruments) 
" Cassets and slides writer-Lamb MicroWriter (RaymondALamb) 
" Hotplate (RaymondALamb) 
" Microtome-Retraction AS325 (Shandon) 
" Waterbath (RaymondALamb) 
" Tissue Processor-TissueTek VIP (Miles Scientific) 
" Embeding centre-Tissue Tek III (Miles Scientific) 
 
1.2.Immunohisto- and Immunocytochemistry 
" Vortex-Genie 2 (Scientific Industries) 
" Magnet stirrer/hotplate-RCT basic (Kika Werke) 
" pH meter-3505 (Jeway) 
" Semi-automatic pipettes (Eppendorf, Fisher Brand, Gilson) 
 
1.3. Microscopy and stereology 
" Microfish-100 (Canon) 
" Microscope-Laborlux S (Leitz) 
" Microscope-BH-2 (Olympus) 
" Fluorescent microscope-Optihot-2 (Nikon) 
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" Microcator (Heidenhain) 
1.4. Preparation of acellular matrix 
" Incubator-Windsor Incubator, range 37-70ºC (Sandrest) 
" Pump-pulsatile, perfusion pump SCIQ 323, range 1-300rpm (Watson Marlow) 
" Dissecting microscope (Leica) 
 
1.5. Molecular biology  
" Microwave-800W (Panasonic) 
" Micro-centrifuge-FugeOne (Eppendorf) 
" Centrifuge-Avanti 30 (Beckman) 
" UV illuminator-Dual Intensity Transilluminator (UVP) 
" Power station for electrophoresis-PowerPac HC (BioRad) 
" Thermo block-Dri Block DB-2D (Techne) 
" Microscale-Sartorius 2001MFZ (SBDHRD-Asset) 
 
1.6. Tissue/cell isolation and culture 
" CO2 incubator-Galaxy R (Jencons Millenium) 
" Hybridisation Oven/Shaker-SI20H, range 25-80º (Stuart Scientific) 
" Centrifuge-Harrier 15/80 (MSE) 
" Inverted microscope-Axiovert 25 (Zeiss) 
" Tissue chopper-McILWAIN (The Mickle Laboratory Engineering LTD) 
" Microflow Biology Safety Cabinet (Prior Laboratory Supplies LTD) 
" Dymax 5 Vacum Pump (Fisher Scientific) 
 
2. Laboratory reagents 
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2.1. Tissue preparation and histology 
" Xelene (Genta Medicals) 
" IMS (Genta Medicals) 
" Gill’s Haematoxylin (PioneerResearch Chemicals) 
" Harris’s Haematoxylin (PioneerResearch Chemicals) 
" Eosin (Sigma)  
" HCl(Fisher Scientific)  
" DPX (Surgipath) 
" Water based mounting medium- Immu-Mount (Shandon) 
" Potassium Permanganate (Sigma) 
"  Sulfuric Acid (Sigma)  
" Oxalic Acid (Sigma)  
" Miller’s Stain (Pioneer Research Chemicals) 
" Weighert’s Haematoxylin: Solutions A and B (PioneerResearch Chemicals)  
" Sirius Red (Sigma)  
" Saturated Aqueous Solution of Picric Acid (Sigma) 
" Histology Wax (Leica) 
" 10% NBF (Genta Medicals)  
" EtOH(Fisher Scientific)  
" IPA (Genta Medicals)  
" ‘Fairy’ liquid (Proctor & Gamble)  
" PFA (Sigma)  
" Vectashield HardSet MountingMedium with DAPI (Vector Laboratories) 
 
2.2.Immunohisto- and Immunocytochemistry 
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" 30% H2O2aqueous solution (Sigma) 
" MeOH (Fisher Scientific) 
" 2.5% Normal Horse Serum (Vector Laboratories LTD) 
" ImmPress Anti-Rabbit Ig (peroxidase) Kit (Vector Laboratories LTD) 
" ImmPress Anti-Mouse Ig (peroxidase) Kit (Vector Laboratories LTD) 
" ImmPACT DAB (Vector Laboratories LTD) 
" Non-specific protein block (Dako) 
" Vectastain Elite ABC kit  (Vector Laboratories LTD) 
" Acetone (Sigma) 
" APTS (Sigma) 
" PBS (Sigma) 
" Trizma Base (Sigma) 
" Tween-20 (Sigma) 
" Anti-!-SMA antibody, clone 1A4 (Sigma) 
" Anti-Col I antibody, clone COL-1 (AbCam) 
" Anti-Col III antibody, ab778 (AbCam) 
" Anti-Ki67 antibody, ab833 (AbCam) 
" Anti-S-100 antibody, clone SH-B1 (Sigma) 
" Anti-CK 8 antibody, clone phosphor AE3 (AbCam) 
" Anti-CD163 antibody, clone ED2 (Cambridge Bioscience) 
" Anti-CCR7 antibody, clone Y59 (Insight Biotechnology) 
" Anti-CD68  antibody, ED1 (AbDSerotec) 
" Anti-DCAMKL-1 antibody, AP72196 (Abgent) 
" Anti-VEGF antibody, clone A-20 (Santa Cruz) 
" Anti-VEGF-R antibody, ab2349 (AbCam) 
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" Anti-CD133 antibody, SC19365 (Insight Biotechnology) 
" Anti-CD31 antibody, 250589 (Bioquote LTD) 
" Anti-FVIII antibody, CP099C (Biocar Medical) 
" Anti-FVIII antibody, A0082 (Dako) 
" Anti-VWF antibody, MCA 127 (Serotec) 
" Proteinase K (Dako) 
" Citric acid (Sigma) 
" Trypsin 250 (Defco) 
" Vector Unmasking Solution (Vector Laboratories) 
" BSA (Sigma) 
" NaCl (Sigma) 
" KCl (Sigma) 
" Biotinylated Anti-Rabbit antibodies (Vector Laboratories) 
" Biotinylated Anti-Mouse antibodies, rat absorbed (Vector Laboratories) 
" Biotinylated Anti-Goat antibodies (Vector Laboratories) 
 
2.3.Preparation of acellular matrix and hybrid scaffold  
" Chloroform (Fisher Scientific) 
" SDS (Sigma) 
" EDTA (Sigma) 
" PA (Sigma) 
" DNaseI (Sigma) 
 
2.4. Tissue/cell isolation and culture 
" HBSS (Sigma) 
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" D-glucose (Sigma)  
" Dispase (Gibco) 
" Collagenase Type I (Sigma) 
" Collagnase F (Sigma) 
" DMEM (Sigma) 
" FBS (Sigma) 
" Sorbitol (Sigma) 
" Penicillin/Streptomycin (Sigma) 
" EGF (Pepro Tech EC LTD) 
" HGF (Pepro Tech EC LTD) 
" VEGF (Pepro Tech EC LTD) 
" FGF (Pepro Tech EC LTD) 
" R3IGF (Pepro Tech EC LTD) 
" Essential amino acids mix (Sigma) 
" Endothelial cell basal medium 2 with supplement pack (PromoCell) 
" Ascorbic Acid (Sigma) 
" Insulin (Sigma) 
" ECM Gel (Sigma) 
" Porcine mucosal heparin (Sigma) 
" 0.4% Trypan Blue aqueous solution (Sigma) 
" Percoll (Sigma) 
" M199 Medium (Sigma) 
" Gelatin (Sigma) 
" Nitric acid (Sigma) 
" Copper (II) sulphate 
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" D-PBS (Sigma) 
 
2.5. Molecular biology  
" Agarose (Sigma) 
" TBE (Sigma) 
" Gel Loading Buffer (BioLabs) 
" Ethidium Bromide (Sigma) 
" DNA Ladder (BioLabs) 
" GenElute Mammmalian Genomic DNA Miniprep Kit (Sigma) 
" GAG’s Blyscan Assay (Biocolor) 
" Papain (Sigma) 
" Cystein (Sigma) 
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Appendix 5 
Xylene-based tissue processing 
 
Table 4. Procedure for xylene-based processing to wax. 
REAGENT TIME TEMPERATURE 
10% NBF 2 hours Room temperature 
70% IMS* 1 hour Room temperature 
90% IMS 1 hour Room temperature 
100% IMS 1 hour Room temperature 
100% IMS 1 hour Room temperature 
100% IMS 1 hour Room temperature 
IMS / Xylene 1 hour Room temperature 
Xylene 30 minutes Room temperature 
Xylene 1 hour Room temperature 
Xylene 30 minutes Room temperature 
56ºC paraffin wax 30 minutes 60ºC 
56ºC paraffin wax 90 minutes 60ºC 
56ºC paraffin wax 90 minutes 60ºC 
*IMS-Industrial Methylated Spirits 
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Appendix 6 
Xylene-based histology-slides preparation 
 
Table 5. Protocol for de-waxing and rehydration (xylene-based protocol). Slides were bathed 
sequentially in the solutions below. 
 REAGENT TIME 
1. Xylene 1 5 minutes 
2. Xylene 2 2 minutes 
3. 100% IMS 2 minutes 
4. 95% IMS 2 minutes 
5. 70% IMS 2 minutes 
6. Running water 2 minutes  
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Appendix 7 
H&E staining 
 
Table 6. H&E staining. Slides were bathed sequentially in the solutions below. 
 REAGENT TIME 
1. Gill’s Haematoxylin 90 seconds 
2. Running water 5 minutes 
3. 1% HCl* in 70% IMS 3 seconds (agitate) 
4. Running water 4 minutes 
5. 0.5% aqueous Eosin 5 minutes 
6. Running water 20 seconds (agitate) 
7. Dehydrate and mount with DPX**  
*HCl-hydrochloric acid; **DPX- Di-N-Butyle Phthalate in Xylene 
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Appendix 8 
Picro-Sirius Red/Miller’s Elastin staining 
Table 7. Protocol for Picro-Sirius Red/Miller’s Elastin staining. Rehydrated slides were bathed 
sequentially in the following solutions. 
 REAGENT TIME 
1. Acid Potassium Permanganate* 5 minutes 
2. Distilled water 1 minutes 
3. 1% aqueous solution of Oxalic acid 2 minutes 
4. Distilled water 5 minutes 
5. 70% IMS 1 minute 
6. 90% IMS 1 minute 
7. Miller’s stain 1 hour 
8. 95% IMS 1 minute 
9. Tap water 2 minutes 
10. Weighert’s Haematoxylin** 10 minutes 
11. Tap water 1 minute 
12. 1% HCl in 70% IMS 5 seconds 
13. Tap water 5 minutes 
14. Distilled water 30 seconds 
15. Picro Sirius Red*** 45 minutes 
16. Dehydrate and mount with DPX  
*0.25% Potassium permanganate in aqueous solution of 1.5% sulphuric acid;**A and B solutions-1:1 
ratio;***1% Sirius Red in Saturated aqueous solution of picric acid
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Appendix 9 
Immunohistochemical stainings 
Table 8. IHC staining protocols. 
Primary antibody 
specificity 
Cell/protein 
target 
Tissue/species Antigen 
retrieval 
H
2
O
2 
solution 
[%] (time 
of 
incubation) 
Wash buffer Non-specific block 
(incubation time) 
Primary 
antibody 
dilution (time 
of incubation) 
Secondary 
antibody 
(dilution/time of 
incubation) 
DAB 
incubation 
time  
Chapter 
number 
!SMA Smooth muscle 
actin 
Subcutaneous 
implants/Rat 
- 3% 
(30 min) 
PBS* 2.5% normal 
horse serum  
(30 min) 
1:4 000 
(30 min) 
Anti-mouse 
ImmPRESS 
kit  
(30 min) 
30 sec 4 
!SMA Smooth muscle 
actin 
Acellular 
matrix 
grafts/Pig 
- 3% 
(30 min) 
PBS 2.5% normal 
horse serum  
(30 min) 
1:4 000 
(30 min) 
Anti-mouse 
ImmPRESS 
kit  
(30 min) 
20 sec 6 
CCR7 Activated B 
and T 
lymphocytes 
and M1 
macrophages 
Subcutaneous 
implants/Rat 
5 min 
0.25% 
citrate 
buffera 
10% 
(30 min) 
PBS 2.5% normal 
horse serum  
(75 min) 
1:100 
(overnight) 
Biotinylated 
anti-rabbit 
1:100 
followed by 
ABC 
(1 h) 
35 sec 5 
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CD31 Endothelial 
cell 
intercellular 
junction 
Acellular 
matrix 
grafts/Pig 
20 min 
0.5% 
citrate 
buffera 
10% 
(30 min) 
PBS 2.5% normal 
horse serum  
(30 min) 
1:10 
(overnight) 
Anti-rabbit 
ImmPRESS 
kit  
(30 min) 
15 sec 6 
CD68 Macrophages Subcutaneous 
implants/Rat 
1 min 
Proteinase 
Kb 
10% 
(30 min) 
PBS 2.5% normal 
horse serum  
(1 h) 
1:100 
(2 h) 
Biotinylated 
anti-mouse 
1:100 
followed by 
ABC 
(1 h) 
35 sec 5 
CD68 Macrophages Acellular 
matrix 
grafts/Pig 
Trypsin 
digestionc 
3% 
(30 min) 
PBS 2.5% normal 
horse serum  
(30 min) 
1:100 
(2 h) 
Anti-mouse 
ImmPRESS 
kit  
(30 min) 
20 sec 6 
CD133 Hematopoietic 
stem cells, 
endothelial 
progenitor 
cells, 
Acellular 
matrix 
grafts/Pig 
5 min 
Proteinase 
Kc 
10% 
(1 h) 
TBS-T** 2.5% normal 
horse serum (2 h) 
1:10 
(overnight) 
Biotinylated 
anti-goat 
1:100 
followed by 
ABC 
(1 h) 
7 sec 6 
CD163 M2 
macrophages 
Subcutaneous 
implants/Rat 
3 min 
Proteinase 
Kc 
10% 
(30 min) 
PBS 2.5% normal 
horse serum  
(75 min) 
1:10 
(overnight) 
Biotinylated 
anti-mouse 
1:100 
followed by 
ABC 
(1 h) 
2 min 5 
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CK8 Epithelial 
cells 
Subcutaneous 
implants/Rat 
- 3% 
(30 min) 
PBS 2.5% normal 
horse serum  
(30 min) 
1:100 
(1 h) 
Biotinylated 
anti-mouse 
1:150 
followed by 
ABC 
(1 h) 
30 sec 4 
COL I Collagen type 
I  
Acellular 
matrix /Pig 
Vector 
unmasking 
solutiond 
3% 
(30 min) 
PBS 2.5% normal 
horse serum  
(30 min) 
1:200 
(2 h) 
Anti-mouse 
ImmPRESS 
kit  
(1 h) 
20 sec 3 
COLIII Collagen type 
III 
Acellular 
matrix /Pig 
- 3% 
(30 min) 
PBS 2.5% normal 
horse serum  
(30 min) 
1:100 
(overnight) 
Anti-rabbit 
ImmPRESS 
kit  
(30 min) 
20 sec 3 
DCAMKL-1 Intestinal 
stem cells 
Organoid 
units and 
small 
intestine/Pig 
2 min 
Proteinase 
Kc 
10% 
(1 h) 
PBS Streptavidin/biotin 
block followed by 
2.5% normal 
horse serum  
(30 min) 
1:50 
(overnight) 
Biotinylated 
anti-rabbit 
1:200 
followed by 
ABC 
(1 h) 
20 sec 7 
FVIII 
(CP099C) 
Blood vessels Subcutaneous 
implants/Rat 
2 min 
Proteinase 
Kc 
15% 
(30 min) 
TBS-T 2.5% BSA*** in 
TBS (1h) 
1:50 
(1 h) 
Biotinylated 
anti-rabbit 
1:150 
followed by 
ABC 
(30 min) 
70 sec 4 
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Ki67 Proliferating 
cells 
Subcutaneous 
implants/Rat 
10 min 
0.25% 
citrate 
buffera 
3% 
(30 min) 
PBS 2.5% normal 
horse serum  
(30 min) 
1:100 
(1 h) 
Biotinylated 
anti-rabbit 
1:100 
followed by 
ABC 
(30 min) 
30 sec 4 
S-100 Neuronal 
progenitors 
Subcutaneous 
implants/Rat 
1 min 
Proteinase 
Kc 
3% 
(30 min) 
PBS 2.5% normal 
horse serum  
(30 min) 
1:100 
(2 h) 
Biotinylated 
anti-mouse 
1:150 
followed by 
ABC 
(1 h) 
5 sec 4 
VEGF Vascular 
endothelial 
growth factor 
Subcutaneous 
implants/Rat 
- 3% 
(30 min) 
PBS 2.5% normal 
horse serum (2 h) 
1:50 
(overnight) 
Biotinylated 
anti-rabbit 
1:100 
followed by 
ABC 
(1 h) 
10 sec 4 
VEGF Vascular 
endothelial 
growth factor 
Acellular 
intestinal 
scaffold/Pig 
- 3% 
(30 min) 
PBS 2.5% normal 
horse serum (2 h) 
1:50 
(overnight) 
Biotinylated 
anti-rabbit 
1:100 
followed by 
ABC 
(1 h) 
25 sec 4 
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VEGF-R Receptor for 
vascular 
endothelial 
growth factor 
Subcutaneous 
implants/Rat 
15 min 
0.25% 
citrate 
buffera 
3% 
(30 min) 
PBS 2.5% normal 
horse serum  
(30 min) 
1:50 
(overnight) 
Biotinylated 
anti-rabbit 
1:200 
followed by 
ABC 
(1 h) 
10 sec 4 
VWF Blood vessels Acellular 
matrix 
grafts/Pig 
2 min 
Proteinase 
Kc 
3% 
(30 min) 
PBS 2.5% normal 
horse serum  
(45 min) 
1:400 
(1 h) 
Anti-rabbit 
ImmPRESS 
kit  
(45 min) 
10 sec 6 
acitrate buffer, pH 6.0 at 95°C followed by 15 minutes of cooling down the sections submerged in citrate buffer solution 
bProteinase K digestion in 25°C 
c5min in distilled water at 37ºC followed by 30 min in 1% trypsin solution in TBS, pH 7.8 at 37ºC 
dVector Unmasking Solution for 15 minutes at 80°C0.01M 
* PBS-Phosphate Buffer Saline (5 tablets in 1l of distilled water) 
** TBS-T-Tris-Buffer Saline with Tween-20 (6% Trizma base, 9% sodium chloride (NaCl), pH7.6, 0.5%Tween-20) 
***BSA-Bovine serum albumin
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Appendix 10  
Solutions used in Chapter 2 
 
Solutions used in experiments described in Chapter 2 
 
! Wash solution  
o  Hank’s Balanced Salt Solution (HBSS) with low calcium and 
magnesium  
o 2% D-glucose 
o 0.035% sodium carbonate (NaHCO3) 
! Enzyme solution, pH 7.4 
o HBSS 
o 0.01% Dispase  
o 0.02% Collagenase type XI-S 
! DMEM solution 
o Dulbecco’s Modified Eagle’s Medium (DMEM) 
o 5% Fetal Bovine Serum (FBS) 
o 2% Sorbitol 
o 0.6% Penicillin/Streptomycin cocktail 
! Growth medium  
o Dulbecco’s Modified Eagle’s Medium (DMEM) 
o 5% Fetal Bovine Serum (FBS) 
o 2% Sorbitol 
o 0.6% Penicillin/Streptomycin cocktail 
o 0.000 005% HGF 
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o 0.00025% Insulin 
o 0.01% Porcine Mucosal Heparin 
o ECM gel (! volume of DMEM)  
! Soap Water 
o Distilled water 
o 1.7% ‘Fairy’ liquid 
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Appendix 11  
Xylene-free tissue processing 
 
 
Table 9. Procedure for xylene-free tissue processing. 
REAGENT TIME TEMPERATURE 
10% NBF 30 minutes 35ºC 
10% NBF 30 minutes 35ºC 
50% EtOH* 1 hour 35ºC 
50% EtOH 1 hour 35ºC 
50% EtOH 1 hour 35ºC 
80% EtOH in IPA** 1 hour 35ºC 
80% EtOH in IPA 1 hour 35ºC 
80% EtOH in IPA 1 hour 35ºC 
IPA 1 hour 35ºC 
IPA 1 hour 35ºC 
56ºC paraffin wax 30 minutes 60ºC 
56ºC paraffin wax 90 minutes 60ºC 
56ºC paraffin wax 90 minutes 60ºC 
*EtOH-ethanol 
**IPA-isopropanol 
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Appendix 12  
Solutions used in Chapter 3 
 
 
Solutions used in experiments described in Chapter 3 
 
 
! 0.05% Trypsin solution, pH 7.5 
o  PBS  
o 0.05% Trypsin  
o 0.05% ethylene-diamine-tetraacetic acid (EDTA) 
 
! 0.2% Trypsin solution, pH 7.5 
o  PBS  
o 0.2% Trypsin  
o 0.05% ethylene-diamine-tetraacetic acid (EDTA) 
 
! Triton X-100 solution  
o PBS 
o 1% Triton X-100 
 
! 0.075% SDS solution 
o PBS 
o 0.075% sodium dodecyl sulphate (SDS) 
 
! 1.5% SDS solution 
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o PBS 
o 1.5% SDS 
! SDX solution 
o PBS 
o 4% sodium deoxycholic acid solutions (SDX) 
! Antibiotics solution 
o PBS 
o 0.2% Streptomycin/Penicillin cocktail (penicillin: 100IE/ml; 
streptomycin:100"g/ml) 
 
! DNase I solution 
o PBS 
o 2.000 U /l deoxyribonuclease type I (DNase I)  
 
! PA solution 
o Sterile PBS 
o 0.1% paracetic acid (PA) 
 
! Evans Blue solution 
o Distilled water  
o 0.01% Evans Blue solution 
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 Volumes of implanted scaffolds 
Table 14. Estimated volumes along with CE values of explanted scaffolds. 
Animal number Scaffold Volume 
[mm3] 
CE 
[%] 
1 P5914-1 323.76 
 
11 
1 P5914-2 574.56 
 
15 
2 P5915-1 611.04 
 
9 
2 P5915-2 647.52 
 
10 
3 P5916-1 638.4 
 
13 
3 P5916-2 574.56 
 
9 
4 P5983-1 893.76 
 
9 
4 P5983-2 633.84 
 
10 
5 P5984-1 551.76 
 
9 
5 P5984-2 611.04 
 
10 
6 P5985-1 497.04 
 
12 
6 P5985-2 606.48 
 
10 
7 P6033-1 647.52 
 
10 
7 P6033-2 611.04 
 
11 
8 P6034-1 775.2 
 
10 
8 P6034-2 601.92 
 
10 
9 P6035-1 542.64 
 
10 
9 P6035-2 779.76 
 
9 
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Appendix 14 
 Cell-densities of implanted scaffolds 
Table 16. Estimated densities along with CE of cells infiltrating the scaffolds implanted 
subcutaneously into rat recipients. 
Animal 
number 
Scaffold 
Total 
cells Nv 
[1/mm3] 
Total 
cells CE 
[%] 
CD68 
Nv 
[1/mm3] 
CD68 
CE 
[%] 
CD163 
Nv 
[1/mm3] 
CD163 
CE 
[%] 
CCR7 
Nv 
[1/mm3] 
CCR7 
CE 
[%] 
1 P5914-1 1.57E-
12 
9 6.05E-
13 
14 2.18E-
13 
13 2.09E-
13 
9 
1 P5914-2 1.68E-
12 
9 6.88E-
13 
12 2.03E-
13 
13 2.27E-
13 
11 
2 P5915-1 1.81E-
12 
9 7.2E-13 12 1.61E-13 
16 3.18E-
13 
9 
2 P5915-2 1.7E-12 9 6.82E-13 
13 2.2E-13 13 2.39E-13 
12 
3 P5916-1 1.79E-
12 
11 7.29E-
13 
17 2.72E-
13 
15 2.5E-13 11 
3 P5916-2 1.72E-
12 
11 7.61E-
13 
15 3.06E-
13 
11 1.87E-
13 
13 
4 P5983-1 7.13E-
13 
15 3.02E-
13 
20 5.98E-
14 
22 1.22E-
13 
18 
4 P5983-2 1.19E-
12 
11 4.51E-
13 
16 1.37E-
13 
17 1.66E-
13 
16 
5 P5984-1 1.53E-
12 
9 5.33E-
13 
18 2.46E-
13 
13 1.49E-
13 
14 
5 P5984-2 1.72E-
12 
11 9.04E-
13 
15 1.72E-
13 
20 1.73E-
13 
12 
6 P5985-1 1.56E-
12 
10 5.55E-
13 
13 1.9E-13 15 1.35E-13 
14 
6 P5985-2 1.37E-
12 
11 4.96E-
13 
15 1.93E-
13 
18 1.2E-13 17 
7 P6033-1 1.25E-
12 
10 4.86E-
13 
16 2.29E-
13 
13 6.85E-
14 
19 
7 P6033-2 1.44E-
12 
10 5.32E-
13 
10 2.02E-
13 
14 7.23E-
14 
17 
8 P6034-1 1.25E-
12 
13 4.85E-
13 
19 1.91E-
13 
16 5.78E-
14 
20 
8 P6034-2 1.34E-
12 
11 4.81E-
13 
16 1.97E-
13 
16 7.07E-
14 
17 
9 P6035-1 1.28E-
12 
10 5.19E-
13 
13 2.52E-
13 
12 7.28E-
14 
20 
9 P6035-2 1.25E-
12 
10 4.22E-
13 
14 1.74E-
13 
19 5.1E-14 15 
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Appendix 15  
Total cell numbers of implanted scaffolds 
 
Table 17. Total number of cells infiltrating each of the scaffolds, and pan, M1 and M2 macrophages 
within the implants. 
Animal 
number 
Scaffold 
Total cells 
NTOT 
CD68 
NTOT 
CD163 
NTOT 
CCR7 
NTOT 
1 P5914-1 5.06879E-10 1.9594E-10 7.04502E-11 6.7504E-11 
1 P5914-2 9.64744E-10 3.95412E-10 1.16521E-10 1.30253E-10 
2 P5915-1 1.10806E-09 4.39704E-10 9.8133E-11 1.94555E-10 
2 P5915-2 1.10111E-09 4.41868E-10 1.42713E-10 1.54628E-10 
3 P5916-1 1.1458E-09 4.65394E-10 1.73709E-10 1.59345E-10 
3 P5916-2 9.8652E-10 4.36953E-10 1.757E-10 1.07443E-10 
4 P5983-1 6.37519E-10 2.69826E-10 5.34468E-11 1.09039E-10 
4 P5983-2 7.55411E-10 2.85735E-10 8.69628E-11 1.05027E-10 
5 P5984-1 8.43476E-10 2.94143E-10 1.35898E-10 8.23226E-11 
5 P5984-2 1.04842E-09 5.5238E-10 1.04793E-10 1.05893E-10 
6 P5985-1 7.73146E-10 2.75758E-10 9.42388E-11 6.71501E-11 
6 P5985-2 8.29968E-10 3.01057E-10 1.17233E-10 7.25957E-11 
7 P6033-1 8.10954E-10 3.14954E-10 1.48347E-10 4.43227E-11 
7 P6033-2 8.80997E-10 3.25257E-10 1.23186E-10 4.41782E-11 
8 P6034-1 9.65357E-10 3.76127E-10 1.48373E-10 4.47678E-11 
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8 P6034-2 8.04165E-10 2.89343E-10 1.18578E-10 4.25377E-11 
9 P6035-1 6.94362E-10 2.81467E-10 1.36474E-10 3.94933E-11 
9 P6035-2 9.77663E-10 3.28981E-10 1.35522E-10 3.97756E-11 
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Appendix 16  
Solutions used in Chapter 7 
 
Solutions used in experiments described in Chapter 7 
 
 
! Enzyme solution for isolation of OU from a piglet, pH 7.4 
o  HBSS with low calcium and magnesium  
o 0.025% Dispase 
o 6.4% Collagenase type I 
! Enzyme solution for isolation of OU from an adult pig, pH 7.4 
o HBSS 
o 0.08% Dispase  
o 10% Collagenase type I 
! DMEM solution 
o DMEM 
o 10% FBS 
o 4% Sorbitol 
! Gelatin solution 
o Distilled, autoclaved water 
o 0.2% gelatin 
! Nitric acid solution 
o Distilled water 
o 10% Nitric acid 
! Collagenase F solution 
o PBS 
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o 0.5% Collagenase type F 
! Supplemented standard medium 
o RPMI medium  
o 10% FBS 
! Endothelial cells growth medium 
o 50% DMEM 
o 50% Endothelial Cell Basal Medium 2 with supplement pack 
! Trypsin solution 
o PBS 
o 0.005% Trypsin 
o 0.02% EDTA 
! Triton X-100 solution 
o PBS 
o 10% Triton X-100 
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